<![CDATA[Biotech Readout]]>https://biotechreadout.xyzhttps://substackcdn.com/image/fetch/$s_!QlpH!,w_256,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdb900d7d-f509-4536-a185-b99a87cc017b_1260x1260.pngBiotech Readouthttps://biotechreadout.xyzSubstackThu, 20 Aug 2026 21:53:31 GMT<![CDATA[BioMarin to Acquire Alesta]]>https://biotechreadout.xyz/p/biomarin-to-acquire-alestahttps://biotechreadout.xyz/p/biomarin-to-acquire-alestaTue, 18 Aug 2026 21:48:03 GMTDisclaimer: This newsletter is for educational and informational purposes only and does not constitute medical, investment, or financial advice, nor does it establish a provider-patient relationship. Content may include forward-looking statements and discussions of investigational therapeutic candidates that are not FDA/EMA approved; their safety and efficacy remain unestablished and clinical outcomes are unpredictable. While we strive for accuracy, all information is provided as is without guarantees. As of the date of publication, the author holds no direct equity positions in the specific companies mentioned in this issue nor receives third-party compensation for this coverage. Please find a complete version of our disclaimers at the bottom of this article and on our About page.

Introduction

On August 18, 2026, BioMarin Pharmaceutical Inc. announced a definitive agreement to acquire Alesta Therapeutics for an upfront payment of $275 million plus up to $215 million in subsequent payments upon achievement of certain development and regulatory milestones. This acquisition centers on ALE1, an investigational oral small molecule ENPP1 inhibitor for the potential treatment of a rare genetic bone disease called hypophosphatasia (HPP).

In this article, we rediscover the history of HPP, touch on a related acquisition (Enobia-Alexion), explore the founding story of Alesta, and learn how ALE1 could push the frontier of HPP standard-of-care.

Babies With Fragile Bones

The medical history of hypophosphatasia (HPP) evolved over nearly a century, starting in 1948. At the Children’s Hospital in London, Ontario, Dr. John Campbell Rathbun encountered a patient that defied the era’s understanding of pediatric bone disease. A three-month-old infant was brought to him displaying the classic outward signs of advanced, severe rickets: soft, fragile bones, severe skeletal deformities, and painful respiratory distress. Standard medical wisdom dictated a clear course of action: high doses of Vitamin D to spur calcium absorption and restore bone density.

Yet, as Rathbun initiated treatment, the infant’s condition rapidly deteriorated rather than improved. Bone X-rays revealed a stark, almost phantom-like picture: skeletal structures were so severely de-mineralized that the infant’s bones appeared nearly invisible against the radiograph. Mystified by the failure of Vitamin D, Rathbun ordered detailed biochemical blood panels. When the laboratory results returned, they revealed a striking paradox. Rickets typically drove serum alkaline phosphatase, an enzyme crucial for bone mineralization, to exceptionally high levels as the body struggled to build bone. In this infant, serum alkaline phosphatase activity was almost entirely absent. Recognizing that he was witnessing a novel genetic disorder, Rathbun published his seminal paper in the American Journal of Diseases of Children, coining the name hypophosphatasia (HPP) to define this distinct entity marked by subnormal alkaline phosphatase activity.

Beyond naming the condition, Rathbun’s early detailed clinical documentation captured the full, devastating clinical breadth of infantile HPP. He documented the failure of the skull bones to fuse properly, the premature loss of primary teeth due to weak attachment tissues, and the sudden, severe vitamin B6-dependent seizures that frequently accompanied the disease. Though the biochemical pathway explaining the disease’s mechanism was still decades away, Rathbun’s initial case report permanently shifted pediatric pathology, carving out a novel clinical description that helped medical literature categorize and study the HPP. Nevertheless, Rathbun’s discovery left behind a critical question: why did a lack of serum alkaline phosphatase prevent normal bone formation? The answer lay hidden in the biochemical fluids of patients, where researchers began discovering unusual chemical clues that would take three decades to fully decipher.

Hypophosphatasia is associated with premature loss of “baby teeth” with an attached dental root (A) whereas the root is absorbed in normal childhood development (B); Source: Dahir & Nunes, GeneReviews (2007), Figure 1

The first breakthrough came in 1955 when David Fraser and his team identified abnormally high concentrations of phosphoethanolamine (PEA) in the urine and blood of individuals with HPP. It was the first identified biochemical marker of the disease beyond low enzyme levels, confirming that alkaline phosphatase missing from the body caused specific cellular metabolites to back up and spill over into circulation. However, high PEA alone could not explain why bones failed to harden. The missing link emerged in the mid-1960s when Herbert Fleisch and his colleagues demonstrated the physiological role of inorganic pyrophosphate (PPi). They discovered that inorganic pyrophosphate (PPi) acts as a potent natural brake on bone formation by binding directly to calcium and preventing hydroxyapatite crystals from precipitating into solid bone matrix. Shortly thereafter, researchers measured the blood and urine of HPP patients and found overwhelming excesses of PPi. By the 1970s, the mechanism became clear: tissue-nonspecific alkaline phosphatase (TNSALP) didn’t directly build bone, rather it was an enzyme that dis-inhibited bone formation by clearing PPi. Without active TNSALP, excess PPi accumulated at the cell surface, suffocating the skeleton’s ability to calcify.

Crystal structure of Tissue Non-specific Alkaline Phosphatase (TNSALP) bound to inorganic pyrophosphate (PPi); Source: Protein Data Bank (PDB)

Parallel investigations into the neurological complications of severe HPP uncovered a third key substrate: pyridoxal-5’-phosphate (PLP), the active form of Vitamin B6. Researchers discovered that TNSALP was required to dephosphorylate PLP into pyridoxal so it could cross the blood-brain barrier. Without this step, the central nervous system was starved of Vitamin B6, triggering the lethal, intractable seizures observed in infants with the disease. Finally, in 1988, advances in molecular biology allowed researchers to map and clone the human ALPL gene on chromosome 1. Isolating the gene enabled scientists to identify specific missense and nonsense mutations in HPP patients. This fundamental genetic breakthrough finally tied thirty years of biochemical observations (elevated PPi, PEA, and PLP) to a single genetic defect, establishing HPP as a definitive inborn error of metabolism caused by loss-of-function mutations in the ALPL gene.

Led by researchers such as Dr. Michael P. Whyte at Washington University in St. Louis, clinicians formally structured HPP into six distinct clinical subtypes based primarily on the age of onset of skeletal symptoms and phenotypic severity:

  1. Perinatal (Lethal) HPP: Marked by profound skeletal hypomineralization in utero, caput membranaceum (soft, uncalcified skull), chest wall instability, and severe pulmonary hypoplasia. Before modern interventions, this form was almost uniformly fatal within hours or days of birth.

  2. Prenatal Benign HPP: A rare, paradoxical subtype identified via fetal ultrasound. Despite significant prenatal long-bone deformities and bowing, these infants spontaneously improved late in gestation or after birth, transitioning into milder childhood or adult phenotypes.

  3. Infantile HPP: Symptoms appeared before six months of age. Infants presented with failure to thrive, rachitic rib deformities leading to respiratory distress, craniosynostosis (premature cranial suture fusion causing raised intracranial pressure), hypercalcemia, and vitamin B6.

  4. Childhood HPP: Manifesting after six months of age, children exhibited short stature, skeletal deformities (e.g., knock-knees or bowlegs), a classic waddling gait due to muscle weakness, bone and joint pain, and delayed motor milestones. Premature loss of primary teeth—exfoliated fully intact with roots due to cementum aplasia—remained a hallmark feature.

  5. Adult HPP: Typically presenting in mid-adulthood with recurrent poorly healing stress fractures (especially of the metatarsals and subtrochanteric femur), early loss of permanent teeth, premature osteoarthritis, and painful calcium pyrophosphate dihydrate (CPPD) crystal deposition / chondrocalcinosis.

  6. Odontohypophosphatasia: The mildest variant, restricted strictly to dental pathology. Patients suffered premature tooth loss and severe dental caries without overt radiological evidence of skeletal rickets or osteomalacia.

Making Your Bones

With the root cause of HPP in hand (defects in the ALPL gene), small teams of scientists set out to develop a treatment. Early efforts in the 1980s and 1990s to treat HPP via simple intravenous infusions of human alkaline phosphatase (ALP) failed because systemic enzyme administration could not adequately penetrate and accumulate within the hydroxyapatite matrix of bones.

In the late 1990s and early 2000s, Canadian biochemist Dr. Philippe Crine and his team at the Université de Montréal and a relatively small Canadian biotechnology company based in Montreal called Enobia Pharma pioneered a solution. They engineered a soluble, recombinant protein composed of three functional regions:

  • PPi Degradation: The catalytic domain of human tissue-nonspecific alkaline phosphatase (TNSALP).

  • Half-life Extension:The Fc domain of human IgG1 (to increase serum half-life and facilitate purification).

  • Bone Homing: A C-terminal deca-aspartate (Asp10) peptide tag, a negatively charged sequence designed specifically to bind with high affinity to positively charged hydroxyapatite crystals in skeletal matrix.

They collaborated with Dr. Michael P. Whyte to demonstrate that this bone-targeted construct (then code-named ENB-0040) effectively localized to skeletal tissue, cleared accumulated PPi, prevented skeletal rickets, and extended overall survival in Tnsalp knockout mouse model. This preclinical proof-of-concept was published in 2007 in the Journal of Bone Mineral Research.

Long-term (52 days), high-dose (8.2 mg/kg) EzRT efficacy studies in Akp2−/− mice. (A) Long-term survival of EzRT mice contrasts with precipitous, early demise of the vehicle-treated group. (B) Normal appearance of an EzRT mouse compared with a stunted, vehicle-treated animal. (C) Plasma ALP concentration in untreated and treated Akp2−/− mice and WT controls. (D) X-ray image of the hind paw of an 18-day-old untreated Akp2−/− mouse showing absence of secondary ossification centers (arrow). In contrast, note the normal appearances of the hind paws of 46- and 52-day-old Akp2−/− mice receiving EzRT.; Source: Millán et al. J Bone Miner Res (2007), Figure 4

Shortly thereafter, under the clinical leadership of pediatric endocrinologists like Dr. Michael P. Whyte, Enobia Pharma launched a pivotal open-label Phase 1/2 clinical trial. The initial cohort consisted of infants under three years of age whose severe skeletal demineralization meant they faced a grim prognosis, often dying within months due to respiratory failure as fragile rib cages collapsed under the strain of breathing. The clinical results unfolded with a rare speed and clarity. Within weeks of starting daily subcutaneous injections of ENB-0040, infant x-rays showed remarkable evidence of new bone formation. Fractured and non-mineralized ribs began to solidify, enabling infants to be safely weaned off mechanical ventilators. Skeletal pain subsided, motor milestones were achieved, and the lethal, Vitamin B6-dependent seizures that had historically plagued infantile HPP were held at bay.

The dramatic early readouts immediately caught the attention of global biopharmaceutical companies specializing in rare diseases. In December 2011, Alexion Pharmaceuticals moved decisively to secure the asset, acquiring Enobia Pharma in an all-cash deal valued at $610 million upfront plus $470 million in regulatory and commercial milestones. Under Alexion’s stewardship, the drug was designated ALXN-1215 and pushed into expanded, multi-center international trials. Long-term follow-up data published in the New England Journal of Medicine in early 2012 formalized the drug’s transformative profile. Substantial mineral deposition and healing of rickets were evident on bone radiographs as early as week 24, continuing through week 48. Rebuilding of the skeletal chest wall allowed a majority of ventilator-dependent infants to be successfully weaned off mechanical ventilation and breathe unaided by week 48. All 9 patients who completed 1 year of treatment demonstrated motor improvements. Children who previously could only lie on their backs gained the ability to roll over, sit, or pull to stand, while the older children in the trial progressed to walking independently. These clinical improvements came alongside improvements in biomarkers (PPi, PLP).

X-ray of HPP Patient 6 shows hypomineralization of the left hand at baseline (A) with substantial mineralization is apparent at week 24 (B) after treatment with ENB-0040/ALXN-1215; Source: Whyte et al., NEJM (2012)

On October 23, 2015, the FDA officially approved Strensiq (asfotase alfa) as the first disease-modifying treatment for perinatal-, infantile-, and juvenile-onset hypophosphatasia (HPP). The approval marked a key milestone for metabolic genetics, replacing supportive care with a targeted enzyme replacement therapy (ERT). The approval was grounded in pooled data from four prospective, open-label clinical trials (and extension studies) involving 99 patients treated for up to 6.5 years, benchmarked against historical natural history control groups. In infants with perinatal and infantile HPP, Strensiq achieved a 97% overall survival rate at 1 year compared to 42% in historical control patients. Invasive ventilator-free survival reached 96% in treated infants versus 31% in controls. In juvenile-onset trial cohorts (ages 6 to 12), 100% of Strensiq-treated patients achieved substantial skeletal response and bone healing by month 54, compared to just 6% in the natural history cohort. Clinical readouts demonstrated significant improvements in linear growth (height and weight Z-scores), mobility, muscle strength, and systemic substrate clearance (PPi and PLP).

Overall Survival in STRENSIQ-Treated versus Historical Control Patients with Perinatal/ Infantile-Onset HPP; Source: Strensiq label, Figure 1
Perinatal/Infantile-Onset Height and Weight Measurements as Measured by Z-Score; Source: Strensiq label, Table 8

Enter Alesta

While Strensiq dramatically improved the natural history of HPP by turning a previously fatal infant disease into a manageable chronic condition, it wasn’t without its flaws:

  • High Injection Frequency: Strensiq requires lifetime subcutaneous injections administered 3 to 6 times per week. For pediatric patients and adult caregivers, this high-frequency regimen creates severe treatment fatigue and injection anxiety over time.

  • Injection Site Reactivity: Up to 90% of patients experience localized injection site reactions (ISRs), such as erythema, swelling, induration, and severe pain.

  • Hypersensitivity and Anaphylaxis: Life-threatening systemic hypersensitivity reactions and anaphylaxis can occur within minutes of injection or even after more than a year of ongoing therapy.

  • Anti-drug Antibodies: A majority of patients develop anti-asfotase alfa antibodies (89%), and 57% develop neutralizing antibodies (see Strensiq label, Section 6.2). In a subset of patients, neutralizing antibodies increase systemic clearance and reduce drug exposure. Post-marketing reports have highlighted cases where patients who achieved initial clinical improvement experienced a secondary loss of efficacy, with worsening radiographic and biochemical markers.

In contrast, an oral small molecule pill could theoritically avoid injections and immunogenicity risks of an injectable ERT. Alesta Therapeutics formed with exactly this thesis in mind. Founded in 2021 and headquartered in Leiden, the Netherlands, Alesta Therapeutics was created to build targeted oral alternatives for rare diseases where existing care is limited to invasive biologics or supportive management. The company was led by Chief Executive Officer Ilan Ganot, a former Wall Street investment banker and biotech entrepreneur known for founding Solid Biosciences. Ganot launched Alesta to build a pipeline of high-impact rare disease assets, alongside CSO Matthias Van Woensel and CMO Dr. Benit Maru.

In December 2024, Alesta entered into an exclusive global licensing agreement with 1cBio to develop and commercialize OC-1 (renamed ALE1). ALE1 is a potential first-in-class, orally available ENPP1 inhibitor designed to lower systemic inorganic pyrophosphate (PPi) levels at the source. Instead of degrading PPi like Strensiq, ALE1 aimed to block production of PPi though a complimentary mechanism. One month later in January 2025, Alesta formally emerged from stealth with a €65 million ($67 million) Series A financing round. The round was co-led by Frazier Life Sciences and Droia Ventures, with participation from the Novartis Venture Fund, RTW Investments, RV Invest, and Thuja Capital. With this capital, Alesta advanced ALE1 into a Phase 1/2a clinical trial in 2025 to evaluate safety, pharmacokinetics, and PPi biomarker reductions in HPP patients.

While Alesta has yet to release any data from its ongoing clinical trial, Rallybio has published preclinical data on its ENPP1 inhibitor REV102 in the Journal of Bone Mineral Research. Oral administration of REV102 in AlplPrxl/- transgenic mice with later-onset/adult HPP significantly decreased plasma PPi and showed radiographic improvement in various bone structures.

AlplPrxl/- transgenic mice treated with REV102 (pink, orange) reduced plasma PPi (left) and increased tibia length (right); Source: Narisawa et al. J Bone Miner Res (2025), Figures 1I & 2C

If validated in clinical trials and rigorously vetted by the FDA, ALE1’s small-molecule approach could once again shift how we manage HPP care. We’ll just have to see. One thing is for sure: BioMarin is willing to take a flier.

Love biotech? Check out Biotech Readout’s full content library, or navigate directly to a segment that interests you:

Biotech Readout is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

]]><![CDATA[Biotechs post wins in menopause hot flashes, anxiety disorder, polycythemia vera, and more]]>https://biotechreadout.xyz/p/biotechs-post-wins-in-menopause-hothttps://biotechreadout.xyz/p/biotechs-post-wins-in-menopause-hotFri, 14 Aug 2026 20:27:42 GMTDisclaimer: This newsletter is for educational and informational purposes only and does not constitute medical, investment, or financial advice, nor does it establish a provider-patient relationship. Content may include forward-looking statements and discussions of investigational therapeutic candidates that are not FDA/EMA approved; their safety and efficacy remain unestablished and clinical outcomes are unpredictable. While we strive for accuracy, all information is provided as is without guarantees. As of the date of publication, the author holds no direct equity positions in the specific companies mentioned in this issue nor receives third-party compensation for this coverage. Please find a complete version of our disclaimers at the bottom of this article and on our About page.

Press ⬇️ to go down to a section and ⬆️ to go back up to the Table of Contents

Table of Contents

This week, we discuss:

  • China Biotech

    • Financing Activity for China versus Rest of World ⬇️

    • Senate Bill Tightens Scrutiny of China Biotech Investment ⬇️

  • Acquisitions ⬇️

    • Jazz to Acquire Actio

    • AstraZeneca-BMS Merger Cancelled

  • Clinical Trial Data

    • AbCellera - ABCL635 (anti-NK3R mAb) / Phase 2 (menopause hot flashes) ⬇️

    • Silence - Divesiran (TMPRSS6 RNAi) / Phase 2 (polycythemia vera) ⬇️

    • Definium - DT120 (LSD ODT) / Phase 3 (anxiety disorder) ⬇️

    • Cullinan - Zipalertinib (irreversible EGFR inhibitor) / Phase 3 (EGFR mutated NSCLC) ⬇️

China Biotech

Wondering why we discuss China Biotech every week? Tap here to learn more.

Financing Activity for China versus Rest of World

for the week ending August 14, 2026

Senate Bill Tightens Scrutiny of China Biotech Investment

On August 7, 2026, Senators Elissa Slotkin (D-MI) and Pete Ricketts (R-NE) introduced the Biotech Investment National Security Act (BINSA) in the Senate. The bill mirrors a bipartisan House proposal originally written by Representatives John Moolenaar (R-MI) and Debbie Dingell (D-MI). BINSA aims to amend the COINS Act to require the Treasury Department to screen outbound investments into biotechnology within “countries of concern,” specifically targeting China. The legislation instructs the Treasury to pay specific attention to joint ventures, equity investments, and licensing deals involving Chinese companies. It is currently awaiting consideration by the House Committee on Financial Services. This comes after a previous attempt by Rep. Moolenaar to attach the bill to the annual defense spending bill failed to advance. The Senate introduction applies pressure on the Treasury Department as it drafts regulations on outbound investment screening rules.

The bill has sparked significant division and lobbying efforts within the pharma and biotech sectors. Critics argue that strict restrictions could harm innovation rather than strengthen the U.S. sector. John Stanford, Executive Director of the VC trade group Incubate, pushed back against the measure, stating that “we cannot restrict our way to leadership” and emphasizing that the U.S. does not need to compromise innovation for national security.

Sources: Endpoints article

Link to top ⬆️

Acquisitions

Link to top ⬆️

Clinical Trial Data

AbCellera - ABCL635 (anti-NK3R mAb) / Phase 2 (menopause hot flashes)

AbCellera released top-line Phase 2 data for ABCL635, an investigational monoclonal antibody (mAb) targeting the neurokinin 3 receptor (NK3R) for moderate-to-severe vasomotor symptoms (VMS; commonly known as “hot flashes”) associated with menopause.

Vasomotor symptoms (VMS), or hot flashes, are caused by menopausal estrogen decline triggering hyperactive neurokinin B (NKB) signaling on hypothalamic KNDy neurons, which disrupts thermoregulation and causes sudden heat-dissipation responses. While hormone therapy remains the traditional standard of care, it is contraindicated in many women due to cardiovascular and cancer risks, leading to non-hormonal alternatives like off-label CNS drugs and oral NK3R antagonists. ABCL635 directly addresses this pathway as a monoclonal antibody that selectively blocks NK3R to restore thermal stability. Unlike daily oral NK3R inhibitors, its ~24-day half-life offers a highly convenient, long-acting subcutaneous dosing option (monthly or less frequent) for patients seeking non-hormonal relief.

In a Phase 1/2 placebo-controlled trial of 92 postmenopausal women, a single 600 mg subcutaneous injection of ABCL635 demonstrated potentially best-in-class efficacy for moderate-to-severe hot flashes, driving an 83% reduction in daily event frequency (-8.8 events/day) and a 58% drop in severity at four weeks. This yielded a statistically significant, placebo-adjusted net frequency reduction of 5.3 episodes per day (-50% relative net improvement, p < 0.001), roughly doubling the historical placebo-adjusted benchmark (~2.5 to 3.0 episodes/day) set by oral competitors like Astellas’s Veozah and Bayer’s Lynkuet on a cross-trial basis. Beyond superior efficacy and convenient monthly or quarterly dosing, ABCL635 showed a clean safety profile with no serious adverse events, discontinuations, or liver enzyme (ALT/AST) elevations. This reduces the risk of black-box liver toxicity warnings and blood-monitoring burdens associated with oral NK3R small molecules while validating AbCellera’s proprietary GPCR antibody discovery platform.

ABCL635 reduced VMSM-S frequency (left) and improved in VMSM-S severity compared to placebo (right); Source: AbCellera press release

AbCellera plans to advance ABCL635 to pivotal Phase 3 trials to confirm durability beyond 4 weeks (standard regulatory endpoints require 12-week primary efficacy endpoints and 52-week safety follow-up). They aim to further establish multi-dose maintenance schedules (e.g., monthly vs. Q8W or Q12W dosing) and evaluate subcutaneous autoinjector formulations.

Sources: AbCellera press release, AbCellera slide deck

Link to top ⬆️

Silence - Divesiran (TMPRSS6 RNAi) / Phase 2 (polycythemia vera)

Silence Therapeutics announced positive topline results from its Phase 2 SANRECO trial evaluating divesiran (formerly SLN124), an investigational siRNA (TMPRSS6 RNAi), in phlebotomy-dependent patients with polycythemia vera (PV). The trial met its primary endpoint with high statistical significance, demonstrating durable hematocrit control, a dramatic reduction in phlebotomy burden, and a clear path toward Phase 3 development.

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm driven by JAK2 mutations that cause hyperactive, erythropoietin-independent red blood cell overproduction, increasing blood viscosity, thrombotic risk, and systemic symptoms. While current standard of care relies on therapeutic phlebotomy alongside cytoreductive therapies (such as hydroxyurea, interferons, or ruxolitinib) to keep hematocrit below 45%, these approaches require frequent blood draws and can induce severe iron deficiency. Divesiran addresses this by using small interfering RNA (siRNA) to silence liver-expressed TMPRSS6, which upregulates hepcidin (the body’s master iron regulator) to restrict iron delivery to the bone marrow and selectively suppress red cell production. By targeting this iron-restriction pathway at the genetic level, divesiran controls hematocrit without invasive phlebotomy and, unlike daily or weekly alternatives, offers a long-acting profile that enables infrequent quarterly subcutaneous dosing.

In the Phase 2 SANRECO trial of 48 phlebotomy-dependent polycythemia vera patients on background standard of care, divesiran met its primary endpoint with an 88% pooled response rate versus 19% for placebo (p < 0.0001), dramatically reducing mean phlebotomies to 0.2 over 36 weeks compared to 2.1 for placebo. Treatment was well tolerated with mostly mild-to-moderate adverse events and no new safety signals. Importantly, divesiran’s 88% overall response rate (and 81.3% response on a quarterly schedule) outperforms the 76.9% response rate reported for Protagonist/Takeda’s weekly rusfertide in its Phase 3 VERIFY trial on a cross-trial basis, establishing potential best-in-class efficacy. By delivering consistent hematocrit control and iron stabilization with once-every-three-months (Q12W) subcutaneous dosing, divesiran significantly reduces patient treatment burden compared to weekly injections while helping prevent chronic iron deficiency.

Significantly higher proportion of clinical responders among the divesiran treated PV patients compared to those who received placebo during weeks 18-36 (p<0.0001); Source: Silence presentation, slide 12

All trial participants from the Phase 2 trial have entered a 3-year extension period to monitor long-term safety and durability. Full results from the SANRECO Phase 2 trial have been submitted for presentation at an upcoming medical conference. Silence plans to hold an end-of-Phase 2 meeting with the FDA before year-end to finalize pivotal trial design. They also plan to initiate a pivotal Phase 3 trial in the first half of 2027 (1H 2027), evaluating the Q12W (once every 3 months) dosing regimen versus placebo.

Sources: Silence press release, Silence slide deck

Link to top ⬆️

Definium - DT120 (LSD ODT) / Phase 3 (anxiety disorder)

Definium Therapeutics announced positive topline results from its pivotal Phase 3 Voyage trial evaluating DT120 (lysergide D-tartrate / LSD in an orally disintegrating tablet [ODT] formulation) in adults with moderate-to-severe generalized anxiety disorder (GAD). The trial met its primary endpoint and all key secondary endpoints with high statistical significance, demonstrating rapid, durable, and clinically meaningful anxiety reduction from a single dose.

Generalized anxiety disorder (GAD) is characterized by persistent, excessive worry and somatic symptoms driven by dysregulation in prefrontal-limbic circuits and neurotransmitter imbalances (GABA, serotonin, norepinephrine). While standard care relies on psychotherapy alongside SSRIs/SNRIs or second-line agents like benzodiazepines and buspirone, traditional oral drugs often take weeks to demonstrate efficacy and carry adverse effects like sedation, weight gain, or dependence. Definium’s DT120 addresses these limitations as a fast-dissolve orally disintegrating tablet (ODT) of lysergide (LSD), acting as a serotonin 2A (5-HT2A) receptor partial agonist and monoaminergic modulator. By promoting rapid neuroplasticity and synaptogenesis to reset hyper-rigid neural networks within the default mode network and limbic system, DT120 provides a standalone pharmaceutical mechanism designed to deliver rapid, durable anxiety relief from a single dose without requiring co-administered psychotherapy.

In the Phase 3 Voyage trial evaluating 214 adults with moderate-to-severe generalized anxiety disorder (GAD), a single oral dose of DT120 demonstrated rapid, statistically significant, and durable efficacy, achieving an 11.6-point reduction on the Hamilton Anxiety Rating Scale (HAM-A) at Week 12 compared to 6.2 points for placebo (a net 5.4-point placebo-adjusted improvement, p < 0.0001, Cohen’s d = 0.81). Statistically significant anxiety relief emerged by Day 2 and persisted through 12 weeks, driving superior clinical response rates (43% vs. 16%), full clinical remission (14% vs. 4%, p < 0.001), and early improvements on the CGI-S scale (-0.8 points at Day 2, -0.6 points at Week 12). DT120 was well tolerated with mostly mild-to-moderate, transient adverse events clustered on dosing day, no serious adverse events or suicidality signals, and an average in-clinic monitoring duration of 6.4 hours (with 92% meeting discharge criteria within 8 hours). As the second positive Phase 3 readout for DT120 following its successful major depressive disorder (MDD) trial, these preliminary Phase 3 findings suggest a potential alternative mechanism in GAD care, offering rapid single-dose relief that warrants further Phase 3 confirmation.

DT120 effect size is more than double the GAD standard of care; Source; Definium presentation, slide 9

Definium plans to complete Panorama, its second pivotal Phase 3 study in GAD. Upon completion, the company plans to file a comprehensive New Drug Application (NDA) with the US FDA covering both GAD and MDD indications. Lastly, Definium aims to finalize health economics outcomes research (HEOR), physician training, and site readiness for single-day in-clinic administration models.

Sources: Definium press release, Definium slide deck

Link to top ⬆️

Descriptive data releases without numerical data

  • Cullinan - Zipalertinib (irreversible EGFR inhibitor) / Phase 3 (EGFR mutated NSCLC): Zipalertinib (CLN-081/TAS6417) is an oral, irreversible tyrosine kinase inhibitor specifically designed to target epidermal growth factor receptor (EGFR) exon 20 insertion mutations in non-small cell lung cancer (NSCLC). In a planned interim analysis of the randomized, global Phase 3 REZILIENT3 trial evaluating 285 treatment-naive adults with locally advanced or metastatic EGFR exon 20 insertion–mutated NSCLC, zipalertinib combined with platinum-based chemotherapy met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant and clinically meaningful improvement compared to chemotherapy alone alongside a manageable safety profile. These positive findings validated the combination as a potential first-line treatment option for a genetically defined NSCLC subgroup with high unmet medical need, prompting an Independent Data Monitoring Committee recommendation to unblind the study for continued follow-up. Cullinan Therapeutics and co-development partner Taiho Oncology plan to submit full dataset results for presentation at a future international medical conference while engaging with the FDA to pursue regulatory approval for the combination regimen. Sources: Cullinan press release

Link to top ⬆️

Love biotech? Check out Biotech Readout’s full content library, or navigate directly to a segment that interests you:

Biotech Readout is a reader-supported publication. To receive new posts and support my work, consider becoming a free subscriber.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

]]><![CDATA[Jazz to Acquire Actio]]>https://biotechreadout.xyz/p/jazz-to-acquire-actiohttps://biotechreadout.xyz/p/jazz-to-acquire-actioMon, 10 Aug 2026 23:00:24 GMTDisclaimer: This newsletter is for educational and informational purposes only and does not constitute medical, investment, or financial advice, nor does it establish a provider-patient relationship. Content may include forward-looking statements and discussions of investigational therapeutic candidates that are not FDA/EMA approved; their safety and efficacy remain unestablished and clinical outcomes are unpredictable. While we strive for accuracy, all information is provided as is without guarantees. As of the date of publication, the author holds no direct equity positions in the specific companies mentioned in this issue nor receives third-party compensation for this coverage. Please find a complete version of our disclaimers linked here.

If you are a paid subscriber, go to epilepsy landscape here ⬇️

If you are a free reader or subscriber, enjoy the whole article free of charge and consider upgrading for competitive landscapes of disease areas & therapeutics modalities; view samples here.

Introduction

On August 10, 2026, Jazz Pharmaceuticals plc announced a definitive agreement to acquire Actio Biosciences, Inc. for $820 million upfront and up to $500 million in contingent consideration (Jazz press release, Actio press release). This acquisition centers on three investigational pipeline programs:

  • ABS-1230 (KCNT1 inhibitor for KCNT1+ epilepsy; Phase 1b/2 ongoing): This is Actio’s lead asset and attracted special interest from Jazz, as indicated by its more prominent position in their press release. ABS-1230 is an investigational “potential first-in-class precision therapy for KCNT1+ epilepsy”, according to Jazz. Currently in clinical evaluation in the KYRON Phase 1b/2 trial in pediatric patients (ages 1 month to 21 years) with KCNT1-related epilepsy and received FDA Fast Track, Orphan Drug (ODD), and Rare Pediatric Disease (RPDD) designations.

  • ABS-0871 (TRPV4 inhibitor for CMT2C & OAB; Phase 1 completed): This is an oral small-molecule inhibitor of TRPV4, a calcium-permeable cation channel. It has completed Phase 1 single- and multiple-ascending dose (SAD/MAD) trials in healthy volunteers and was granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) by the FDA for CMT2C.

  • Unnamed preclinical program (undisclosed mechanism for rare genetic epilepsy or common CNS disorder)

In this article, we dive into the founding story of Actio, expand on its “one to many” thesis, and explore how they generated a clinical dataset that caught the eye of Jazz Pharma.

One to Many

The scientific foundation of Actio stems directly from the work of its CEO and co-founder, Dr. David Goldstein. A world-renowned human geneticist (formerly Director of the Institute for Genomic Medicine at Columbia University and founder of Duke’s Center for Human Genome Variation), Goldstein spent decades pioneering genomic screening methods to identify pathogenic mutations behind rare, severe genetic conditions. While diagnostic genome sequencing became adept at pinning down these rare, severe mutations, Goldstein recognized a recurring gap: identifying the genetic driver rarely translated into an actionable treatment. To bridge this gap from genetics to therapeutics, Goldstein co-founded Actio in 2021 alongside biotech veteran Dr. John McHutchison, former Chief Scientific Officer and Head of R&D at Gilead Sciences.

“I tried to convince a few pharma companies to create rare disease units. That was a complete failure. I spent so many years trying to do that. I just got absolutely nowhere. So I eventually decided if I can’t get someone else to do it, I’ll do it myself”

David Goldstein (CEO of Actio) in a June 2025 interview with Endpoints News

The company’s founding thesis was predicated on a philosophy the founders called “From One to Many”. Actio planned to use rare, genetically defined human diseases as beachhead indications to rapidly prove target modulation before expanding into broader, high-prevalence indications that share the same underlying pathway. In doing so, they hoped to overcome two historic challenges in neuroscience drug discovery: high biological failure rates in common disease trials and limited commercial scale in rare disease programs.

To fit this criteria, Actio selected rare conditions that are driven by highly penetrant, severe gain-of-function (GoF) mutations in a single gene. Since nature has already performed a genetic knock-in experiment of sorts, the target’s role in driving disease physiology already has genetic validation in humans. This is only one piece of the puzzle because the underlying ion channel, receptor, or enzyme needs to be biologically relevant outside of that rare disease in order to theoretically scale from “one to many”. Once the molecule’s safety, potency, and target engagement are proven in the rare population, Actio might be able to expand the asset into more common conditions sharing that same mechanism. Beyond scalability, Actio’s “One to Many” approach had the possibility of improving multiple challenges in neuroscience drug development:

  • More Translatable Animal Models: Traditional drug discovery often fails in Phase 2 because target hypotheses based on animal models do not translate to human disease biology. In rare GoF monogenic disorders, human patient genetics strongly support target involvement, potentially improving the alignment of translational biomarkers between preclinical models and clinical trials.

  • Higher Signal-to-Noise Ratio: Genetically homogeneous rare disease cohorts exhibit more consistent phenotypes. This could potentially enable smaller trial sizes, more rapid readout timelines, and less biomarker/clinical endpoints.

  • Regulatory Tailwinds: Target indications qualify for Orphan Drug (ODD), Fast Track, and Rare Pediatric Disease (RPDD) designations, shortening regulatory review cycles and granting market exclusivity.

To realize their vision, Actio built the Rare Disease Target Atlas, a proprietary platform integrating deep genomic profiling, structural biology, bioinformatics, and medicinal chemistry. The atlas allowed Actio to systematically scan human genetic data, map severe monogenic mutations to specific ion channels or enzymes, and assess their druggability for broader indications.

Securing a Beachhead

Establishing a founding thesis is one thing, but putting a thesis into practice is a whole other thing entirely. History is replete with companies built on a “thesis” or “platform” that raised money for years (sometimes decades), only to close up shop before ever advancing a single pipeline program to clinical proof-of-concept. Actio is not one of those companies. Rather, it was an execution engine that aimed to deliver on the promise of its founding thesis.

Actio Biosciences emerged from stealth in September 2023 with a $55 million Series A financing round co-led by Canaan and Droia Ventures, with participation from Deerfield Management, Euclidean Capital, and EcoR1 Capital (which previously participated in Actio’s $8 million seed funding). To validate its genetic targets and rapidly translate genomic discoveries into preclinically vetted drug candidates, Actio established a strategic research partnership with animal model powerhouse Jackson Laboratory (JAX). A key challenge in rare disease drug development is the lack of animal models that faithfully mirror human gain-of-function mutations. In collaboration with JAX, custom transgenic and CRISPR/Cas9 knock-in rodent strains were deployed to recapitulate pathogenic variants of rare genetic disease in vivo.

At the time, ABS-0871 (TRPV4 inhibitor) was their lead program. TRPV4 encodes a calcium-permeable cation channel expressed across peripheral nerves, chondrocytes, and vascular endothelial cells. Through genomic screening and structural modeling, Actio identified severe pathogenic mutations in TRPV4 as potent gain-of-function (GoF) drivers. In diseases like Charcot-Marie-Tooth Disease Type 2C (CMT2C), these GoF mutations trigger toxic intracellular calcium overload, destroying blood-neural barrier integrity and driving peripheral nerve degeneration. To address this toxicity, Actio engineered ABS-0871, an oral, potent, and highly selective small-molecule TRPV4 channel antagonist. In preclinical models of CMT2C, ABS-0871 demonstrated target inhibition that was associated with reduced cell-barrier breakdown and improvements in preclinical measures of motor and respiratory function. This earned ABS-0871 FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations. CMT2C was the rare disease, but the scale-up strategy revolved around Overactive Bladder (OAB), in which TRPV4 functions as a crucial mechanosensor in the urothelium and detrusor muscle.

Actio initiated human testing for ABS-0871 as its first-ever clinical-stage asset in early March 2025. The randomized, double-blind, placebo-controlled Phase 1a single- and multiple-ascending dose (SAD/MAD) trial in healthy adult volunteers was designed to evaluate human safety, tolerability, pharmacokinetics (PK), and target engagement (pharmacodynamics). Establishing safety and PK in healthy subjects served as the necessary bridge to launch patient trials in CMT2C and overactive bladder (OAB).

Meanwhile, Actio’s Rare Disease Target Atlas surfaced a second opportunity that fit their thesis. KCNT1-related developmental and epileptic encephalopathy (DEE) is caused by dozens of distinct gain-of-function mutations across the gene, resulting in a high seizure burden and resistance to anti-seizure medications. There are currently no U.S. Food and Drug Administration (FDA) approved therapies for KCNT1+ epilepsy.

KCNT1+ epilepsy is a rare genetic developmental and epileptic encephalopathy (DEE) affecting approximately 2,500 patients in the United States. Patients suffering from KCNT1+ epilepsy typically endure a profound seizure burden, with most experiencing dozens to hundreds of episodes daily that remain highly resistant to antiseizure medications. Approximately 80% of individuals with KCNT1+ epilepsy experience disease onset during infancy; many of these children never achieve fundamental developmental milestones, such as walking or speaking, and tragically, some do not survive into adulthood. For those with later-onset disease, the condition typically manifests as disruptive nocturnal seizures, often accompanied by significant cognitive and psychiatric comorbidities.

Jazz Pharmaceuticals press release

To address this unmet medical need, Actio engineered ABS-1230 as a brain-penetrant small molecule designed to inhibit all tested pathogenic GoF variants with the hopes that the drug would work broadly across the KCNT1 patient population rather than requiring mutation-specific therapies. In HEK293 cells that expressed wild type (WT) or 63 different mutant KCNT1 proteins, ABS-1230 blocked current through the sodium-activated potassium channels with nanomolar potency, as assessed by patch clamp (see graph below). Separate experiments, confirmed that ABS-1230 demonstrated selectivity for KCNT1 and did not significantly inhibit other ion channels (tested 22 potassium channels, 9 sodium channels, 2 calcium channels, 11 other ion channels, >40 GPCRs, and >400 kinases).

IC50 values for ABS-1230 in HEK293 cells expressing Wild type (WT) or mutant KCNT1 proteins, as assessed via patch clamp electrophysiology; Source: Actio AES 2026 poster, Figure 1A & 2B

In 8-week-old transgenic mice harboring two KCNT1 mutations (Kcnt1R409Q/R409Q mice), ABS-1230 was shown to suppress spontaneous seizures, with seizures returning after a 14-day washout period (see graph below). Additional patch clamp experiments confirmed that GABAergic neurons isolated from wild-type (WT) and Kcnt1R409Q/R409Q mice were inhibited with nanomolar potency (see graph below). Lastly, ABS-1230 demonstrated high oral bioavailability and CNS penetration in preclinical species. While promising in rare epilepsies bearing KCNT1 mutations, an inhibitor might have broader applicability (true to Actio’s “One to Many” thesis). Hyper-excitable neural networks in common epilepsies often rely on unbalanced potassium and sodium conductance to sustain rapid firing spikes. Therefore, it’s possible that a KCNT1 inhibitor could have utility in broader epilepsy populations (although there isn’t yet any clinical evidence supporting this).

ABS-1230 demonstrated seizure control in Kcnt1R409Q/R409Q mice (left, middle) and inhibits GABAergic neurons isolated from WT and Kcnt1R409Q/R409Q mice (right); Source: Actio AES 2026 poster, Figure 1B & 4

Armed with significant progress in two beachhead programs, Actio Biosciences closed a $66 million Series B financing round in June 2025. The financing was co-led by Regeneron Ventures (a new institutional investor) and returning lead investor Deerfield Management with participation from Canaan, Droia Ventures, and Euclidean Capital. This raise was earmarked to fund clinical execution and “proof-of-concept” readouts across Actio’s two pipeline programs.

Two months later, the FDA cleared Actio’s Investigational New Drug (IND) application for ABS-1230 (KCNT1 inhibitor) and granted it Fast Track, Orphan Drug, and Rare Pediatric Disease designations. Actio dosed the first participant in its Phase 1a SAD/MAD healthy volunteer and food-effect trial in Australia (under combined TGA approval and FDA IND clearance). The trial established that ABS-1230 possessed favorable safety and PK profiles with no serious adverse events. Building on Phase 1a safety data, Actio expanded into the KYRON Phase 1b/2 clinical trial in pediatric and young adult patients (ages 1 month to 21 years) with KCNT1-related epilepsy. According to Jazz, the trial is designed to potentially support a future U.S. New Drug Application (NDA) submission, subject to regulatory agreement and clinical outcomes. The program was also accepted into the FDA’s Rare Disease Evidence Principles (RDEP) process to streamline its path toward potential registration.

Smooth Jazz

While Actio never publicly released data from their KYRON Phase 1b/2 trial, Jazz highlighted in its transaction disclosures that ABS-1230 “demonstrated meaningful seizure reductions in an early clinical proof-of-concept trial in children with KCNT1 epilepsy”. Based on public statements, these preliminary findings likely served as a primary catalyst for the acquisition. Renee Gala, president and CEO of Jazz Pharmaceuticals, commented, “The emerging clinical profile of ABS-1230 is highly encouraging, and we look forward to closing the proposed transaction and collaborating with our new Actio Biosciences colleagues to address an urgent patient need. Together, we are committed to working alongside the epilepsy patient community and regulators to bring this important medicine to children and families, who currently have no treatment options for a devastating disease.”

Jazz is no stranger to neuroscience. Their two blockbuster medicines Xywav (oral oxybate) and Epidiolex (oral canabidiol) are neuro drugs that are approved to treat narcolepsy and seizures, respectively. Actio’s precision neuroscience candidates jive well with Jazz’s pipeline and, if they eventually pass FDA muster after rigorous clinical trials, they could be a good fit for Jazz’s neurology-focused commercial infrastructure. Most importantly, the Jazz-Actio partnership bolsters the effort to develop new therapeutic options for the thousands of patients living with rare epilepsies.

Epilepsy Competitive Landscape

All charts reflect data current as of the specified date and may not include every drug development program, although we aimed to capture the vast majority. Please feel free to email me at biotechreadout@gmail.com with “CHARTS” in the subject line to share suggestions or request chart updates.

Press ⬇️ to navigate to a section

  • Notable Acquisitions in Epilepsy ⬇️

  • Top Selling Medicines in Epilepsy ⬇️

  • R&D Pipeline in Epilepsy ⬇️

Read more

]]><![CDATA[AstraZeneca-BMS Merger Cancelled]]>https://biotechreadout.xyz/p/astrazeneca-bms-merger-cancelledhttps://biotechreadout.xyz/p/astrazeneca-bms-merger-cancelledSat, 08 Aug 2026 15:12:38 GMTDisclaimer: This newsletter is for educational and informational purposes only and does not constitute medical, investment, or financial advice, nor does it establish a provider-patient relationship. Content may include forward-looking statements and discussions of investigational therapeutic candidates that are not FDA/EMA approved; their safety and efficacy remain unestablished and clinical outcomes are unpredictable. While we strive for accuracy, all information is provided as is without guarantees. As of the date of publication, the author holds no direct equity positions in the specific companies mentioned in this issue nor receives third-party compensation for this coverage. Please find a complete version of our disclaimers at the bottom of this article and on our About page.

Introduction

On August 2, 2026, the Financial Times reported that two big pharma companies, AstraZeneca and Bristol Myers Squibb, “held discussions about a tie-up in recent months, according to people familiar with the matter”. Three days later on August 5, 2026, Reuters threw cold water on the theorized mega-merger, reporting that “there are no discussions ongoing ​between AstraZeneca and Bristol Myers Squibb over a potential deal, ‌[according to] a senior source close to the matter”.

Mega-merger cancelled.

This got me thinking: what would the world look like if the merger actually went through?

In this article, we discuss the central challenge of every big pharma CEO and imagine what the world would look like if AstraZeneca and Bristol Myers Squibb had indeed merged.

The Sun That Never Sets

If history has taught us anything, it’s that even the most formidable empires can fall as quickly as they rise. Over the past two millennia, various empires competed with one another until the British Empire reached its territorial apex in 1920. This remains the largest continuous or non-contiguous empire by total land area in human history, covering roughly 25% of the Earth’s total land surface and encompassing about 23% of the global population at the time.

A map of the British Empire in 1910; Source: Cornell University Library, Public domain, via Wikimedia Commons

Ironically, this territorial high-water mark occurred just as the Pax Britannica (Latin for “British Peace”) was structurally weakening. During the early 19th century, Britain was the unchallenged workshop of the world. However, by the late 1800s, rapid second-stage industrialization in Germany and the United States began outpacing British steel, chemical, and heavy manufacturing output. World War I severely drained British financial reserves, turning London from a primary global creditor into a nation heavily indebted to the United States. The seamless global free-trade system organized around the pound sterling disintegrated as wartime blockades, tariffs, and inflation disrupted global commerce. Independence movements across India, Ireland, and the Middle East accelerated rapidly during the 1920s. By 1941, Britain was virtually bankrupt. To secure American military supplies, Britain was forced to sign agreements like Lend-Lease and agree to the Atlantic Charter (1941), which pledged post-war self-determination for colonies and open global trade, effectively dismantling the British imperial preference system. The 1944 Bretton Woods Conference officially established the U.S. Dollar (backed by gold) as the world’s primary reserve currency, replacing the British Pound Sterling.

Just as the Pax Britannica fell, the Pax Americana (Latin for “American Peace”) rose to take its place. Following the end of World War II in 1945, the economic, military, political, and cultural hegemony of the United States defined the new world order. The final straw arrived in the 1956 when Britain, France, and Israel invaded Egypt to retake the Suez Canal. Under severe financial and diplomatic pressure from U.S. President Dwight D. Eisenhower, who threatened to collapse the British pound, Britain was forced into a humiliating withdrawal, demonstrating to the world that no major British geopolitical action could occur without explicit American backing.

Much like the changing world order, big pharma companies must race against patent cliffs to maintain a portfolio of cutting-edge medicines that keep sales aloft; a Pax Pharmaceutica if you will.

In the pharmaceutical industry, a patent cliff refers to the sharp, sudden drop in revenue a pharmaceutical company experiences when the patent protection on its highly profitable blockbuster drugs (drugs generating >$1 billion in annual sales) expires. Once this market exclusivity lapses, cheaper generic or biosimilar alternatives can enter the market. This exposes the original drug maker to intense competition and breaks its monopolistic pricing power. Unlike a slow transition, a patent cliff can trigger a 30% to 90% drop in brand revenue within the very first year of generic competition. Multi-billion-dollar revenue streams shift away from the innovator firm and directly benefit generic manufacturers, insurance payers, and patients through drastically lower prices.

An excerpt from China Biotech: Feast or Famine? by Biotech Readout

Illustrative example of patent cliffs for archetypal base case (green) and worst case (red) branded medications, assuming similar growth rates and non-saturating total addressable markets (TAMs); Source: China Biotech: Feast or Famine? by Biotech Readout

In the 16th century, King Charles V of the Holy Roman Empire remarked, “In my realm, the sun never sets.” (Spanish: “En mis dominios no se pone el sol.”). This is the central challenge of every big pharma CEO: to develop or acquire new & better medicines faster than the older medicines tumble over their patent cliffs, thereby ensuring that the sun never sets on their empire.

Subscribe now

Share

The Big Fish Eat Other Big Fish

Pascal Soriot, CEO of AstraZeneca, and Chris Boerner, CEO of Bristol Myers Squibb are both running this race. The now-debunked the Financial Times report would have you believe that these two big pharmas were closing in on a mega-merger.

When a patent cliff is too steep to fight off with legal maneuvers alone, pharmaceutical companies can use their massive cash reserves to buy out the very companies, platforms, or specific assets that can immediately replace eroding revenue. This can involve buying out smaller biotech firms with a few medicines in their pipeline (called “bolt-on acquisitions”) or a mega-merger with a large, diversified pipeline.

An excerpt from China Biotech: Feast or Famine? by Biotech Readout

Let’s take a step back and opine on the grand irony of the AZ-BMS situation: both AstraZeneca (AZ) and Bristol Myers Squibb (BMS) were themselves born out of mega-mergers.

Founded in 1913 by Swedish apothecaries and physicians, Astra grew into a Scandinavian pharmaceutical power. By the late 1990s, Astra’s core engine was its mega-blockbuster GI drug Prilosec (omeprazole), the world’s best-selling prescription drug at the time, along with a strong respiratory and local anesthetic portfolio. Zeneca was formed in 1993 when British industrial giant Imperial Chemical Industries (ICI) demerged its pharmaceutical, agrochemical, and specialty chemical units. Zeneca held a world-class oncology portfolio featuring targeted cancer treatments like Nolvadex (tamoxifen) and the ACE inhibitor Zestril (lisinopril). Astra faced an existential revenue cliff as Prilosec neared its US patent expiration in the early 2000s. Merging with Zeneca diversified its cash flows immediately. Astra’s commercial strength in North America paired cleanly with Zeneca’s deep distribution networks in Europe and emerging markets. In December 1999, the two companies announced a cross-border “merger of equals”, which was completed in April 1999. The resulting AstraZeneca was valued at approximately $67 billion, with Zeneca shareholders receiving 53.5% of the new entity, while Astra shareholders retained 46.5%. The combined entity created the world’s 4th-largest pharma company at the time, establishing deep domain authority across gastrointestinal, cardiovascular, oncology, and respiratory disease.

Bristol Myers Squibb’s path was similar but different. Tracing its origins back to 1887 in Clinton, NY, Bristol-Myers was a diversified healthcare and consumer giant. While it maintained prescription pharmaceutical franchises, particularly early chemotherapy agents, a large portion of its revenue came from household products (Windex, Drano via Drackett), hair care (Clairol), and infant nutrition (Mead Johnson). Founded in 1858 in Brooklyn by Dr. Edward Robinson Squibb, the eponymous company Squibb was an early pioneer in pharmaceutical quality control and the leading producer of penicillin during WWII. By 1989, Squibb was powered by Capoten (captopril), the first-in-class ACE inhibitor that revolutionized hypertension therapy. The friendly union was partly structured to preempt hostile overseas takeovers, most notably preventing Britain’s Glaxo from acquiring Squibb. The mega-merger was completed in July 1989 to form, Bristol Myers Squibb, the 2nd-largest pharmaceutical company in the world behind only Merck & Co., boasting combined revenues of $8.6 billion. Following the merger, Bristol Myers Squibb systematically divested its non-pharma consumer goods divisions (such as selling Drackett to S.C. Johnson) to redeploy capital into high-margin, innovation-driven prescription drug R&D.

The resulting pharmaceutical behemoths remained acquisitive, having purchased at least 30 companies for more than $200 billion in total deal value (see graph below).

>$200 billion combined acquisitions by AstraZeneca & Bristol Myers Squibb; Source: SEC filings for AstraZeneca & Bristol Myers Squibb

These include two of the largest and most strategically decisive mega-mergers in modern biotech history:

  • Bristol Myers Squibb’s Acquisition of Celgene ($95 billion): This deal was announced in January 2019 and closed in November 2019. Celgene brought the undisputed gold-standard immunomodulatory drugs (IMiDs) for multiple myeloma, Revlimid (lenalidomide) and Pomalyst (pomalidomide), alongside a leading pipeline of autologous CAR-T cell therapies (yielding Abecma and Breyanzi). To secure FTC antitrust clearance due to overlap in psoriasis treatments, BMS was forced to divest Celgene’s immunology blockbuster Otezla (apremilast) to Amgen for $13.4 billion before the deal could close.

  • AstraZeneca’s Acquisition of Alexion Pharmaceuticals ($39 billion): The deal was announced in December 2020 and closed in July 2021. Before this acquisition, AstraZeneca had little presence in rare diseases. Alexion was the undisputed leader in complement biology, anchored by its blockbusters Soliris (eculizumab) and its long-acting successor Ultomiris (ravulizumab). While AstraZeneca’s oncology engine (Tagrisso, Imfinzi, Enhertu) was growing rapidly, adding Alexion provided immediate, non-dilutive, high-margin cash flows to fund ongoing clinical development.

All Talk, No Walk

This brings us back to the “talks” reported by the Financial Times and now debunked by the Reuters report. As of today, it appears that AstraZeneca and Bristol Myers Squibb are not merging. But, what if they did merge?

The resulting MergeCo between AstraZeneca & Bristol Myers Squibb would become the 4th largest pharmaceutical company by enterprise value (see graph below).

A hypothetical MergeCo (green) between AstraZeneca (yellow) & Bristol Myers Squibb (pink) would be the 4th largest pharmaceutical company by enterprise value; Source: SEC filings for AstraZeneca & Bristol Myers Squibb

BMS’ cardiovascular and immuno-oncology heavyweights Eliquis and Opdivo would complement AstraZeneca’s blockbuster franchises in solid tumors (Tagrisso, Enhertu, Lynparza) and I&I (Ultomiris, Fasenra, Soliris).

Sales mix of hypothetical MergeCo between AstraZeneca & Bristol Myers Squibb; Source: SEC filings for AstraZeneca & Bristol Myers Squibb

While AstraZeneca’s patent cliff appears relatively shallow, Bristol Myers Squibb’s patent cliff appears much steeper with 48% of revenue remaining after 5 years, assuming each genericized drug sees an 80% loss of revenue after patent expiration. The combined MergeCo would meaningfully raise BMS’ patent cliff from 48% to 65% of intact revenue after 5 years. Note that this model likely exaggerates the true size of their respective patient cliffs, as it neither accounts for revenue growth among approved drugs nor does it account for new revenue from approvals/launches in the clinical-stage pipeline.

5-year patent cliff of hypothetical MergeCo (green), AstraZeneca (yellow), Bristol Myers Squibb (pink) compared to 11 other big pharma companies (grey); Source: SEC filings for companies listed

Speaking of the clinical-stage pipeline, the hypothetical merger would result in the near-doubling of programs in the solid tumor, heme tumor, I&I therapeutic, and neurology therapeutic areas.

Clinical-stage pipeline of hypothetical MergeCo between AstraZeneca & Bristol Myers Squibb; Source: SEC filings for AstraZeneca & Bristol Myers Squibb

Subscribe now

Share

Conclusion

History shows us that no imperial hegemony, whether built on naval dominance or blockbuster medicines, lasts forever without active reinvention. The AstraZeneca & Bristol Myers Squibb mega-merger may remain a “what-if” footnote in biopharma M&A history, but it serves as a stark reminder of the central challenge of every big pharma CEO: to develop or acquire new & better medicines faster than the older medicines tumble over their patent cliffs, thereby ensuring that the sun never sets on their empire. As key revenue drivers like Eliquis and Opdivo approach their patent cliffs, the industry’s perpetual appetite for new & better medicines won’t diminish. Whether through sweeping cross-border mega-mergers or smaller bolt-on acquisitions, pharmaceutical titans will continue to fortify their Pax Pharmaceutica. After all, in an industry defined by swift generic erosion, standing still is the only guaranteed way to let the sun set on your empire.

Love biotech? Check out Biotech Readout’s full content library, or navigate directly to a segment that interests you:

Biotech Readout is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

]]><![CDATA[Surprise approvals of Replimune's RP1 & Moderna's flu vaccine, orexin unlocks narcolepsy, and more]]>https://biotechreadout.xyz/p/surprise-approvals-of-replimuneshttps://biotechreadout.xyz/p/surprise-approvals-of-replimunesFri, 07 Aug 2026 20:26:19 GMTDisclaimer: This newsletter is for educational and informational purposes only and does not constitute medical, investment, or financial advice, nor does it establish a provider-patient relationship. Content may include forward-looking statements and discussions of investigational therapeutic candidates that are not FDA/EMA approved; their safety and efficacy remain unestablished and clinical outcomes are unpredictable. While we strive for accuracy, all information is provided as is without guarantees. As of the date of publication, the author holds no direct equity positions in the specific companies mentioned in this issue nor receives third-party compensation for this coverage. Please find a complete version of our disclaimers at the bottom of this article and on our About page.

Press ⬇️ to go down to a section and ⬆️ to go back up to the Table of Contents

Table of Contents

This week, we discuss:

  • China Biotech

    • Financing Activity for China versus Rest of World ⬇️

    • FDA Lays Out Accelerated IND Plan as Competition with China Heats Up ⬇️

  • Approvals

    • Replimune - Tudriqev (HSV-1 expressing GALV-GP-R- & GM-CSF) / Approved (melanoma) ⬇️

    • Moderna - mFLUSIVA (antigen mRNA) / Approved (influenza) ⬇️

    • Takeda - Orzeyful (selective OX2 agonist) / Approved (NT1) ⬇️

    • Novartis - Pluvicto (PSMA radioligand) / Approved (PSMA+ mHSPC) ⬇️

  • Clinical Trial Data

    • Otsuka - Voyxact (anti-APRIL mAb) / Phase 3 (IgAN) ⬇️

    • Rhythm - RM-718 (MC4R agonist) / Phase 2 (HO) ⬇️

China Biotech

Wondering why we discuss China Biotech every week? Tap here to learn more.

Financing Activity for China versus Rest of World

for the week ending August 7, 2026

Link to top ⬆️

FDA Lays Out Accelerated IND Plan as Competition with China Heats Up

On August 6, 2026, Endpoints News reported an exclusive interview with Karim Mikhail, acting director of the Center for Biologics Evaluation and Research (CBER) at the FDA. Mikhail emphasized that the FDA wants to act as a steward of new science rather than an impediment (see our discussion the “Cautious Regulator” problem and how it acts as the bottleneck for biotech innovation here).

True to their cause, the FDA is launching a pilot program designed to accelerate the timeline for bringing new drugs into Phase 1 clinical trials. The initiative aims to enhance US competitiveness against faster regulatory frameworks abroad (particularly China) by streamlining the trial startup process and reducing internal bureaucratic delays. Applications open in September 2026, with reviews and selections scheduled for 4Q 2026. The pilot is set to officially launch next year. The agency plans to select 8 to 10 programs. To manage reviewer workloads, no single review team will oversee more than one pilot program. Participating drug sponsors must pair with a “qualified research institution”, such as academic research centers or private contract research organizations (CROs). These partnerships are intended to assist smaller biotechs with regulatory strategy and expedite Institutional Review Board (IRB) activations. Private CROs are specifically highlighted for their ability to move faster than often-bureaucratic academic medical centers.

Development of the pilot began in July 2025 and included consultations with Australian human research ethics committees, the FDA’s China office, US academic medical centers, and dedicated cancer centers. Despite current leadership operating in acting roles, the pilot’s implementation is being managed by a working group of career FDA officials across divisions to ensure continuity.

Sources: Endpoints article

Link to top ⬆️

Approvals

Replimune - Tudriqev (HSV-1 expressing GALV-GP-R- & GM-CSF) / Approved (melanoma)

On August 6, 2026, the FDA granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg; formerly RP1), an engineered oncolytic herpes simplex virus type 1 (HSV-1) expressing GALV-GP-R- and human GM-CSF, in combination with Opdivo (nivolumab) for the treatment of adult patients with unresectable or metastatic cutaneous melanoma who progressed on or after a prior anti-PD-1 blocking antibody regimen.

The approval caps a tumultuous review history that included two Complete Response Letters (CRLs) issued in July 2025 and April 2026. FDA reviewers originally expressed strong opposition to the BLA, arguing that the single-arm trial design made it difficult to isolate RP1’s individual contribution to efficacy within the combination, while also pointing to patient population heterogeneity. However, internal agency restructuring (including a new review team and broader leadership shifts) ultimately facilitated the accelerated pathway. The story changed when on July 30, 2026, the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) voted 10-3 in favor of Tudriqev‘s efficacy and clinical risk-benefit profile.

The approval was supported by efficacy and safety results from the primary anti–PD-1 refractory cohort of the IGNYTE trial (NCT03767348), where patients received intralesional RP1 injections combined with systemic nivolumab. Among the 140 enrolled patients, 91 with at least one non-injected lesion were evaluable for response. Treatment resulted in an Objective Response Rate (ORR) of 32.9% to 34.0% by independent central review using modified/unmodified RECIST v1.1. The Complete Response (CR) rate was 15%, reflecting deep and durable responses. Median Duration of Response (DOR) was 24.8 months, demonstrating sustained anti-tumor responses following anti-PD-1 progression. A key issue raised by reviewers was whether efficacy was limited to injected lesions. Data showed a ≥30% tumor reduction in 93.6% (73/78) of injected lesions and 79.0% (94/119) of non-injected lesions. Lesion-level responses were confirmed in deep visceral sites (e.g., liver and lung metastases), supporting systemic immune activation driven by localized viral lysis, GM-CSF expression, and systemic PD-1 blockade.

Efficacy Results for the IGNYTE Study; Source: Tudriqev label, Table 3

Sources: Replimune press release, Replimune slide deck, new Tudriqev label

Link to top ⬆️

Moderna - mFLUSIVA (antigen mRNA) / Approved (influenza)

On August 5, 2026, the FDA approved mFLUSIVA (mRNA-1010), Moderna’s messenger RNA-based seasonal influenza vaccine encoding hemagglutinin glycoproteins for influenza A and B strains. This milestone marks the first mRNA-based flu vaccine to earn regulatory approval in the United States. Standard approval was granted for adults aged 50 to 64 years, while accelerated approval was granted for adults aged 65 and older. Continued approval in this senior population is contingent upon a post-marketing confirmatory trial directly comparing mFLUSIVA against an enhanced/high-dose flu vaccine.

The approval follows a turbulent regulatory path in early 2026 when CBER issued a Refusal-to-File (RTF) letter under recently ousted CBER director Vinay Prasad. Reviewers and division leads initially expressed reservations regarding trial design and comparator selection. Following high-level discussions in mid-February 2026, Moderna submitted a modified BLA proposing this split age-stratified strategy (full approval for 50–64; accelerated approval for 65+), which the FDA accepted. In June 2026, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously that the clinical benefit-risk profile supported approval for adults 50 and older.

Approval was primarily supported by findings from the pivotal Phase 3 trial (FLUENT / NCT06602024), a randomized, double-blind, active-controlled, case-driven trial enrolling 40,805 adults aged 50 and older across 11 countries. mFLUSIVA demonstrated a statistically superior 26.6% relative vaccine efficacy (95% CI: 16.7%, 35.4%) compared to a standard-dose, active-comparator influenza vaccine. RT-PCR–confirmed protocol-defined influenza-like illness occurred in 2.0% of mFLUSIVA recipients compared to 2.8% of standard-dose comparator recipients. Among participants aged 65 and older in the trial, relative vaccine efficacy was 27.4% (95% CI: 12.1%, 40.0%) against standard-dose comparator. Accelerated approval for the ≥65 cohort was anchored by a dedicated active-controlled immunogenicity trial (NCT05827978, n=2,992) demonstrating non-inferior hemagglutination inhibition (HAI) antibody titers relative to licensed high-dose/adjuvanted influenza vaccines. As seen across the mRNA platform, local and systemic solicited adverse reactions (e.g., transient injection-site pain, fatigue, myalgia, and headache) occurred with higher frequency in the mFLUSIVA arm compared to traditional egg-based standard-dose comparators. Reactions were overwhelmingly mild-to-moderate and self-resolving. No new or unexpected platform-specific safety signals were identified.

Relative Vaccine Efficacy of MFLUSIVA Versus SD Comparator Against RT-PCR-Confirmed ILI* in Participants ≥50 Years of Age (Study 1; Per-Protocol Analysis Set); Source: mFLUSIVA label, Table 5

Sources: Moderna press release, new mFLUSIVA label

Link to top ⬆️

Takeda - Orzeyful (selective OX2 agonist) / Approved (NT1)

On August 5, 2026, the FDA granted approval to Orzeyful (oveporexton, formerly TAK-861), Takeda’s oral, highly selective orexin receptor 2 (OX2R) agonist for the treatment of narcolepsy type 1 (NT1) in adults. Orzeyful represents a breakthrough in sleep medicine: it is the first and only approved therapy that directly targets the underlying pathophysiology of NT1 by restoring lost orexin/hypocretin peptide signaling. Rather than acting purely as a wake-promoting agent or symptom-specific management option, it treats the entire spectrum of NT1 symptoms holistically. Orzeyful received regulatory approval in China (NMPA) two weeks prior. The FDA approval is subject to DEA scheduling under the Controlled Substances Act (expected within 90 days) prior to commercial availability. Takeda previously discontinued its early-generation agonist (TAK-994) due to hepatotoxicity signals. Oveporexton was engineered with optimized chemical selectivity and safety, showing zero hepatotoxicity issues in Phase 2/3 development.

The FDA decision was anchored by pivotal data from two Phase 3 trials, FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002). Treated patients showed statistically significant, near-complete normalization of daytime wakefulness. Average sleep latency on Maintenance of Wakefulness Test (MWT) increased by +17.2 to +20.1 minutes from baseline at optimal dosing (2 mg BID) compared to placebo (near-baseline). Subjective daytime sleepiness demonstrated dramatic, rapid reductions. Mean Epworth Sleepiness Scale (ESS) score reductions reached -11.1 to -11.2 points at 8-12 weeks compared to -1.4 to -1.6 points for placebo (p < 0.001), dropping total scores into the non-pathological/normal range for many participants.

Efficacy Results for Maintenance of Wakefulness Test, Epworth Sleepiness Scale, and Weekly Cataplexy Rate in Patients with Narcolepsy Type 1 at 12 Weeks (Studies 1 and 2); Source: Orzeyful label, Table 3

Sources: Takeda press release, new Orzeyful label

Link to top ⬆️

Novartis - Pluvicto (PSMA radioligand) / Approved (PSMA+ mHSPC)

On July 31, 2026, the FDA granted expanded approval to Pluvicto (lutetium Lu 177 vipivotide tetraxetan), Novartis’ targeted radioligand therapy (RLT), in combination with an androgen receptor pathway inhibitor (ARPI) and androgen deprivation therapy (ADT) for patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMA+ mHSPC). This regulatory milestone moves Pluvicto into the frontline metastatic setting. According to Novartis, treating mHSPC earlier in the disease cascade nearly doubles the eligible patient population compared to its previous indications in post-chemotherapy and pre-chemotherapy metastatic castration-resistant prostate cancer (mCRPC).

The FDA decision was supported by efficacy and safety outcomes from the pivotal Phase 3 PSMAddition trial (NCT04720157), which randomized 1,144 patients with PSMA-positive mHSPC to receive either Pluvicto (7.4 GBq / 200 mCi every 6 weeks for up to 6 cycles) plus standard of care (SoC; ARPI + ADT) or SoC alone. Pluvicto plus SoC demonstrated a statistically significant 28% reduction in the risk of radiographic progression or death compared to SoC alone (HR=0.72, P=0.002).

Efficacy Results in PSMAddition (table) and Kaplan-Meier Plot of Radiographic Progression-Free Survival in PSMAddition (graph); Source: Pluvicto label, Table 11 & Figure 1

Sources: Novartis press release, updated Pluvicto label

Link to top ⬆️

Clinical Trial Data

Otsuka - Voyxact (anti-APRIL mAb) / Phase 3 (IgAN)

On August 3, 2026, Otsuka presented results from the 2-year Phase 3 VISIONARY trial readout for Voyxact (sibeprenlimab-szsi) presented at GlomCon Hawaii 2026.

IgA nephropathy (IgAN) is an autoimmune kidney disease characterized by a “four-hit” pathogenesis where the overproduction of galactose-deficient IgA1 (Gd-IgA1) triggers autoantibody production and circulating immune complex deposition in the renal mesangium, driving complement activation, localized inflammation, and progressive glomerular fibrosis. While standard of care relies on optimized supportive care with maximum tolerated RAS inhibitors, dual endothelin/angiotensin receptor antagonists, blood pressure management, and targeted immunosuppressants or corticosteroids for high-risk patients, novel therapies target upstream drivers like A-PRoliferation-Inducing-Ligand (APRIL). Selectively neutralizing this key TNF-family cytokine with Voyxact, a monthly subcutaneous anti-APRIL monoclonal antibody, halts APRIL-driven B-cell and plasma cell overproduction of pathogenic Gd-IgA1 to prevent immune complex deposition and nephron loss without broadly depleting total B-cell pools.

In the Phase 3 VISIONARY trial evaluating adult patients with primary IgA nephropathy (IgAN) at risk of disease progression, Voyxact demonstrated compelling 2-year efficacy by becoming the first and only IgAN therapy to achieve complete stabilization of kidney function, yielding an annualized eGFR slope of +0.3 mL/min/1.73m2/year compared to -4.2 mL/min/1.73m2/year for placebo (see graphs below). This +0.3 slope surpasses the KDIGO therapeutic benchmark for aligning renal function loss with healthy age-related physiological decline (<1.0 mL/min/1.73m2/year). Alongside robust efficacy, Voyxact maintained a favorable and comparable safety profile to placebo (90.7% vs. 90.0% overall adverse events), with equivalent overall infection rates (51.4% vs. 51.0%), fewer serious infections (1.9% vs. 4.0%), and an anti-drug antibody incidence (~34% overall, ~8% neutralizing) that did not impact long-term eGFR trajectory preservation.

Otsuka is completing its rolling supplemental Biologics License Application (sBLA) to convert Voyxact’s November 2025 accelerated approval into full FDA approval, while expanding marketing authorization filings across the EMA, PMDA (Japan), and other international regions.

Sources: Otsuka press release

Link to top ⬆️

Rhythm - RM-718 (MC4R agonist) / Phase 2 (HO)

On August 4, 2026, Rhythm Pharmaceuticals reported positive Phase 2 clinical trial data evaluating RM-718, its investigational once-weekly subcutaneous MC4R agonist, in patients with acquired hypothalamic obesity (HO).

Hypothalamic obesity (HO) is a severe neuroendocrine disorder caused by structural damage to the hypothalamus (frequently resulting from craniopharyngiomas, brain tumors, or cranial procedures) that disrupts leptin-melanocortin signaling to induce hyperinsulinemia, decreased energy expenditure, and relentless hyperphagia driving refractory weight gain. While traditional supportive care, lifestyle interventions, and hormone replacements offer limited long-term efficacy against damaged central satiety pathways, novel targeted options like RM-718 directly address this pathology. As an investigational once-weekly subcutaneous melanocortin-4 receptor (MC4R) agonist engineered to be MC1R-sparing, RM-718 activates downstream satiety signaling to drive therapeutic weight loss while minimizing off-target MC1R activation, thereby avoiding the generalized skin hyperpigmentation seen with earlier-generation MC4R agonists like setmelanotide.

In an ongoing open-label, single-arm Phase 2 trial of 11 adult and pediatric patients with acquired hypothalamic obesity (HO), RM-718 demonstrated compelling 16-week efficacy with a -11.6% mean BMI reduction in 7 evaluable patients, numerically exceeding historical benchmarks set by setmelanotide (-10.1% at 16 weeks) and bivamelagon (-10.1% at 14 weeks), with long-term extensions reaching -20% to -25% BMI reduction. Crucially, the trial validated its MC1R-sparing strategy by observing zero cases of generalized skin hyperpigmentation, limiting hyperpigmentation strictly to two localized injection-site events, thereby decoupling MC4R-mediated weight loss from systemic skin darkening. While mild-to-moderate injection-site reactions (81.8%), nausea (54.5%), and vomiting (27.3%) were the most common adverse events (leading to 2 discontinuations).

RM-718 Exhibited Comparable Reductions to Setmelanotide and Bivamelagon; Source: Rhythm presentation, slide 10

Rhythm is continuing to follow patients in the Phase 2 extension phase to monitor sustained weight loss and longer-term safety profiles. The company is planning for alignment with regulatory agencies (FDA/EMA) for a registration-enabling Phase 3 trial program in acquired hypothalamic obesity and potentially broader neuroendocrine/MC4R pathway disorders.

Sources: Rhythm press release, Rhythm slide deck

Link to top ⬆️

Love biotech? Check out Biotech Readout’s full content library, or navigate directly to a segment that interests you:

Biotech Readout is a reader-supported publication. To receive new posts and support my work, consider becoming a free subscriber.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

]]><![CDATA[Hepatitis C, Part 2]]>https://biotechreadout.xyz/p/hepatitis-c-part-2https://biotechreadout.xyz/p/hepatitis-c-part-2Sat, 01 Aug 2026 12:18:18 GMTDisclaimer: This newsletter is for educational and informational purposes only and does not constitute medical, investment, or financial advice, nor does it establish a provider-patient relationship. Content may include forward-looking statements and discussions of investigational therapeutic candidates that are not FDA/EMA approved; their safety and efficacy remain unestablished and clinical outcomes are unpredictable. While we strive for accuracy, all information is provided as is without guarantees. As of the date of publication, the author holds no direct equity positions in the specific companies mentioned in this issue nor receives third-party compensation for this coverage. Please find a complete version of our disclaimers at the bottom of this article and on our About page.

Prologue

In Part 1, we dug into the Nobel-prize winning discovery of Hepatitis C and explored how Schering-Plough, Roche, Merck, Vertex, and Janssen turned the tide from a public health epidemic to an 80% cure rate.

The Interferon Era and Protease Era represent the first two legs of the race for the Hepatitis C cure. Researchers at Chiron mapped the virus’ genome and developed a biomarker-based diagnostic, revealing the enormous scope of Hepatitis C’s scourge. Schering-Plough figured out how to manufacture interferon at scale, pioneering the first FDA-approved treatment for Hepatitis C. Schering-Plough and Roche introduced a long-acting peginterferon, which reduced the injection burden from three times weekly to once weekly. After Schering-Plough merged with Merck, the team hosted a second act and pioneered NS3/4A protease inhibitors with Vertex close behind. By the end of 2013, Schering-Plough/Merck had a 16-year track record as the juggernaut in Hepatitis C. Two years later, Janssen lowered the overall pill burden from five a day to three a day. All told, Hepatitis C went from a public health epidemic to an 80% cure rate.

In a vacuum, this progress is astounding, but the story doesn’t end here. It’s only with the clarity of hindsight that we can talk about the weaknesses of the standard of care regimen for Hepatitis C circa 2013. NS3/4A protease inhibitors could not be used alone. They required co-administration with pegylated interferon and ribavirin, which were notorious for debilitating side effects like severe fatigue, depression, flu-like symptoms, and anemia. These regimens required complex dosing schedules (e.g., every 8 hours) and specific dietary protocols (Victrelis with a light snack and Incivek with a high-fat meal) to ensure proper absorption. Since they had a low barrier to resistance, any lapse in adherence could quickly render the virus resistant not only to the drug being taken but potentially to other protease inhibitors in the same class.

Beyond the specific issues of the first-generation drugs, the protease inhibitor class as a whole faced persistent clinical challenges. Early protease inhibitors were contraindicated or carried strong warnings for patients with moderate to severe liver impairment (Child-Pugh B or C cirrhosis). In these cases, the drugs could cause further liver dysfunction, failure, and death, likely due to altered hepatic metabolism. Protease inhibitors were also typically potent inhibitors or substrates of cytochrome P450 enzymes (particularly CYP3A). This made them prone to significant interactions with a wide array of other medications, necessitating careful clinical management when treating patients with comorbidities. Finally, the efficacy of certain protease inhibitors (such as Olysio) was compromised by pre-existing viral resistance mutations, most notably the Q80K polymorphism in HCV genotype 1a. This required mandatory baseline resistance testing, adding complexity and cost to the treatment process.

As the sun set on the Protease Era, Schering-Plough/Merck looked back on a 16-year track record of success and a blockbuster Hepatitis C franchise. Roche, Vertex, and Janssen also constructed blockbuster franchises, racking up peak annual sales of $1 billion (mid-2000s), $1.2 billion (2012), and $2.3 billion (2014), respectively. High fives all around.

[But] remember Gilead, the underdog of our story? They’re about to shift into overdrive. The Gold Rush has barely begun. The race for the cure is just getting started.

In Part 2, we explore how Pharmasset teamed up with Gilead and bested big pharma in the race for a cure.

Estimated cumulative net sales from Hepatitis C since 2009; Source: 10-Ks and 10-Qs from Gilead, AbbVie, and Merck

Soul Searching

The history of Gilead reads like a roller coaster feels: lots of twists and turns but, in the end, satisfaction that you were along for the ride. The company was founded in June 1987 in Foster City, California, by Michael L. Riordan, a 29-year-old physician. Riordan brought an unusually tailored blend of clinical, technical, and financial training to the table. His academic credentials were stellar. Riordan held degrees in chemical engineering and biology from Washington University in St. Louis, an M.D. from Johns Hopkins University School of Medicine, and an MBA from Harvard Business School. Before founding Oligogen, Riordan spent a year working as an associate at Menlo Ventures. This brief stint gave him insider access to Silicon Valley venture networks, term-sheet mechanics, and syndicate building, which proved critical for early non-dilutive and dilutive fundraising. Beyond his background, Riordan was personally motivated by a bout of dengue fever he contracted while working in the Philippines. The lack of direct-acting antiviral treatments for tropical and systemic viral illnesses convinced him that targeting viral genetic replication was one of biopharma’s greatest unmet frontiers.

Gilead was initially named Oligogen to reflect its initial focus on antisense oligonucleotides (ASOs), short strands of synthetic DNA/RNA aimed at silencing disease-causing genes. From the beginning, Oligogen ran into branding limitations. According to Riordan, “Gilead Sciences” was actually his preferred name from the start. Riordan drew the name from the historical and biblical Balm of Gilead, a rare aromatic resin renowned throughout antiquity for its curative and healing properties. When incorporating the company in June 1987, he ran into a temporary trademark conflict with a California non-profit organization that was already operating under the name “Gilead”. As a placeholder while clearing the legal and trademark hurdles, he registered the company as Oligogen, a functional, clinical descriptor reflecting its early focus on synthetic oligonucleotides (oligo- + -gen). Once the trademark issues were cleared in early 1988, the company officially re-registered as Gilead Sciences, Inc.

In the late 1980s, antisense technology was emerging as a promising frontier in molecular biology. The core premise was that by synthesizing a specific short nucleotide sequence complementary to viral mRNA, the molecule would selectively bind to the target viral gene and prevent the host ribosome from translating it into functional viral proteins. To build immediate credibility around this complex chemistry, Riordan recruited a formidable scientific advisory board (SAB), which included:

  • Peter Dervan (Caltech), a pioneer in sequence-specific DNA-binding molecules.

  • Doug Melton (Harvard), a leading authority on molecular gene expression.

  • Harold Weintraub (Fred Hutchinson Cancer Research Center), a structural molecular biologist.

  • Walter Gilbert, a 1980 Nobel laureate in Chemistry for DNA sequencing techniques.

Leveraging his ties at Menlo Ventures, Riordan raised an initial $2 million seed round in 1988, allowing the young team to set up dedicated laboratory facilities in Foster City, California. In 1989, Gilead secured a $10 million Series A financing led by Menlo Ventures and a syndicate of private institutional investors, providing the runway needed to explore early chemistry. While Gilead’s early focus on ASOs generated significant academic excitement, the platform faced major physiological hurdles in the late 1980s and early 1990s. Unmodified oligonucleotides were large, negatively charged molecules that struggled to cross cell membranes effectively without rapidly degrading in plasma via endogenous nucleases. Furthermore, achieving therapeutic target concentrations inside virally infected cells without triggering systemic toxicity proved exceedingly difficult with first-generation antisense chemistry. Recognizing these delivery hurdles, Riordan and his scientific team executed a crucial strategic pivot.

Rather than remaining strictly anchored to antisense gene silencing, Gilead redirected its chemistry engine toward small-molecule nucleotide analogs. By modifying nucleosides and nucleotides to act as chain terminators for viral polymerases, Gilead bypassed early antisense delivery issues. This pivot laid the foundation for its subsequent in-licensing of two molecules, establishing the antiviral platform that ultimately built the company.

Subscribe now

Share

Going Viral

Having established a dedicated small-molecule nucleotide focus, Gilead possessed the scientific framework to recognize promising external assets that larger pharmaceutical companies had overlooked. This culminated in an international cross-border intellectual property deal centered around Acyclic Nucleoside Phosphonates (ANPs), a novel class of compounds discovered through a long-running research collaboration between two academic groups:

  • Antonín Holý at the Institute of Organic Chemistry and Biochemistry (IOCB) in Prague (Czechoslovakia/Czech Republic).

  • Erik De Clercq at the Rega Institute for Medical Research in Leuven (Belgium).

Holý and De Clercq had originally licensed their ANP patent portfolio to Bristol-Myers in the late 1980s. However, following the 1989 merger between Bristol-Myers and Squibb, the newly formed Bristol-Myers Squibb (BMS) opted to discontinue the ANP program to focus on other internal assets. Per their contract, the commercial patent rights reverted to the academic institutes. Dr. John C. Martin, a seasoned medicinal chemist who had been leading antiviral chemistry at BMS, strongly believed in the therapeutic potential of the ANP platform. In 1990, Martin left BMS to join Gilead as Vice President of Research (later becoming CEO in 1996). Martin convinced Gilead’s executive team to aggressively pursue the ANP portfolio. In 1991-1992, Gilead entered into an exclusive, global licensing agreement with IOCB Prague and the Rega Institute for the ANP compound library.

The first major validation of this platform deal came with cidofovir, a broad-spectrum antiviral that targets DNA viruses. In 1996, the FDA approved cidofovir under the brand name Vistide for Cytomegalovirus (CMV) retinitis in patients with late-stage AIDS. While Vistide was never a commercial blockbuster due to renal toxicity risks requiring intravenous co-administration with probenecid, it provided Gilead with its first independent FDA approval and commercial product, validating the ANP chemistry platform and building out its clinical trial and regulatory infrastructure.

Among the licensed compounds was PMPA, later named tenofovir. Unmodified tenofovir was poorly absorbed in the human gastrointestinal tract. Gilead’s internal chemists solved this by designing an ester prodrug called Tenofovir Disoproxil Fumarate (TDF), which masked the negative charges of the molecule to permit intestinal absorption before converting back to active tenofovir in the plasma. In 2001, TDF received FDA approval for HIV treatment under the name Viread, offering high antiviral potency with a low risk of initial resistance. Two years later in 2004, Gilead combined TDF with emtricitabine (FTC) to create Truvada, establishing a standard two-drug nucleoside backbone for HIV treatment globally. In 2012, Truvada made history by becoming the first FDA-approved medication for HIV Pre-Exposure Prophylaxis (PrEP), opening an entirely new market in preventative medicine.

Chemical structure of tenofovir disoproxil prodrug, with labile ester groups highlighted in purple; Source: Anypodetos, CC0, via Wikimedia Commons

Subscribe now

Share

An Attractive Pharma-ssetup

By 2011, Gilead’s leadership, under CEO John C. Martin, faced two impending strategic pressures. While Gilead’s HIV franchise (anchored by Viread and Truvada) dominated the antiretroviral landscape, the executive team recognized that its primary patent protections would begin expiring in the late 2010s. Gilead would need to build a new franchise to diversify their pipeline and, in doing so, they set their sights on Hepatitis C.

What made Hepatitis C an attractive opportunity? The standard of care for chronic Hepatitis C virus involved 24 to 48 weeks of pegylated interferon plus ribavirin. Interferon injections caused severe flu-like side effects, depression, and anemia, with cure rates (Sustained Virologic Response, or SVR) hovering around 50%. While early direct-acting antivirals like Vertex’s Incivek (telaprevir) hit the market in 2011, they still required co-administration with interferon. Gilead recognized that the “holy grail” of Hepatitis C therapy was an all-oral, interferon-free regimen with short duration, high barrier to resistance, and broad pan-genotypic coverage. For the next decade, this would be Gilead’s North Star.

Evolution of Hepatitis C cure rates in the Interferon & Protease Eras

Gilead didn’t scale the Hepatitis C cure rate alone. Their secret weapon was Pharmasset, a company that went from a niche, university-spun research outfit to the creator of a medical revolution, culminating in the largest and most lucrative single-asset acquisition in pharmaceutical history. Pharmasset was incorporated in 1998 in Atlanta, Georgia. It was founded as an Emory University spinout by two prominent medicinal chemists and virology researchers:

  • Dr. Raymond F. Schinazi: A pioneer in antiviral drug discovery who had previously co-founded Triangle Pharmaceuticals (later acquired by Gilead) and played a major role in the discovery of key HIV drugs, including 3TC (lamivudine) and FTC (emtricitabine).

  • Dr. Dennis C. Liotta: Professor of Chemistry at Emory and co-inventor of several foundational HIV antiretrovirals.

The company’s name was a compound of “Pharmaceutical Assets.” Its core mission was to leverage advanced nucleoside and nucleotide chemistry to design direct-acting antivirals for chronic, life-threatening diseases. Like Gilead, Pharmasset focused heavily on synthetic organic chemistry, specifically modifying nucleosides to act as chain terminators for viral RNA/DNA polymerases. While Pharmasset initially evaluated several compounds for HIV and Hepatitis B, its clinical destiny was altered by its focus on Hepatitis C.

In the mid-2000s, Pharmasset relocated its corporate headquarters to Princeton, New Jersey, while maintaining research operations in Georgia. It completed an initial public offering (IPO) on the NASDAQ in April 2007, raising approximately $45 million to fund its clinical pipeline. Shortly thereafter in the late 2000s, Pharmasset’s chemistry team, led by Dr. Michael J. Sofia (Vice President of Chemistry), synthesized a novel uracil nucleotide analog designated PSI-7977 (sofosbuvir). Before entering human trials, PSI-7977 demonstrated three key differentiators in vitro:

  • Novel target with pan-genotypic coverage: Sofosbuvir targeted the highly conserved active site of the HCV NS5B RNA-dependent RNA polymerase. Since the target site was essential for viral replication across all HCV genotypes, the compound possessed broad pan-genotypic activity (Genotypes 1-6).

  • Higher Barrier to Resistance: Unlike first-generation Hepatitis C protease inhibitors, viruses could not easily mutate around sofosbuvir without sacrificing their own fitness to replicate.

  • Low Potential for Mitochondrial Toxicity: Unlike earlier generations of nucleoside antivirals, which inhibited human mitochondrial DNA polymerase gamma and caused severe lactic acidosis or neuropathy, sofosbuvir showed no significant inhibition of human mitochondrial DNA polymerase gamma.

Phase 1 dose-escalation data released between 2009 and 2010 showed that once-daily oral administration produced rapid, multi-log drops in viral RNA within days, confirming potent human liver target engagement. This set the stage for two Phase 2 trials that would forever change the Hepatitis C treatment landscape.

The Phase 2b PROTON trial was a randomized, double-blind, placebo-controlled trial designed to establish dose selection, resistance profiles, and whether adding PSI-7977 could safely shorten standard treatment regimens in treatment-naïve patients infected predominantly with Genotype 1 Hepatitis C, the hardest-to-treat and most common variant in Western countries. By Week 4, over 90% of patients receiving the 400 mg daily dose achieved a Rapid Virologic Response (RVR, defined as undetectable serum HCV RNA). The 400 mg dose yielded Sustained Virologic Response rates (SVR12 / SVR24) ranging between 91% and 98%. Crucially, once treatment ceased, no treatment-emergent primary active-site resistance mutations (such as S282T) were detected during the 12-week dosing window. Unlike first-generation protease inhibitors (telaprevir, boceprevir), no primary active-site resistance mutations (such as S282T) emerged in patients during the 12-week dosing window.

Rapid onset of Hepatitis C clearance observed after treatment with PSI-7977 (sofosbuvir) in combination with peginterferon + ribavirin in Phase 2b PROTON trial; Source: Pharmasset EASL 2011 abstract, Figure 1

If PROTON showed that sofosbuvir was a potent add-on to existing therapy, ELECTRON was the disruptive trial that rendered injectable interferon obsolete. Conducted primarily in New Zealand, ELECTRON was an open-label Phase 2a study designed to systematically dismantle background therapy components. Pharmasset researchers began removing peginterferon from the treatment regimen entirely, testing whether an all-oral regimen of sofosbuvir (400 mg QD) plus oral ribavirin (RBV) for 12 weeks could cure patients. In treatment-naïve patients with Hepatitis C Genotypes 2 and 3 receiving sofosbuvir plus ribavirin for 12 weeks, 100% (10 out of 10 patients) achieved SVR12. This was the second time in medical history that chronic Hepatitis C was cured using an all-oral, interferon-free regimen (it’s often misremembered as the first, but we’ll get to that later). By stripping out interferon, the grueling systemic side effects that had defined Hepatitis C therapy for two decades disappeared (severe depression, debilitating flu-like symptoms, bone marrow suppression, and hair loss).

Gilead’s CEO, John C. Martin, recognized that Pharmasset held the “holy grail” of Hepatitis C that he had been looking for. However, Pharmasset’s Phase 2 success made it a target for every major player in infectious disease, including Roche, Bristol-Myers Squibb, and Merck. To secure unpartnered global rights to PSI-7977, Gilead moved with extreme speed. On November 21, 2011, Gilead announced a definitive agreement to acquire Pharmasset for at approximately $11 billion, representing an 89% premium to the company’s closing price on the prior Friday.

Subscribe now

Share

Striking Gold

While Gilead had gained conviction in Pharmasset, biotech analysts were perplexed by the purchase. They argued that Gilead was paying over a third of its own market capitalization ($11 billion out of $33 billion) for a pre-commercial company with no significant product revenues and a drug candidate that had not yet completed Phase 3 registration studies. Critics questioned whether Pharmasset’s small Phase 2 sample sizes (e.g., 10 out of 10 patients in key ELECTRON arms) would hold up across thousands of diverse patients in global Phase 3 trials.

Gilead answered by using its clinical, regulatory, and industrial footprint to run a number of global Phase 3 registration programs (NEUTRINO, FISSION, POSITRON, and FUSION). This sweeping clinical suite enrolled thousands of diverse chronic Hepatitis C virus patients across multiple genotypes, treatment backgrounds, and disease severities. Within months, the results rolled in:

  • Phase 3 NEUTRINO trial (treatment naïve, genotypes 1, 4, 5, 6): This trial evaluated sofosbuvir + peginterferon + ribavirin (SOF+Peg-IFN+RBV) for 12 weeks in treatment-naïve patients. The combination achieved an unprecedented 90% SVR12 cure rate, proving that adding sofosbuvir allowed Genotype 1 patients to cut interferon duration down from 48 weeks to just 12 weeks (see table below).

    SVR12 for Treatment-Naïve Subjects with Genotype 1 or 4 Hepatitis C in Phase 3 NEUTRINO trial; Source: Sovaldi label, Table 12

  • Phase 3 FISSION trial (treatment naïve, genotypes 2 & 3): This was a 24-week head-to-head non-inferiority study comparing 12 weeks of all-oral sofosbuvir + ribavirin against the standard 24 weeks of peginterferon + ribavirin. Sofosbuvir + ribavirin had higher & more rapid virologic remission rates with less frequent relapses compared to peginterferon while dramatically reducing systemic side effects (see table below).

    SVR12 in Treatment-Naïve Subjects with Genotype 2 Hepatitis C in Phase 3 FISSION trial, Source: Sovaldi label, Table 14

  • Phase 3 POSITRON trial (interferon-ineligible/intolerant, genotypes 2 & 3): This trial evaluated 12 weeks of all-oral sofosbuvir + ribavirin versus placebo in patients who could not take interferon due to psychiatric, cardiac, or autoimmune contraindications. It demonstrated a 78% overall SVR12 (and 93% in Genotype 2) with virtually no dropouts (see table below).

    SVR12 in Interferon Intolerant, Ineligible or Unwilling Subjects with Genotype 2 Hepatitis C in Phase 3 POSITRON trial; Source: Sovaldi label, Table 16

  • Phase 3 FUSION trial (treatment-experienced, genotypes 2 & 3): This trial assessed 12 versus 16 weeks of sofosbuvir + ribavirin in patients who had failed prior interferon regimens, establishing that longer treatment durations improved cure rates in hard-to-treat subgroups. While effective, the 16-week regimen didn’t meaningfully improve efficacy over the 12-week regimen (see table below).

SVR12 in Previous Interferon Relapsers and Nonresponders with Genotype 2 Hepatitis C in Phase 3 FUSION trial; Source: Sovaldi label, Table 18

As if these stellar results weren’t enough, Gilead submitted top-line data from two supplementary Phase 3 studies to optimize labeling during the formal FDA review process in mid-2013:

  • Phase 3 VALENCE trial (treatment naïve & treatment-experienced, genotypes 2 & 3): This trial established that extending all-oral sofosbuvir + ribavirin treatment to 24 weeks boosted SVR12 cure rates, even for hard-to-treat Genotype 3 patients who failed to achieve viral remission with peginterferon (see table below).

    SVR12 Rates for Selected Subgroups by Genotype in Subjects with Genotype 2 or 3 Hepatitis C in Phase 3 VALENCE trial; Source: Sovaldi label, Table 21

  • Phase 3 PHOTON-1 trial: This trial confirmed the safety and efficacy of sofosbuvir + ribavirin in patients co-infected with HIV-1 and Hepatitis C (HCV).

SVR12 in Treatment-Naïve or Treatment-Experienced Subjects with Genotype 1, 2, or 3 HCV in Phase 3 PHOTON-1 trial; Source: Sovaldi label, Table 22

On October 25, 2013, the FDA Antiviral Drugs Advisory Committee voted unanimously (20-0) to recommend approval for Hepatitis C Genotypes 1-4. Less than two months later on December 6, 2013, FDA granted full regulatory approval for sofosbuvir under the commercial name Sovaldi as a foundational component of combination therapy across four major viral genotypes:

  • Genotypes 1 & 4: 12 weeks of Sovaldi + peginterferon + Ribavirin.

  • Genotype 2: 12 weeks of all-oral Sovaldi + Ribavirin, the first FDA approved interferon-free approved regimen

  • Genotype 3: 24 weeks of all-oral Sovaldi + Ribavirin

In its first full commercial year (2014), Sovaldi recorded $10.3 billion in global sales, becoming the fastest commercial drug launch in pharmaceutical history and almost fully recuperating Gilead’s $11 billion purchase price of Pharmasset within the first 12 months of Sovaldi’s launch. It turned the critics into cheerleaders.

Subscribe now

Share

Harvesting Nuggets

While Sovaldi (sofosbuvir monotherapy) broke ground as a potent nucleotide backbone, it still required co-administration with ribavirin or peginterferon for many patient groups (genotypes 1 & 4). Gilead leveraged their expertise in HIV drug development to build on Sovaldi’s foundation.

Ledipasvir, a NS5A protease inhibitor, was optimized by Gilead chemists led by John O. Link and colleagues to specifically pair with once-daily sofosbuvir. It had picomolar efficacy, demonstrating extreme potency in cellular replicon models (EC50 31 pM against Hepatitis C genotype 1a). It also matched the half-life of Sovaldi (plasma elimination half-life of 47 hours), potentially supporting coformulation with sofosbuvir in a once-daily pill. While ledipasvir monotherapy retained a liability seen with prior NS5A protease inhibitors (resistance mutations), combining ledipasvir with sofosbuvir’s high resistance barrier protected both drugs from treatment failure. Gilead evaluated the ledipasvir/sofosbuvir fixed-dose combination across three major global registration studies known as the ION program, enrolling over 1,900 patients with chronic Genotype 1 Hepatitis C. The results raised the bar even higher:

  • Phase 3 ION-1 trial (treatment-naïve, genotype 1): This trial evaluated 12 or 24 weeks of ledipasvir/sofosbuvir with or without ribavirin in 865 patients, including those with compensated cirrhosis. The combo pill achieved 97% to 99% SVR12 (cure) rates across all dosing arms and adding ribavirin provided no extra benefit, proving that ribavirin could be completely removed from Genotype 1 treatment.

  • Phase 3 ION-2 trial (treatment-experienced, genotype 1): This trial evaluated enrolled 440 patients who had failed prior regimens, including those who failed early protease-inhibitor therapies (telaprevir/boceprevir). The combo pill achieved 94% to 99% SVR12 rates. Extending treatment to 24 weeks cleared the virus even in patients with underlying liver cirrhosis who had failed previous treatments.

  • Phase 3 ION-3 trial (treatment-naïve, genotype 1, 8-week short-course): This trial evaluated non-cirrhotic, treatment-naïve patients receiving ledipasvir/sofosbuvir for 8 weeks versus 12 weeks. The 8-week arm achieved a 94% SVR12 rate, matching the 12-week regimen. This allowed a substantial portion of non-cirrhotic patients to be cured with just two months of once-daily therapy.

Gilead filed its New Drug Application (NDA) for the fixed-dose combination tablet in February 2014. The FDA granted it Priority Review and Breakthrough Therapy designation. On October 10, 2014, the FDA approved Harvoni (ledipasvir 90mg / sofosbuvir 400mg) for Genotype 1 chronic Hepatitis C. It was the first single-tablet, all-oral, interferon- and ribavirin-free treatment cleared by the FDA.

Harvoni generated $13.8 billion in revenue in 2015 alone. Combined with Sovaldi, Gilead’s total Hepatitis C franchise sales topped $19.1 billion in a single year, turning Gilead into one of the most profitable healthcare companies in the world. While the medicine’s high price tag ignited international debates over healthcare budgets, the ability to cure a chronic liver disease in 8 to 12 weeks transformed hepatology, sharply reducing long-term rates of liver transplantations and hepatocellular carcinoma globally. In less than four short years since the approval of Merck’s Victrelis on May 13, 2011 (the first approved NS3/4A protease inhibitor), Pharmasset & Gilead reduced the Hepatitis C treatment burden from five pills a day + once weekly injection to a single pill a day, and increased the Hepatitis C cure rate from from 66% to 99%. As Gilead/Pharmasset’s Hepatitis C empire rose, Merck/Schering-Plough’s peginterferon and protease monotherapy empire dwindled (see below). Merck wouldn’t sit idle for long. Nor would two other slumbering giants.

Estimated annualized revenue run rates for Gilead (top) and Merck (bottom) Hepatitis C franchises from 2009 to 2015; Source: 10-Ks and 10-Qs from Gilead and Merck

Subscribe now

Share

Awaken the Slumbering Giants

Big pharma companies seeking to disrupt Gilead’s Sovaldi & Harvoni Hepatitis C franchise

Even before the arrivals of Sovaldi and Harvoni, pharma giant Abbott had started dipping their toes into the Hepatitis C space. In December 2006, Abbott signed a global alliance with Enanta Pharmaceuticals to discover and develop Hepatitis C protease inhibitors. Abbott had extensive internal expertise in viral protease chemistry through its blockbuster HIV drugs Norvir (ritonavir) and Kaletra (lopinavir+ritonavir). Abbott believed that their ritonavir booster might be able to give them an edge over the other players in the Protease Era (ritonavir extend the half-life of other drugs by blocking CYP3A4). Abbot’s collaboration with Enanta ultimately yielded paritaprevir (ABT-450), a NS3/4A protease inhibitor. Yet, Hepatitis C was capable of rapidly mutating around these two components. Furthermore, Pharmasset/Gilead’s newly minted Sovaldi significantly raised the bar, requiring regimens that were potent enough to obviate the need for peginterferon. How could Abbott remedy the situation?

The answer would come from another pharma company, Bristol Myers-Squibb (BMS). Yes, they walked away from Sovaldi, which Pharmasset picked up and developed, but that wouldn’t stop them from generating breakthroughs in Hepatitis C. In the mid-2000s, most regimens targeted Hepatitis C’s enzymatic machinery: the NS3/4A protease or the NS5B RNA polymerase. BMS scientists, led by Nicholas Meanwell, Min Gao, and colleagues, pursued a strategy to uncover new targets. They set up a phenotypic screen using the GT-1b subgenomic replicon in Huh-7 liver cells to look for any small molecule that blocked viral replication, regardless of its target. Out of over a million compounds screened, a single iminothiazolidinone chemotype showed selective, sub-micromolar activity against the Hepatitis C replicon (daclatasvir). Since the target was unknown, BMS scientists generated drug-resistant viral mutants. Sequencing the resistant replicon RNA revealed mutations exclusively mapped to NS5A, a phosphoprotein that lacked any intrinsic enzymatic cleavage or polymerase activity. It was later determined that NS5A functioned as a master structural scaffold, molecular hub, and regulatory switch that coordinated viral replication, virion assembly, and host immune evasion.

SDS-PAGE identifying Hepatitis C’s NS5A scaffold protein as the target of daclatasvir; Source: Gao et al. Nature (2010), Figure 2

The BMS team published their landmark discovery of the first ever Hepatitis C NS5A scaffold inhibitor in the Nature in 2010. The paper revealed that daclatasvir (BMS-790052) possessed lower half-maximal effective concentration values than any antiviral drug ever reported at the time (EC50 9 pM) and demonstrated broad pan-genotypic coverage across all Hepatitis C Genotypes (1-6) in cell culture models. BMS then tested daclatasvir in combination with an investigational protease inhibitor, asunaprevir (BMS-650032), in Genotype 1 patients who had previously failed interferon therapy. In the all-oral dual DAA group, 4 out of 11 patients (36%) overall achieved SVR12/SVR48. Crucially, 2 out of 2 patients (100%) infected with HCV genotype 1b achieved a complete cure without ever receiving a single injection of interferon. These data were presented at AASLD in November 2011, making it the first evidence in medical history that Hepatitis C could be completely cured with a combination of oral direct-acting antivirals (DAAs) without interferon. Yes, they beat out the interferon-free cohort in Pharmasset’s ELECTRON trial by 4 months (this was first presented at EASL in April 2012; their earlier May 2010 press release only included interferon combo data but is often misremembered to be the first). BMS’ results were later published in the New England Journal of Medicine in 2012.

However, BMS’ combo would never see the light of day in the United States due to numerous commercial dynamics. BMS initially filed with the FDA to approve Daklinza (daclatasvir) in combination with Sovaldi (Gilead’s drug) because BMS’ drug asunaprevir performed poorly in Genotype 1a (rapid emergence of viral resistance variants). However, Gilead chose not to pursue a joint fixed-dose single pill with BMS because they were developing their own internal NS5A inhibitor (ledipasvir) based on the daclatasvir structure to create Harvoni (approved on October 10, 2014). The FDA requested more standalone U.S. clinical data for Daklinza, pushing its U.S. approval date as a monotherapy to July 24, 2015 (specifically for Genotype 3).

BMS’ discovery inspired Abbott to get back on the horse. They created their own NS5A scaffold inhibitor based on the daclatasvir structure (ombitasvir), added it to their NS3/4A protease inhibitor (paritaprevir) + ritonatir booster, and added a non-nucleoside NS5B polymerase inhibitor (dasabuvir) for good measure. Together, these four ingredients simultaneously hit the Hepatitis C polymerase, protease, scaffolding protein with ritonavir extending half-life. AbbVie (a therapeutics-focused company spun out of Abbott in 2011) evaluated the four-drug regimen in over 2,300 patients across six major global Phase 3 clinical trials, proving that a multi-drug non-nucleoside regimen could match Gilead’s cure rates:

  • SAPPHIRE-I & SAPPHIRE-II: Evaluated treatment-naïve and treatment-experienced Genotype 1 patients receiving the four-drug regimen plus ribavirin for 12 weeks. The studies demonstrated 95% to 96% SVR12 rates.

  • PEARL-III & PEARL-IV: Designed to evaluate whether ribavirin was strictly necessary. In Genotype 1b patients (PEARL-III), the four-drug regimen achieved a 99.5% cure rate without ribavirin. In Genotype 1a patients (PEARL-IV), cure rates were higher with ribavirin (97%) than without it (90%), establishing sub-type specific dosing recommendations.

  • TURQUOISE-II: The first major Phase 3 study dedicated exclusively to challenging patients with compensated liver cirrhosis (Child-Pugh A). Treating cirrhotic Genotype 1 patients with the four-drug regimen plus ribavirin for 12 to 24 weeks yielded 92% to 96% SVR12 rates.

On December 19, 2014, the FDA approved Viekira Pak for chronic Genotype 1 Hepatitis C under Priority Review and Breakthrough Therapy designation, just two months after Gilead’s Harvoni approval. They were neck-and-neck, but big pharma AbbVie had more weight to throw around. Just days after approval, AbbVie struck an exclusive distribution deal with Express Scripts, the largest pharmacy benefit manager (PBM) in the U.S. at the time. Express Scripts removed Gilead’s Harvoni and Sovaldi from its national formulary for Genotype 1 patients in exchange for a significant, undisclosed discount on Viekira Pak. Despite the aggressive pricing deal, Viekira Pak faced commercial headwinds due to its higher pill burden (4 to 6 pills daily versus Harvoni‘s 1 pill daily), the need for co-administered ribavirin in GT1a patients, and drug-drug interaction risks caused by the ritonavir CYP3A4 booster. In October 2015, the FDA issued a safety communication warning that Viekira Pak could cause serious liver injury or hepatic decompensation, primarily in patients with underlying moderate-to-severe hepatic impairment (Child-Pugh B and C). The label was updated to contraindicate its use in patients with decompensated liver disease.

Slumping interferon & protease sales shook incumbent Merck out of its slumber. Gilead’s Harvoni and AbbVie’s Viekira Pak were nipping at Merck’s heals and they would respond with a strategy focused on second-generation molecule design, subpopulation targeting (specifically chronic kidney disease), and disruptive commercial pricing. Merck’s first-generation protease inhibitor, Victrelis (boceprevir), suffered from low genetic barriers to resistance and severe side effect profiles. Merck medicinal chemists synthesized a novel macrocyclic scaffold constrained between the P2 and P4 positions. Grazoprevir was engineered to retain binding potency against common baseline resistance-associated variants (RAVs) in the NS3/4A protease, such as the R155K and D168V mutations that caused treatment failure in earlier drugs. Building on the symmetrical C2-dimeric template pioneered by BMS with daclatasvir, Merck optimized elbasvir (NS5A scaffold inhibitor) to achieve low picomolar potency (EC50 0.2-3 pM) across multiple Hepatitis C genotypes. Recognizing that Gilead’s sofosbuvir-based regimens dominated the broad Genotype 1 market, Merck designed its clinical trial architecture (the C-WORTHy Phase 2 and C-EDGE Phase 3 programs) to evaluate the two-drug combo in hard-to-treat patient niches:

  • C-SURFER (Severe Renal Impairment): Merck specifically targeted patients with Stage 4 or Stage 5 chronic kidney disease (CKD), including those on hemodialysis. Since Gilead’s Sovaldi is renally cleared and was initially contraindicated in patients with severe renal impairment, the two-drug combo (which is eliminated hepatically) demonstrated a 94% SVR12 cure rate in CKD patients, earning an FDA Breakthrough Therapy designation.

  • C-EDGE TN & TE (Genotype 1 & 4): Evaluated treatment-naïve and treatment-experienced Genotype 1 and Genotype 4 patients (with or without compensated cirrhosis and HIV co-infection), achieving 95% to 97% cure rates.

On January 28, 2016, the US FDA approved Zepatier (elbasvir + grazoprevir FDC) for chronic HCV Genotype 1 and 4 infection. When Zepatier entered the market in 2016, Gilead’s Harvoni carried a wholesale acquisition cost (WAC) of $94,500 per 12-week course, and AbbVie’s Viekira Pak was priced around $83,300. Merck executed a commercial price disruption by launching Zepatier at a WAC list price of $54,600, roughly 42% lower than Harvoni. This aggressive list price strategy forced pharmacy benefit managers (PBMs) and insurers to demand much higher rebates from Gilead and AbbVie, accelerating the steep price degradation across the global Hepatitis C market. This would get Merck back on the board, but Gilead had already planned their next chess move.

Subscribe now

Share

Take No Genotype Prisoners

By 2014, Gilead had already captured majority market share in Hepatitis C with Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir). However, even Harvoni had clear clinical limitations:

  • Genotype Restriction: Harvoni was optimized specifically for Genotypes 1, 4, 5, and 6. It performed poorly against Genotype 2 and especially Genotype 3, the second most common genotype globally, known for causing rapid liver fibrosis progression and steatosis.

  • Diagnostic Bottleneck: Doctors still had to run expensive, complex genotype blood tests before prescribing therapy. In low- and middle-income countries, the lack of lab infrastructure to determine Hepatitis C genotype was the single largest bottleneck to widespread treatment.

Gilead’s medicinal chemistry objective was clear: combine sofosbuvir (the high-barrier nucleotide anchor) with a next-generation, broad-spectrum NS5A scaffold inhibitor that improved on ledipasvir by potently hitting all six major Hepatitis C genotypes (Genotypes 1-6) in a once daily pill. To build a true pan-genotypic single tablet, Gilead needed an NS5A inhibitor that bound with low picomolar affinity to the Domain 1 binding pockets of NS5A across diverse viral sequences. Gilead chemists engineered velpatasvir (GS-5816), a novel symmetric, core-modified NS5A inhibitor. Velpatasvir achieved single-digit picomolar or sub-picomolar half-maximal effective concentrations (EC50) across genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a. Gilead overcome significant solubility and chemical stability challenges to co-formulate 400 mg of sofosbuvir with 100 mg of velpatasvir into a stable, once-daily fixed-dose combination pill. Gilead evaluated the two-drug combo pill across four landmark Phase 3 trials collectively known as the ASTRAL program, testing the drug in over 1,500 patients across all major genotypes and clinical stages. The ASTRAL data proved that a 12-week course of Gilead’s new two-drug combo pill alone (without interferon or ribavirin) cured 95-99% of patients across all genotypes, including those with compensated cirrhosis (see table below).

Summary of Gilead’s ASTRAL series of registrational Phase 3 clinical trials evaluating Epclusa

On June 28, 2016, the US FDA approved Epclusa as the first single-tablet regimen to treat all six major genotypes of chronic Hepatitis C, making it the first single-tablet, pan-genotypic cure. Epclusa effectively rendered routine Hepatitis C genotype testing obsolete, simplifying global treatment algorithms and unlocking mass-scale eradication programs. Since Epclusa achieved >95% cure rates regardless of genotype, public health authorities (including the WHO) could recommend a simplified “Test and Treat” strategy. Clinicians only needed a simple antibody/RNA confirmation of Hepatitis C before starting treatment. Furthermore, Gilead included velpatasvir in its royalty-free licensing agreements with generic manufacturers in India and other developing nations. This allowed low-income countries to manufacture generic Epclusa for under $100 per 12-week cure, enabling national eradication campaigns in countries with heavy disease burdens like Egypt, India, and Georgia. A little more than 1 year later on July 18, 2017, Gilead would add a protease inhibitor (voxilaprevir) to their polymerase-scaffold duo, with the approval of Vosevi. This served as a salvage treatment for the < 5% of patients who relapsed on Epclusa with both the NS5A and NS3 protease escape mutations. Since Epclusa cured almost everyone on the first try, the addressable market for a salvage therapy like Vosevi was relatively small.

Evolution of Hepatitis C cure rates in the Direct Acting Antiviral (DAA) Era

One month later, AbbVie ditched Viekira Pak in favor of their newly approved pan-genotypic scaffold-protease combo Mavyret (approved on July 18, 2017) to compete with Epclusa (8-week cure compared to Gilead’s 12-week standard). AbbVie launched Mavyret at a wholesale list price of $26,400 for an 8-week course, a fraction of Gilead’s $74,000-94,000 list prices. Mavyret quickly captured over 40-50% of the US Hepatitis C market within months of launch, splitting the market with Gilead’s Epclusa (although the bulk of the value had already been captured & the bulk of warehoused addressable patients had already been cured by Gilead’s Sovaldi, Harvoni, and Epclusa by the time AbbVie’s Mavyret came along; see graph below).

Dominance of Gilead’s Hepatitis C franchise compared that of Merck (incumbent) and AbbVie (only pharma that caught up to Gilead); Source: 10-Ks and 10-Qs from Gilead, AbbVie, and Merck
Zoomed in sales of Merck’s and AbbVie’s Hepatitis C franchises since 2009; Source: 10-Ks and 10-Qs from Gilead, AbbVie, and Merck
Estimated peak sales versus FDA approval date; Source: 10-Ks and 10-Qs from Gilead, AbbVie, and Merck

Subscribe now

Share

Spoils of Victory

The California Gold Rush began in January 1848 when James W. Marshall found gold at Sutter’s Mill. By 1849, tens of thousands of “Forty-Niners” had descended on the Sierra Nevada foothills. In the early years, gold was easily accessible in riverbeds and loose gravel. By 1852-1853, simple placer gold was largely picked clean. Individual prospectors with pan and shovel could no longer make a living. To reach the gold trapped deep in quartz veins or under hillside debris, extraction required massive capital, heavy machinery, and large crews. Independent miners were forced to either become wage-earning employees for large mining corporations or abandon mining entirely. As gold yields per person plummeted, many stayed to build permanent lives. California’s rapid population growth allowed it to achieve U.S. statehood in 1850. Former prospectors transitioned into farming, ranching, timber, and trade, establishing California as an agricultural powerhouse rather than a transient mining camp.

The winding down of biopharmaceutical R&D for Hepatitis C following the approvals of Epclusa (Gilead), Vosevi (Gilead), and Mavyret (AbbVie) follows a similar dynamic. Pharma companies essentially abandoned active discovery programs not because they failed, but because they achieved absolute clinical and commercial saturation. By 2017, the scientific problems had been solved, and the underlying economics of the market collapsed. The biotech industry extracted every nugget of gold and found that there was none left (see graph below). Much of the winnings were parlayed into the next wave of breakthroughs in oncology (immuno-oncology, ADCs, CAR-T), rare disease, and gene therapies.

Thus ends the story of Hepatitis C: in total victory.

As for Gilead, our story’s underdog, their Hepatitis C victory transformed them into a big pharma. True to the George Merck adage, “medicine is for people […] if we have remembered that, [profits] have never failed to appear”.

Evolution of Hepatitis C cure rates across all three Eras (Interferon, Protease, DAA)
Full Hepatitis C landscape ranked by FDA approval date (oldest at the top, newest at the bottom)
Death rate from acute hepatitis, measured as the number of deaths per 100,000 individuals, with landmark events in the therapeutic landscape; Source: Our World in Data

Subscribe now

Share

Love biotech? Check out Biotech Readout’s full content library, or navigate directly to a segment that interests you:

Biotech Readout is a reader-supported publication. To receive new posts and support my work, consider becoming a free subscriber.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

]]><![CDATA[Obesity drug treats alcoholism, a China-originated drug pursues $30 billion market, and more]]>https://biotechreadout.xyz/p/obesity-drug-treats-alcoholism-ahttps://biotechreadout.xyz/p/obesity-drug-treats-alcoholism-aFri, 31 Jul 2026 21:18:05 GMTDisclaimer: This newsletter is for educational and informational purposes only and does not constitute medical, investment, or financial advice, nor does it establish a provider-patient relationship. Content may include forward-looking statements and discussions of investigational therapeutic candidates that are not FDA/EMA approved; their safety and efficacy remain unestablished and clinical outcomes are unpredictable. While we strive for accuracy, all information is provided as is without guarantees. As of the date of publication, the author holds no direct equity positions in the specific companies mentioned in this issue nor receives third-party compensation for this coverage. Please find a complete version of our disclaimers at the bottom of this article and on our About page.

Press ⬇️ to go down to a section and ⬆️ to go back up to the Table of Contents

Table of Contents

This week, we discuss:

  • China Biotech

    • Financing Activity for China versus Rest of World + Caldera-Synlogic Merger ⬇️

  • Acquisitions ⬇️

    • Argenx to Acquire Forte Biosciences

  • Approvals

    • Otsuka - Simtriyo (SNDRI) / Approved (ADHD) ⬇️

    • Outlook - Lytenava (anti-VEGF mAb) / Approved (nAMD) ⬇️

  • Clinical Trial Data

    • Altimmune - Pemvidutide (GLP-1 x glucagon dual agonist) / Phase 2 (alcohol use disorder) ⬇️

    • Atea Pharma - Bemnifosbuvir/Ruzasvir (polymerase inhibitor + NS5A inhibitor) / Phase 3 (Hepatitis C) ⬇️

    • Pfizer - Litfulo (JAK3 x TEC inhibitor) / Phase 3 (vitiligo) ⬇️

    • Biogen - BIIB091 (peripheral BTK inhibitor) / Phase 2 (RRMS) ⬇️

    • AstraZeneca - Sonesitatug vedotin (Claudin 18.2 ADC) / Phase 3 (claudin 18.2+ gastric cancer) ⬇️

China Biotech

Wondering why we discuss China Biotech every week? Tap here to learn more.

Financing Activity for China versus Rest of World + Caldera-Synlogic Merger

for the week ending July 31, 2026

China-related financing shown above (red) includes the merger agreement of Caldera Therapeutics and Synlogic, Inc. announced on July 27, 2026. While Caldera is domiciled in the U.S., their lead asset CLD-423 (an investigational TL1A x IL-23p19 bsAb for ulcerative colitis and Crohn’s disease) originated in China, where it was discovered and engineered by Qyuns Therapeutics Co., Ltd. As such, we categorize the $278 million private placement that will accompany the merger as a financing mechanism for a China-originated asset.

The asset itself appears to be a “bio-better” of approved anti-IL23 blockbusters, namely AbbVie’s Skyrizi and J&J’s Tremfya and Stelara which have an annualized revenue run rates of $17.9 billion, $8.2 billion, and $3 billion respectively, based on recent quarterly company filings. CLD-423 stacks a second mechanism, TL1A, which was most authoritatively validated by Merck / Prometheus’ Phase 2 ARTEMIS-UC for tulisokibart, which demonstrated statistically significant superiority over placebo in inducing clinical remission in patients with moderately to severely active ulcerative colitis (26% vs 1% in Cohort 1, see graph below). At least three other companies are developing a TL1A x IL23p19 mAb including Xencor, Earendil, and Bionyra. At least two companies have stacked a third mechanism, targeting integrin α4ß7, including Sanofi (an FDC licensed from Earendil) and Attovia.

Primary and Secondary End Points at Week 12 in Cohort 1 of Phase 2 ARTEMIS-UC trial; Source: Sands et al. NEJM (2024), Figure 1

Link to top ⬆️

Acquisitions

Link to top ⬆️

Approvals

Otsuka - Simtriyo (SNDRI) / Approved (ADHD)

On July 24, 2026, the U.S. FDA approved Simtriyo (centanafadine), a once-daily extended-release capsule developed by Otsuka Pharmaceutical, for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients aged 6 years and older (weighing at least 20 kg). Simtriyo is the first FDA-approved norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) for ADHD. Unlike traditional stimulants which focus heavily on rapid dopamine/norepinephrine release or selective dual inhibition, centanafadine simultaneously blocks the reuptake of all three monoamine neurotransmitters:

  • Norepinephrine transporter (NET): Drives focus and executive function.

  • Dopamine transporter (DAT): Enhances motivation, task engagement, and reward processing.

  • Serotonin transporter (SERT): Helps regulate mood, impulse control, and emotional dysregulation.

The approval was supported by data from four pivotal Phase 3 trials spanning adult, adolescent (13-17 years old), and pediatric populations (6-12 years old). Across all four trials, centanafadine established a consistent profile: high-dose regimens consistently delivered rapid-onset (Week 1) efficacy and robust executive function gains across age groups, while lower-dose cohorts in younger populations fell short of statistical significance, establishing a well-defined therapeutic window for the first-in-class triple reuptake inhibitor.

LS Mean Change from Baseline in AISRS Total Score in Adults with ADHD; Source: Simtriyo label, Figure 3

Since centanafadine engages central dopaminergic pathways, the FDA classified it as a central nervous system (CNS) stimulant, triggering mandatory controlled-substance scheduling by the U.S. Drug Enforcement Administration (DEA). Otsuka plans to launch Simtriyo later in 2026 following the DEA’s official scheduling decision.

Sources: Otsuka press release, Simtriyo label

Link to top ⬆️

Outlook - Lytenava (anti-VEGF mAb) / Approved (nAMD)

On July 24, 2026, the FDA approved Lytenava (bevacizumab-vikg), developed by Outlook Therapeutics, for the treatment of neovascular (wet) age-related macular degeneration (nAMD). Lytenava is the first and only FDA-approved, cGMP-manufactured ophthalmic formulation of bevacizumab specifically engineered and labeled for intravitreal injection into the eye. As an innovator biologic, Lytenava is expected to be eligible for up to 12 years of Reference Product Exclusivity in the U.S. under the Biologics Price Competition and Innovation Act (BPCIA). By blocking the interaction between VEGF-A and its receptors (VEGFR-1 and VEGFR-2) on endothelial cells, Lytenava inhibits abnormal choroidal neovascularization (blood vessel proliferation) and vascular leakage/permeability, suppressing the drivers of rapid vision loss in wet AMD.

The clinical evaluation program for Lytenava (ONS-5010) encompassed multiple clinical trials evaluating efficacy, safety, and pharmacokinetics. The primary driver of efficacy was NORSE TWO, a randomized, active-controlled Phase 3 trial (n = 228) comparing monthly intravitreal injections of ONS-5010 against a labeled regimen of Lucentis (ranibizumab) over 12 months. At Month 11, 41.7% of patients in the Lytenava (ONS-5010) intent-to-treat arm gained 15 or more Best Corrected Visual Acuity (BCVA) letters (about 3 lines on an ETDRS eye chart), compared to 23.1% in the ranibizumab control group (p = 0.0052). Patients treated with Lytenava achieved a mean BCVA improvement of +11.2 letters from baseline versus +5.8 letters for the control group (p = 0.0043). NORSE ONE & THREE trials provided initial clinical proof-of-concept and broad safety evaluation across wet AMD and other retinal diseases. Across these studies, ONS-5010 demonstrated a safety profile consistent with historical intravitreal anti-VEGF agents, with low rates of ocular inflammation. NORSE EIGHT was a non-inferiority safety and efficacy study performed under a Special Protocol Assessment (SPA) to provide additional confirmatory exposure and safety data. In clinical studies, Lytenava was generally well-tolerated. Serious ocular adverse events were rare (<1%) and rates of intraocular inflammation were minimal. Transient increases in intraocular pressure (IOP) may occur post-injection. Consistent with the anti-VEGF class label, there is a low potential risk of arterial thromboembolic events (ATEs).

Mean Change in Best Corrected Visual Acuity (BCVA) from Baseline in Phase 3 NORSE TWO trial; Source: Lytenava label, Figure 1

Sources: Outlook press release, Lytenava label

Link to top ⬆️

Clinical Trial Data

Altimmune - Pemvidutide (GLP-1 x glucagon dual agonist) / Phase 2 (alcohol use disorder)

On July 28, 2026, Altimmune announced positive topline results from its Phase 2 RECLAIM trial, establishing clinical proof-of-concept for its dual GLP-1/glucagon receptor agonist, pemvidutide, in treating moderate-to-severe alcohol use disorder (AUD). Technically, a team out of the Mental Health Center Copenhagen in Copenhagen, Denmark produced the first clinical evidence that incretin-based weight loss drugs might be effective in alcohol use disorder (we covered that here), but Altimmune’s results are the first of its kind sponsored by a biotech in an effort to bring a specific medicine to patients.

Alcohol use disorder (AUD) stems from chronic ethanol-driven neuroadaptations that disrupt GABA/glutamate balance and hypersensitize mesolimbic dopamine pathways, causing compulsive craving, altered reward processing, and severe withdrawal; current treatment combines behavioral therapies (such as CBT and 12-step support) with FDA-approved drugs like naltrexone, acamprosate, and disulfiram, alongside off-label options like gabapentin. Pemvidutide aims to address these neuropathological and systemic challenges through a balanced 1:1 GLP-1/glucagon dual receptor agonist mechanism. Its GLP-1 component modulates dopaminergic signaling within the ventral tegmental area and nucleus accumbens to dampen reward feedback and curb compulsive drinking, while its glucagon component boosts hepatic energy expenditure and lipid clearance to combat the liver metabolic dysfunction and fibrosis characteristic of alcohol-associated liver disease (ALD).

The Phase 2 RECLAIM trial enrolled 100 adults with moderate-to-severe Alcohol Use Disorder and a BMI ≥25 kg/m². Patients were randomized 1:1 to once-weekly subcutaneous pemvidutide 2.4 mg or placebo over a 24-week treatment period. Over 24 weeks of once-weekly subcutaneous treatment (2.4 mg), pemvidutide achieved its primary efficacy endpoint by driving a statistically significant and clinically meaningful reduction in heavy drinking days per week. Patients receiving pemvidutide experienced an average reduction of 4.20 heavy drinking days per week from baseline, compared to a reduction of 2.75 days per week in the placebo group. This translated to a net treatment benefit of -1.45 heavy drinking days per week (p = 0.0014). Beyond the primary outcome, pemvidutide delivered consistent efficacy across secondary metrics commonly evaluated in pivotal registration trials. Nearly two-thirds (64.4%) of pemvidutide-treated patients achieved a ≥2-level reduction in World Health Organization (WHO) Risk Drinking Levels, compared to 34.8% on placebo (p = 0.0049). During the final month of the evaluation period (Weeks 21–24), 42.2% of patients in the pemvidutide arm experienced zero heavy drinking days, compared to just 17.4% in the placebo arm (p = 0.0066). Pemvidutide-treated patients achieved significantly higher rates of overall abstinent days (38.9% vs. 20.5% for placebo, p = 0.0075). Importantly, objective laboratory testing showed a dramatic drop in serum phosphatidyl ethanol (PEth), a direct biomarker of alcohol consumption, with a mean change of -153.4 in the treatment arm versus +22.0 on placebo (p < 0.0001), confirming that self-reported reductions reflected genuine behavioral shifts. In addition to curbing compulsive alcohol intake, pemvidutide’s balanced dual-agonist mechanism delivered a placebo-adjusted body weight loss of 9.1% at 24 weeks (p < 0.0001) without reaching an efficacy plateau. This dual effect is particularly relevant in AUD, where alcohol consumption and metabolic dysregulation frequently compound liver injury.

Select results from Phase 2 RECLAIM trial evaluating GLP-1/glucagon dual receptor agonist pemvidutide in alcohol use disorder (AUD); Source: Altimmune presentation, slides 7-9

By demonstrating that GLP-1/glucagon co-agonism effectively reduces compulsive alcohol intake, pemvidutide expands the potential clinical utility of incretin therapies into addiction medicine. If ultimately approved by the FDA, it could address an enormous unmet need for the more than 28 million Americans with AUD, of whom less than 2% currently receive pharmacotherapy due to the real-world limitations and adherence issues of existing options like naltrexone, acamprosate, and disulfiram. Furthermore, since AUD remains the primary driver of progressive liver disease, pemvidutide’s synergistic combination of addiction control, weight loss, and glucagon-mediated hepatic lipid clearance could offer a novel, highly targeted therapeutic approach for AUD patients suffering from co-occurring liver damage, such as Metabolic Dysfunction-Associated Steatohepatitis (MASH) and alcohol-associated liver disease (ALD).

Altimmune plans to schedule an End-of-Phase 2 (EOP2) meeting with the FDA to align on Phase 3 trial design, primary endpoints, and dosing regimens. Altimmune aims to leverage Fast Track status to advance pemvidutide into Phase 3 trials for AUD while simultaneously progressing its Phase 3 registration program in MASH. Notably, Eli Lilly is evaluating a GLP1/GIP dual agonist called brenipatide for alcohol use disorder (AUD) in two Phase 3 clinical trials with estimated completion dates in April 2028.

Sources: Altimmune press release, Altimmune slide deck

Link to top ⬆️

Atea Pharma - Bemnifosbuvir/Ruzasvir (polymerase inhibitor + NS5A inhibitor) / Phase 3 (Hepatitis C)

On July 28, 2026, Atea Pharmaceuticals reported positive topline data from its pivotal North American Phase 3 C-BEYOND trial evaluating the oral fixed-dose combination of bemnifosbuvir and ruzasvir in patients with chronic hepatitis C virus (HCV). The landmark study successfully met its primary endpoint, demonstrating non-inferiority to Gilead’s Epclusa while offering a shortened treatment duration for non-cirrhotic patients.

We have published extensive coverage on Hepatitis C (read Part 1 here & Part 2 here).

Bemnifosbuvir/Ruzasvir (BEM/RZR) is an all-oral, once-daily, protease inhibitor-free fixed-dose combination (FDC) direct-acting antiviral (DAA) regimen. Bemnifosbuvir is an oral guanosine nucleotide analog prodrug that inhibits the HCV NS5B RNA-dependent RNA polymerase, stopping viral RNA synthesis via chain termination. In vitro, it demonstrates ~10-fold greater potency than sofosbuvir against HCV genotypes 1-5 and maintains full activity against common sofosbuvir-resistance mutations (S282T). Ruzasvir is a potent, pan-genotypic NS5A replication complex inhibitor that disrupts viral RNA replication and virion assembly at picomolar concentrations. Combining an NS5B nucleotide analog with an NS5A inhibitor provides a high barrier to resistance, broad pan-genotypic coverage, low risk of drug-drug interactions (DDIs), and no food-effect constraints.

The pivotal Phase 3 C-BEYOND trial evaluated the all-oral, once-daily fixed-dose combination of bemnifosbuvir and ruzasvir (BEM/RZR) across 905 treatment-naive chronic HCV patients with and without compensated cirrhosis at 120 North American sites, meeting its primary endpoint by demonstrating statistical non-inferiority to Gilead’s standard-of-care Epclusa (sofosbuvir/velpatasvir). In the primary modified intent-to-treat (mITT) population, BEM/RZR achieved a 93.9% sustained virologic response (SVR) rate at Week 24 compared to 94.8% for Epclusa. Crucially, in the non-cirrhotic cohort, which represents 80% to 90% of real-world HCV cases, an abbreviated 8-week course of BEM/RZR achieved a 93.5% cure rate, holding non-inferiority against a full 12-week Epclusa regimen (94.6%), while both arms yielded identical 95.4% SVR rates in the 12-week cirrhotic subgroup. BEM/RZR maintained a relatively clean safety profile with zero drug-related serious adverse events and zero treatment-related discontinuations. Beyond shaving a full month off treatment (8 weeks vs. 12 weeks of Epclusa) to boost real-world compliance and support “test-and-treat” public health initiatives, BEM/RZR’s protease inhibitor-free design delivers a potentially cleaner drug-drug interaction profile without food constraints, potentially streamlining co-administration alongside chronic cardiovascular, psychiatric, or metabolic medications.

Atea is currently conducting its second pivotal Phase 3 trial, C-FORWARD, in over 880 patients across 17 countries outside North America. Topline data are expected in early 2027. Pending the readout from C-FORWARD, Atea plans to assemble a comprehensive global regulatory filing package (NDA/MAA) for BEM/RZR as a short-course, pan-genotypic HCV therapy.

Sources: Atea press release

Link to top ⬆️

Descriptive data releases without numerical data

  • Pfizer - Litfulo (JAK3 x TEC inhibitor) / Phase 3 (vitiligo): On July 30, 2026, Pfizer reported positive topline data from two pivotal Phase 3 trials (TRANQUILLO and TRANQUILLO 2) evaluating its oral covalent JAK3/TEC kinase inhibitor, Litfulo (ritlecitinib), in patients with active and stable nonsegmental vitiligo (NSV). Across both studies, which together enrolled 2,174 patients across 271 global sites, once-daily Litfulo (50 mg and 100 mg) met its co-primary U.S. endpoints at Week 52, driving statistically significant and clinically meaningful improvements over placebo in facial repigmentation (≥75% improvement on F-VASI) and total body repigmentation (≥50% improvement on T-VASI). Litfulo maintained a safety profile consistent with its established label in severe alopecia areata, with no new safety signals identified and treatment-emergent adverse event rates comparable across groups. Positioned to potentially become the first approved oral systemic therapy for nonsegmental vitiligo, these landmark Phase 3 results support Pfizer’s planned global regulatory filings seeking to expand Litfulo beyond its current alopecia areata approval. Sources: Pfizer press release

  • Biogen - BIIB091 (peripheral BTK inhibitor) / Phase 2 (RRMS): Biogen reported positive topline proof-of-concept data for BIIB091, its oral, highly selective, reversible peripheral Bruton’s tyrosine kinase (BTK) inhibitor, in a Phase 2 study evaluating adults with relapsing-remitting multiple sclerosis (RRMS). The monotherapy cohort successfully met its key endpoints by demonstrating significant suppression of central nervous system inflammatory activity (as measured by active MRI lesion burden) alongside a favorable safety and tolerability profile. However, the planned combination cohort evaluating BIIB091 co-administered with Vumerity (diroximel fumarate) was halted due to strategic development decisions, focusing future progress entirely on BIIB091 as a standalone therapy. Sources: Biogen press release

  • AstraZeneca - Sonesitatug vedotin (Claudin 18.2 ADC) / Phase 3 (claudin 18.2+ gastric cancer): On July 27, 2026, AstraZeneca reported top-line results from the Phase 3 CLARITY-Gastric01 trial evaluating its Claudin 18.2-targeting antibody-drug conjugate (ADC), sonesitatug vedotin (Sone-Ve), versus investigator’s choice of therapy in 594 patients with CLDN18.2-positive advanced or metastatic gastric/gastroesophageal junction cancers. The study met one of its dual primary endpoints, demonstrating a statistically significant and clinically meaningful overall survival (OS) benefit in patients receiving third-line or later (3L+) therapy. It also hit a key secondary endpoint of OS in the broader second-line or later (2L+) setting. However, the readout was mixed as the other dual primary endpoint, progression-free survival (PFS) in the 2L+ population, showed a positive trend but failed to reach statistical significance. Despite missing the 2L+ PFS benchmark, the drug was well tolerated with no new safety signals, and the significant overall survival advantage across 2L+ and 3L+ settings positions sonesitatug vedotin as a potential first-in-class Claudin 18.2 ADC option for global regulatory filings. Sources: AstraZeneca press release

Link to top ⬆️

Love biotech? Check out Biotech Readout’s full content library, or navigate directly to a segment that interests you:

Biotech Readout is a reader-supported publication. To receive new posts and support my work, consider becoming a free subscriber.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

]]><![CDATA[Argenx to Acquire Forte Biosciences]]>https://biotechreadout.xyz/p/argenx-to-acquire-forte-bioscienceshttps://biotechreadout.xyz/p/argenx-to-acquire-forte-biosciencesMon, 27 Jul 2026 21:26:50 GMTDisclaimer: This newsletter is for educational and informational purposes only and does not constitute medical, investment, or financial advice, nor does it establish a provider-patient relationship. Content may include forward-looking statements and discussions of investigational therapeutic candidates that are not FDA/EMA approved; their safety and efficacy remain unestablished and clinical outcomes are unpredictable. While we strive for accuracy, all information is provided as is without guarantees. As of the date of publication, the author holds no direct equity positions in the specific companies mentioned in this issue nor receives third-party compensation for this coverage. Please find a complete version of our disclaimers linked here.

If you are a paid subscriber, go to vitiligo competitive landscape here ⬇️

If you are a free reader or subscriber, enjoy the whole article free of charge and consider upgrading for competitive landscapes of disease areas & therapeutics modalities; view samples here.

Introduction

On July 27, 2026, Argenx announced a definitive agreement to acquire Forte Biosciences, Inc. for a total equity value of approximately $2.2 billion (Argenx press release, Forte press release). This acquisition centers on Forte’s lead program FB102, a potentially first-in-class anti-CD122 antibody that represents a “pipeline-in-a-product” opportunity, according to Argenx:

  • Vitiligo: Forte published Phase 1b data recently.

  • Celiac Disease: Forte reported Phase 1b data and Argenx expects to report Phase 2 data in 2H 2026.

  • Alopecia Areata: Argenx expects to report Phase 1b data in 2H 2026.

In this article, we follow the journey of Dr. Paul A. Wagner, explore the founding story of Forte Biosciences, and discover how his pivot from microbiome medicines to vitiligo paid off.

Science Meets Spreadsheets

The story of Dr. Paul A. Wagner reflects a rare blend of deep academic science, financial acumen, and hands-on corporate leadership in biopharmaceuticals. Dr. Wagner built his foundation at the intersection of chemistry and quantitative finance. He earned his Bachelor of Science from the University of Wisconsin before pursuing doctoral research at the California Institute of Technology (Caltech), where he completed his Ph.D. in Chemistry. Recognizing the critical role capital markets play in bridging scientific discoveries to commercial therapeutics, he also earned the Chartered Financial Analyst (CFA) designation.

In 1999, Dr. Wagner entered Wall Street, joining Lehman Brothers as Vice President. Over six years in investment banking, he advised biotechnology and pharmaceutical leadership on capital raises, M&A structuring, and public offerings. In 2005, he transitioned directly into industry as Head of Development Licensing at PDL BioPharma, evaluating licensing transactions and strategic asset acquisitions.

Dr. Wagner returned to the buy-side in 2006, joining Allianz Global Investors as Director, Senior Equity Analyst, and Portfolio Manager. For eight years, he managed dedicated public market portfolios, conducting fundamental due diligence on clinical data, regulatory landscapes, and commercial positioning across global drug developers. Armed with extensive experience evaluating life sciences balance sheets and clinical strategy, Dr. Wagner moved back into corporate executive leadership in 2014. At Pfenex Inc. (2014-2017), he served as Chief Financial Officer (CFO), steering financial operations, investor relations, and capital allocation for the biotechnology firm. He then departed Pfenex for a brief stint at CANBridge Life Sciences (2017), where he served as Head of Corporate Strategy and Development, overseeing pipeline expansion, cross-border licensing, and strategic partnerships.

In 2017, Dr. Wagner founded Forte Biosciences, taking on the roles of Chief Executive Officer (CEO) and Chairperson of the Board. Drawing on his background across Wall Street and corporate strategy, he structured Forte to navigate complex biotech markets. In 2020, he orchestrated the reverse merger with Tocagen, securing corporate financing and bringing Forte onto the NASDAQ.

Bugs as Drugs

At the time of its founding, Forte aimed to fill a gap in pediatric dermatology by treating atopic dermatitis (AD), commonly known as eczema. Their thesis was to do so without relying heavily on topical corticosteroids or broad immunosuppressants, which carry risks of skin atrophy, systemic toxicity, and rebound flare-ups.

The scientific cornerstone of Forte’s early program emerged from discoveries at the National Institutes of Health (NIH). Researchers found that the skin of healthy individuals contained specific strains of commensal Gram-negative bacteria, most notably Roseomonas mucosa, which were largely deficient or entirely missing in patients with atopic dermatitis. The hypothesis behind Forte’s lead program, FB-401, was straightforward. By topically reintroducing healthy R. mucosa, the medicine might be able to re-establish skin microbiome diversity. The live bacterial strains produced lipid molecules that could actively suppress the overgrowth of Staphylococcus aureus, a primary driver of eczema flares. Furthermore, R. mucosa activated tissue-repair mechanisms (such as vitamin D pathway signaling) to restore the damaged epidermal barrier.

Forte licensed the technology, developed its proprietary three-strain formulation and moved into early clinical evaluation. The initial open-label Phase 1/2 clinical trial for FB-401 (topical Roseomonas mucosa) was conducted by Dr. Ian Myles and his team at the NIH (NIAID) and evaluated the safety and early clinical activity of live commensal bacteria in patients with mild-to-moderate atopic dermatitis. A 2018 interim analysis published in JCI Insights, showed that FB-401 treatment resulted in deep enough reductions in itch intensity (“pruritus”) and disease severity (“SCORAD”) to reduce the need for steroids (see graphs below). A follow-up analysis of the same trial published in 2022 in Science Translational Medicine showed that 85% of children (17 out of 20) treated with twice-weekly FB-401 achieved a >50% improvement in disease severity (SCORAD index).

Mean (bars) and individual (circles; n = 10) before- and after-treatment scores for objective intensity (A) and subjective pruritus (B) as measured by SCORAD. (C) Antecubital-specific SCORAD; sum of local intensity and pruritus scores. (D) Mean (scarlet) and individual (gray) self-reported steroid use (days/month) from the 6 weeks prior to enrollment (week 0), after treatment (week 6), and after washout (week 10). Patients were instructed to maintain their home regimens throughout active treatment; Source: Myles et al. JCI Insight (2018)

By mid-2020, riding the momentum of positive Phase 1/2a data from the NIH and a fresh public listing via a reverse merger, Forte launched its crucial randomized, double-blind, placebo-controlled Phase 2 clinical trial. The trial enrolled 154 patients (both adult and pediatric, ages 2 and older) diagnosed with mild-to-moderate atopic dermatitis across multiple clinical sites. Participants were randomized 1:1 to receive either topically applied FB-401 or a vehicle placebo spray three times per week over a 16-week period. Expectations were high, as FB-401 was touted as a potential paradigm shift away from standard-of-care topical steroids and calcineurin inhibitors.

However, on September 2, 2021, Forte released topline results that shattered the thesis behind FB-401. Approximately 58% of patients in the FB-401 treatment arm achieved an EASI-50 response, compared to 60% in the vehicle placebo control arm. FB-401 showed no statistically significant difference over placebo at any post-baseline visit. Forte immediately discontinued all further development of FB-401 but, instead of liquidating the company, Forte preserved its remaining treasury (holding tens of millions in cash reserves) to engineer an internal platform transition.

Three lessons emerged from the wake of this setback:

  • The Open-label Trap: Open-label early phase trials can provide initial safety data and mechanistic proof-of-concept, but don’t always predict efficacy in blinded settings. Relying heavily on open-label signals without an early blinded placebo control arm creates a high risk of overestimating drug effect size. The initial excitement for FB-401 was built largely on single-arm, open-label data generated by the NIH. In open-label dermatological trials, both patient-reported outcomes (like itching) and physician-assessed outcomes (like SCORAD or EASI) may have been vulnerable to significant investigator bias.

  • Placebo Inflation: In dermatological trials, the control vehicle is rarely a true “placebo.” The vehicle matrix (e.g., creams, sprays, ointments, emollients) often acts as an active therapeutic agent by hydrating the stratum corneum, restoring skin lipid barriers, and reducing transepidermal water loss. Trial designers must assume high vehicle response rates and explicitly design trials (for example, via run-in periods or vehicle optimization) to suppress background vehicle effects or power the trial size accordingly.

  • Careful Endpoint Selection: The primary endpoint for the FB-401 Phase 2 trial was EASI-50 (a 50% improvement in the Eczema Area and Severity Index). While EASI-50 was historically used in early-stage trials, setting a low threshold allows mild improvements driven by vehicle hydration or patient trial-compliance (the “Hawthorne effect”) to cross the response line, inflating placebo rates. Modern AD trials increasingly rely on EASI-75, EASI-90, or Valid IGA (Investigator Global Assessment) 0/1 (Clear/Almost Clear) as primary or co-primary endpoints. Higher efficacy bars reduce the proportion of placebo responders crossing the threshold, widening the statistical delta between active and control arms. Aligning early-phase endpoints with registration-grade expectations (FDA/EMA standards) prevents false positives during Phase 2 transitions.

Forte’s Second Act

Following the clinical failure of its early topical live biotherapeutic candidate (FB401 for atopic dermatitis), Forte deliberately shifted focus toward scalable, high-value biologic targets in broader immunology. Between late 2022 and 2023, Forte Biosciences initiated the filing of its core global provisional and utility patent applications covering its anti-CD122 monoclonal antibody, FB102.

Forte recognized that previous efforts targeting the IL-2 or IL-15 pathways had failed due to a lack of selectivity (causing vascular leak syndrome or non-selective Treg depletion). By generating a proprietary antibody specifically engineered to block the CD122 (IL-2R-beta) subunit while preserving the high-affinity interactions with CD25 (IL-2R-alpha), they found a distinct therapeutic window that other biologics missed. Forte tested FB102 across non-human primates (NHPs) and ex-vivo human tissue models. They observed that FB102 selectively blocked IL-2/IL-15-mediated phosphorylation of STAT5 in pathogenic effector T and NK cells without triggering cytokine release storms or shutting down baseline Treg signaling. These biomarker readouts gave leadership the conviction needed to commit the entire enterprise to FB102. Indication selection was also key. Rather than competing in crowded markets like psoriasis, Forte focused FB102 on indications with high unmet need and strong IL-15/IL-2 mechanistic drivers, specifically celiac disease (where intraepithelial lymphocytes are IL-15-dependent) and vitiligo.

In June 2025, Forte announced topline data from its Phase 1b trial of FB102 in celiac disease. The trial met the primary composite histological endpoint measuring villous height-to-crypt depth ratio and intraepithelial lymphocyte count (VCIEL) (see graph below). Biopsy analyses showed a statistically significant reduction in CD3+ intraepithelial T-cell density in the gut mucosa compared to placebo, directly validating that targeting CD122 dampens the localized IL-15-driven pathogenic T-cell cascade. Lastly, FB102-treated patients experienced a 42% reduction in acute gastrointestinal symptom events following gluten challenge relative to placebo (mean of 4.0 events per subject on FB102 vs. 6.9 events on placebo). These results served as the first clinical proof-of-concept for FB102, showing that CD122 could be a viable human target in mucosal auto-inflammation. The data enabled Forte to immediately initiate its Phase 2 celiac study.

Statistically significant composite histology benefit for FB102 compared to placebo in a Phase 1b celiac trial; Source: Argenx presentation, slide 8

A little more than a year later on July 9, 2026, Forte announced topline data from its double-blind, placebo-controlled Phase 1b trial of FB102 in vitiligo. In the protocol-defined efficacy-evaluable population, FB102 achieved a 29.6% mean improvement from baseline in the Facial Vitiligo Area Scoring Index (F-VASI) at Week 24, compared to 7.9% for placebo (p = 0.020), representing a placebo-adjusted benefit of 21.7% (see table below). Note that this 24-week timepoint represents repigmentation that continued to deepen after active treatment stopped at Week 12. FB102 subjects gained an additional 8 percentage points in mean F-VASI between Weeks 12 and 24 (and an additional 14 percentage points in the severe baseline subgroup). In a pre-specified subgroup of subjects with more severe facial involvement (25% depigmentation), FB102 produced a 43.2% mean F-VASI improvement versus 0.5% for placebo (p = 0.006). Notably, no treatment-emergent signals of systemic toxicity, broad immunosuppression, or cytokine release syndrome were reported in the trial population, supporting FB102’s rationale for targeting CD122 to hit cytotoxic effector/memory T cells and NK cells without interfering with Tregs.

Statistical significance achieved by FB102 on Week 12 continued through 24 Weeks in Phase 1b vitiligo trial; Source: Argenx presentation, slide 8

Less than a month later on July 27, 2026, Argenx swooped in and secured an agreement to acquire Forte Biosciences for approximately $2.2 billion. Argenx was not coming into the deal cold. They had already taken a strategic minority position in Forte during Forte’s ~$150 million financing round earlier that year in April 2026. Argenx evaluated the full vitiligo dataset alongside last year’s positive Phase 1b celiac data. As Argenx leadership later noted, seeing clear efficacy across two completely different tissue types (skin and gut) provided the definitive proof-of-concept needed to trigger a full takeover (see below). Rather than waiting for Forte’s ongoing Phase 2 celiac data (expected in the second half of 2026), argenx moved quickly to lock up FB102 to support their Vision 2030 immunology growth strategy.

U.S. prevalence figures and unmet need for celiac disease and vitiligo, according to Argenx; Source: Argenx presentation, slide 9

Conclusion

The story of Forte Biosciences is a masterclass in clinical resilience and strategic agility. Dr. Paul Wagner’s willingness to pivot away from a failed live microbione candidate and double down on the targeted immunology of FB102 ultimately unlocked $2.2 billion in value and positioned Argenx to expand its autoimmune footprint across skin and gut conditions. All eyes now turn to Argenx as FB102 advances through Phase 2 trials in celiac disease and beyond.

Vitiligo Competitive Landscape

All charts reflect data current as of the specified date and may not include every drug development program, although we aimed to capture the vast majority. Please feel free to email me at biotechreadout@gmail.com with “CHARTS” in the subject line to share suggestions or request chart updates.

Press ⬇️ to navigate to a section

  • Notable Acquisitions in Vitiligo ⬇️

  • Target Landscape in Vitiligo ⬇️

  • Vitiligo Pipeline of Strategic Acquirers ⬇️

Read more

]]><![CDATA[GSK-Nuvalent buyout bears fruit, diabetic obesity drug raises the bar, and more ]]>https://biotechreadout.xyz/p/gsk-nuvalent-buyout-bears-fruit-diabetichttps://biotechreadout.xyz/p/gsk-nuvalent-buyout-bears-fruit-diabeticFri, 24 Jul 2026 20:46:56 GMTDisclaimer: This newsletter is for educational and informational purposes only and does not constitute medical, investment, or financial advice, nor does it establish a provider-patient relationship. Content may include forward-looking statements and discussions of investigational therapeutic candidates that are not FDA/EMA approved; their safety and efficacy remain unestablished and clinical outcomes are unpredictable. While we strive for accuracy, all information is provided as is without guarantees. As of the date of publication, the author holds no direct equity positions in the specific companies mentioned in this issue nor receives third-party compensation for this coverage. Please find a complete version of our disclaimers at the bottom of this article and on our About page.

Press ⬇️ to go down to a section and ⬆️ to go back up to the Table of Contents

Table of Contents

This week, we discuss:

  • China Biotech

    • Ex-FDA Director Richard Pazdur Talks Streamlining & Global Collaboration Amid Race with China ⬇️

    • Merck CEO Warns Congress About Restricting China Biotech Deals ⬇️

  • Approvals

    • GSK - Jideytro (ROS1 inhibitor) / Approved (ROS1+ NSCLC) ⬇️

    • AstraZeneca - Etcamah (SERD) / Approved in Europe (ESR1m HR+ HER2- BC) ⬇️

  • Clinical Trial Data

    • Eli Lilly - Retatrutide (GGG) / Phase 3 (T2D, obesity) ⬇️

    • J&J - Talvey (GPRC5D x CD3 TCE) & Tecvayli (BCMA x CD3 TCE) / Phase 3 (r/r MM) ⬇️

    • Arrowhead - Plozasiran (APOC3 RNAi) / Phase 3 (sHTG) ⬇️

China Biotech

Wondering why we discuss China Biotech every week? Tap here to learn more.

Ex-FDA Director Richard Pazdur Talks Streamlining & Global Collaboration Amid Race with China

On July 22, 2026, AACR D3 hosted a fireside chat with Richard Pazdur, former director of the FDA’s CDER (a division that oversees small molecule drugs) and founding director of OCE (a division that advises on oncology drugs). Endpoints covered the interview, which I recommend you read in full here. Pazdur argues that broad FDA branches like the CDER are “anachronisms of the past” and should be dismantled. Following the model of the Oncology Center of Excellence (OCE) that Pazdur launched in 2017, he advocates reorganizing the agency around specific therapeutic areas (e.g., oncology, cardiology, psychiatry). Amid concerns over reduced advisory committee (AdComm) meetings and potential political interference, Pazdur called for increased transparency in selecting committee members. He proposed forming a selection committee comprising representatives from the FDA, patient groups, and professional organizations to choose members. Pazdur also stated that China’s growing drug development sector should not be viewed as a threat and that restricting opportunities from the region would be “very short-sighted”. Rather than relying solely on single-country data, he urged collaboration to incorporate advances from China directly into global, multi-regional clinical trials.

These structural reforms, transparency initiatives, and closer collaboration with Chinese R&D appear to be more of a middle ground, in the midst of warring hawks and doves in Washington. FDA reform is sorely needed as the “Cautious Regulator” Problem is a major contributor to Eroom’s Law, a pithy but unfortunate observation that underscores the ballooning cost of domestic biotech R&D. In contrast, China’s drug regulator, the NMPA, has undertaken sweeping reforms that accelerate innovation (we covered this here), leading to ~2.7-fold cost savings relative to the West. Between 2020 and 2025, China’s NMPA approved 94 novel oncology drugs, outpacing the FDA’s 87 approvals according to Collins et al. Health Affairs Scholar (2026).

Pazdur’s comments also mark a shift on his stance toward China Biotech innovation, from strict skepticism to active collaboration. In 2022, as Director of the FDA’s OCE, Pazdur took a firm regulatory stance against drug applications backed exclusively by clinical trial data from China. He penned a 2022 Lancet commentary highlighting that single-country trials in China lack the ethnic and racial diversity representative of the U.S. population, particularly regarding historically underserved groups. The FDA pushed back against drug developers seeking U.S. approval for PD-1/PD-L1 inhibitors based on trials conducted solely in China (such as the landmark vote against Innovent/Eli Lilly’s sintilimab) without consulting the FDA on trial design or standard-of-care comparisons. Pazdur’s remarks earlier this week outlined a much more collaborative and global vision for Chinese drug development. Pazdur emphasized that clinical trials should be treated as a “universal process” rather than fragmented regional efforts. Rather than attempting to bring completed single-country Chinese trials into the U.S. after the fact, he advocated for collaborating with China to integrate their advances directly into Multi-Regional Clinical Trials (MRCTs) as rapidly as possible.

Sources: Endpoints article, McKinsey article, Collins et al. Health Affairs Scholar (2026), Targeted Oncology article

Link to top ⬆️

Merck CEO Warns Congress About Restricting China Biotech Deals

On July 21, 2026, Merck CEO Rob Davis spoke to reporters at PhRMA headquarters to address looming regulatory threats to US-China biopharma collaborations and advocate for balanced national policies. He warned Congress and the Trump administration that overly broad restrictions or bans on US-China biotech dealmaking could threaten the United States’ standing as a global leader in biotechnology and delay access to innovative medicines for American patients. Davis noted that early-stage trials in China can move “twice as fast at half the cost”. He attributed this efficiency to reduced bureaucracy rather than lower safety or scientific standards. These comments arrive as officials at the Treasury Department are reviewing potential limits on US investments in Chinese biotechs, raising concerns over rapid Phase 1 clinical trial speeds and data sharing in cross-border licensing agreements. Both Merck CEO Rob Davis and outgoing PhRMA CEO Steve Ubl stressed that US policy should focus on national security guardrails and boosting domestic competitiveness rather than completely cutting off access to Chinese innovations. Ubl added that blocking these deals would allow China to retain control of critical therapeutic assets and accelerate its own market dominance. Note that Merck is currently co-developing at least three medicines licensed from Chinese Biotechs:

  • Sac-TMT (licensed from Kelun): This is a TROP2 ADC and is currently being evaluated in multiple Phase 3 trials.

  • MK-7262 / HRS-5346 (licensed from Hengrui): This is an oral Lp(a) inhibitor and is currently being evaluated in a Phase 2 trial.

  • MK-2010 / LM-299 (licensed from LaNova Medicines / Sino Biopharma): This is a PD1 x VEGF bsAb and is currently being evaluated in a Phase 1/2 trial.

Sources: Endpoints article

Link to top ⬆️

Approvals

GSK - Jideytro (ROS1 inhibitor) / Approved (ROS1+ NSCLC)

In July 2026, the U.S. Food and Drug Administration (FDA) approved Jideytro (zidesamtinib) for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have previously received a ROS1 kinase inhibitor. The asset joined GSK’s oncology pipeline following their $10.6 billion acquisition of Nuvalent, which we covered here. The approval arrived nearly two months ahead of its original September 18, 2026 PDUFA target date, building upon previously granted FDA Breakthrough Therapy and Orphan Drug designations. Jideytro was engineered to address several persistent limitations of earlier-generation ROS1 inhibitors, including treatment resistance, central nervous system (CNS) relapse, and off-target toxicities. Its structure features high ROS1 selectivity, sparing TRK inhibition to minimize TRK-related neurological side effects like dizziness, alongside broad coverage of resistance mutations (such as ROS1G2032R) and CNS penetrance to target brain metastases.

The FDA approval was supported by results from the global, open-label, single-arm Phase 1/2 ARROS-1 trial evaluating oral zidesamtinib in patients with advanced ROS1-positive solid tumors. The results demonstrated improvements on prior generations of ROS1 inhibitors:

  • Responses in ROS1-experienced patients: In patients who received one prior ROS1 TKI (N=59), the overall response rate was 49%. In patients who received two or more prior ROS1 TKIs (N=58), including lorlatinib, repotrectinib and/or taletrectinib, the overall response rate was 38%.

  • Responses in CNS metastases: Fifty patients had measurable CNS metastases at baseline as assessed by BICR and had not received radiation therapy to the brain within 2 months prior to study entry. Responses were observed in 48% of patients, including 22% of patients with a complete response.

  • Responses in patients with ROS1 resistant mutations: Responses were observed in 21 of the 42 (50%) patients who had ROS1 resistance mutations. Of the 26 patients with the solvent front G2032R resistance mutation, responses were observed in 14 patients (54%). Responses were also observed in patients with other mutations (ROS1G2032K, ROS1D2033N, ROS1F2004C/V, ROS1G1957A).

Efficacy Results for Patients with ROS1-Positive TKI-Pretreated NSCLC in ARROS-1 per BICR Assessment; Source: Jideytro label, Table 5

Sources: GSK press release, new Jideytro label

Link to top ⬆️

AstraZeneca - Etcamah (SERD) / Approved in Europe (ESR1m HR+ HER2- BC)

AstraZeneca’s next-generation selective estrogen receptor degrader (SERD) and complete estrogen receptor antagonist, Etcamah (camizestrant), received European Commission (EC) approval in July 2026, although it has not yet been approved by the U.S. FDA. In May 2026, following a 6-3 vote by the Oncologic Drugs Advisory Committee (ODAC) questioning whether the trial design and immature overall survival (OS) data justified changing standard treatment paradigms, the FDA extended its Prescription Drug User Fee Act (PDUFA) review date. The extension gives the FDA additional time to evaluate requested analyses, including ctDNA clearance rates and second progression-free survival (PFS2) data, before rendering a final decision. In contrast, the European Medicines Agency (EMA) granted marketing authorization for Etcamah in combination with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib). The indication covers adult patients with HR+ HER2- locally advanced or metastatic breast cancer whose tumors develop an emergent ESR1 mutation during first-line endocrine therapy prior to radiographic disease progression.

The regulatory applications in both regions were built on the pivotal, global Phase 3 SERENA-6 trial (N = 315), which introduced a novel trial paradigm by utilizing real-time circulating tumor DNA (ctDNA) monitoring to detect ESR1 mutations and estimate tumor burden. Etcamah plus a CDK4/6 inhibitor demonstrated a statistically significant improvement in investigator-assessed PFS, reducing the risk of disease progression or death by 56% compared to continuing aromatase inhibitor (AI) therapy (HR=0.44; see Kaplan-Meier curve below). The median PFS was 16.8 months for the Etcamah arm versus 9.2 months for the control arm. Exploratory liquid-biopsy analyses revealed a median total ctDNA reduction of 99% in patients switched to Etcamah versus a 64% increase in the control arm. Furthermore, 51% of Etcamah-treated patients achieved complete ctDNA clearance compared to just 1.9% in the control arm, which correlated with favorable long-term outcomes. Data for OS remained immature at the time of regulatory submission, representing a core focus of the FDA’s extended review.

Kaplan-Meier plot of progression-free survival by investigator assessment in SERENA-6; Source: EMA label for Etcamah, Figure 1

Sources: AstraZeneca press release, EMA label for Etcamah

Link to top ⬆️

Clinical Trial Data

Eli Lilly - Retatrutide (GGG) / Phase 3 (T2D, obesity)

On July 23, 2026, Eli Lilly announced headline Phase 3 results from its pivotal TRIUMPH-2 and TRIUMPH-3 trials evaluating the investigational triple-hormone receptor agonist retatrutide in adults with obesity, Type 2 diabetes, and cardiovascular risk.

Obesity complicated by Type 2 diabetes and elevated cardiovascular risk is driven by adipose tissue dysfunction, systemic insulin resistance, and lipotoxicity that accelerate atherogenesis and cardiorenal decline. Modern management pairs lifestyle modification with cardioprotective incretin therapies, such as GLP-1 or GIP/GLP-1 receptor agonists, and SGLT2 inhibitors to achieve glycemic control and weight reduction. To build upon dual-incretin outcomes, retatrutide operates as a single peptide triple-G agonist that simultaneously activates GLP-1, GIP, and glucagon receptors. By coupling GLP-1/GIP-mediated satiety and glucose-dependent insulin secretion with glucagon-driven energy expenditure and hepatic lipid turnover, retatrutide drives greater body weight loss and metabolic clearance than single or dual incretin agonists, offering a multi-pathway therapeutic strategy for high-risk cardiometabolic disease.

The Phase 3 TRIUMPH-2 (N = 1,152; obesity or overweight with Type 2 diabetes) and TRIUMPH-3 (N = 1,949; severe obesity with established cardiovascular disease) trials evaluated weekly subcutaneous retatrutide versus placebo over 80 weeks, assessing primary body weight changes alongside secondary glycemic control, safety, and composite cardiovascular outcomes (MACE-3 and MACE-5). Retatrutide met primary endpoints across both studies, with the 12 mg dose achieving unprecedented 18-month weight loss of -20.8% (and a 1.6 percentage point HbA1c reduction) in T2D patients and -22.6% in severe obesity, outperforming placebo while showing an 18% relative risk reduction in MACE-5 (HR = 0.82) despite low overall event counts yielding a non-significant numerical difference in MACE-3 (HR = 1.12). Retatrutide’s safety profile was typical of incretins, with predominantly mild-to-moderate GI adverse events and manageable discontinuation rates (3.8% to 13.5%). These findings solidify retatrutide as a novel potency benchmark capable of overcoming historical weight loss plateaus in hard-to-treat diabetic and severe obesity populations.

Table of MACE definitions and results from TRIUMPH-3 trial

Eli Lilly plans to present complete datasets and detailed secondary endpoint breakdowns at upcoming medical meetings, including a full TRIUMPH-2 presentation at EASD 2026. Lilly is finalizing the Chemistry, Manufacturing, and Controls (CMC) package and plans to submit its Biologics License Application (BLA) to the U.S. FDA in 1Q 2027. The comprehensive registration package will support global filings across obesity, knee osteoarthritis pain, obstructive sleep apnea, and cardiometabolic diseases.

Sources: Eli Lilly press release

Link to top ⬆️

J&J - Talvey (GPRC5D x CD3 TCE) & Tecvayli (BCMA x CD3 TCE) / Phase 3 (r/r MM)

On July 23, 2026, J&J reported results for their Phase 3 MonumenTAL-6 trial, which evaluated a combination of T-cell engagers (TCEs) in 2nd-to-5th line relapsed/refractory multiple myeloma (RRMM).

Relapsed/refractory multiple myeloma (RRMM) is driven by malignant plasma cells that develop treatment resistance through clonal evolution and marrow microenvironment interactions, resulting in organ dysfunction like bone lesions, anemia, and renal failure. Management relies on anti-CD38 antibody-based triplets or quadruplets in early lines (1-3 prior therapies), whereas triple-class refractory disease shifts toward novel immunotherapies targeting BCMA or GPRC5D. To overcome single-antigen escape, the combination of Tecvayli (teclistamab; BCMA x CD3) and Talvey (talquetamab; GPRC5D x CD3) redirects cytotoxic T cells to simultaneously destroy malignant cells via two distinct targets. This dual-bispecific approach effectively mitigates antigen loss while sparing normal B-cell lineages, offering a potent, non-overlapping immunotherapeutic strategy to deliver durable remissions in refractory populations.

The Phase 3 MonumenTAL-6 trial evaluated Tecvayli + Talvey and Tecvayli + pomalidomide versus standard of care (SOC) in patients with relapsed/refractory multiple myeloma who had received 2 to 5 prior lines of therapy (including an IMiD, PI, and anti-CD38 antibody). Following an IDMC recommendation to unblind early at the first interim analysis due to overwhelming efficacy, the Tecvayli + Talvey combination demonstrated an 89% reduction in the risk of disease progression or death (HR=0.11) and a 62% reduction in the risk of death compared to SOC, with a safety profile consistent with its individual components and manageable rates of CRS, ICANS, and GPRC5D-related toxicities. By validating the simultaneous dual-targeting of BCMA and GPRC5D without cytotoxic chemotherapy backbones, these findings establish a potential shift toward chemotherapy-free, dual-immunotherapy combinations in earlier relapse settings to overcome antigen loss and driver resistance.

J&J plans to present complete dataset presentations at upcoming medical congresses and submit supplemental Biologics License Applications (sBLAs) to the U.S. FDA and European Medicines Agency (EMA) to move both agents into earlier 2L+ indications. They hope to establish outpatient/step-up dosing administration protocols to enable community oncologists to safely manage potential CRS and neurological events. These results also bode well for J&J’s follow-on multi-targeting agent JNJ-5322, a BCMA x GPRC5D x CD3 TCE.

Sources: J&J press release

Link to top ⬆️

Arrowhead - Plozasiran (APOC3 RNAi) / Phase 3 (sHTG)

On July 22, 2026, Arrowhead Pharmaceuticals announced positive top-line results from two pivotal Phase 3 trials, SHASTA-3 and SHASTA-4, evaluating its investigational RNAi therapeutic plozasiran in adults with severe hypertriglyceridemia (sHTG). Note that plozasiran is currently approved for familial chylomicronemia syndrome (FCS) under the brand name Redemplo, but not for sHTG at the time of this article’s publication.

Severe hypertriglyceridemia (sHTG; fasting triglycerides ≥500 mg/dL) stems from the accumulation of triglyceride-rich lipoproteins due to impaired clearance or excessive hepatic secretion, creating cytotoxic free fatty acids that elevate plasma viscosity and trigger life-threatening acute pancreatitis (AP). While standard management relies on strict dietary fat restriction alongside first-line fibrates or high-dose prescription omega-3 fatty acids, genetic or refractory defects often necessitate targeted interventions like plozasiran. Utilizing Arrowhead’s TRiM platform, plozasiran is an investigational subcutaneous siRNA that silences hepatocyte expression of APOC3, a key inhibitor of lipoprotein lipase and hepatic lipid clearance. This approach aims to deliver potent, prolonged triglyceride lowering and pancreatitis risk reduction through a convenient once-quarterly dosing regimen.

The twin Phase 3 SHASTA-3 and SHASTA-4 trials evaluated quarterly subcutaneous plozasiran (25 mg) versus placebo in adults with severe hypertriglyceridemia (TG≥500 mg/dL). Both studies met their primary endpoint with median fasting triglyceride reductions of -79% and -81% at 12 months, outpacing historical 6-month benchmarks set by antisense options like Tryngolza (olezarsen, -68-73%; we covered their sHTG approval here) on a cross-trial basis and demonstrating a favorable safety profile comparable to placebo. Direct head-to-head comparisons against olezarsen have not been conducted in clinical trials. Crucially, a pre-planned pooled analysis showed a 78% reduction in cumulative acute pancreatitis events (100% in high-risk patients with prior pancreatitis), directly validating that APOC3 silencing resolves the disease’s primary life-threatening clinical sequela. With convenient once-quarterly administration and robust clinical event reduction, plozasiran establishes a potential best-in-class RNAi profile in sHTG that advances management beyond surrogate lipid biomarker lowering.

Arrowhead plans to present full Phase 3 data and subgroup analyses at the European Society of Cardiology (ESC) Congress on August 30, 2026 and submit a supplemental New Drug Application (sNDA) to the U.S. FDA before the end of 2026, alongside planned regulatory submissions in Europe and other international markets. Continuing clinical progression in related cardiometabolic indications, including familial chylomicronemia syndrome (FCS; where plozasiran is already FDA-approved) and broader mixed dyslipidemia settings.

Sources: Arrowhead press release

Link to top ⬆️

Love biotech? Check out Biotech Readout’s full content library, or navigate directly to a segment that interests you:

Biotech Readout is a reader-supported publication. To receive new posts and support my work, consider becoming a free subscriber.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

]]><![CDATA[Hepatitis C, Part 1]]>https://biotechreadout.xyz/p/hepatitis-c-part-1https://biotechreadout.xyz/p/hepatitis-c-part-1Sat, 18 Jul 2026 15:29:40 GMTDisclaimer: This newsletter is for educational and informational purposes only and does not constitute medical, investment, or financial advice, nor does it establish a provider-patient relationship. Content may include forward-looking statements and discussions of investigational therapeutic candidates that are not FDA/EMA approved; their safety and efficacy remain unestablished and clinical outcomes are unpredictable. While we strive for accuracy, all information is provided as is without guarantees. As of the date of publication, the author holds no direct equity positions in the specific companies mentioned in this issue nor receives third-party compensation for this coverage. Please find a complete version of our disclaimers at the bottom of this article and on our About page.

Prologue

In Part 1 of this two-part series on Hepatitis C, we dive into the Nobel-prize winning discovery of Hepatitis C and explore how Schering-Plough, Roche, Merck, Vertex, and Janssen turned the tide from a public health epidemic to an 80% cure rate.

Subscribe so you don’t miss Part 2, where we explore how Pharmasset teamed up with Gilead and bested big pharma in the race for a cure.

Subscribe

Estimated cumulative net sales from Hepatitis C since 2009; Source: 10-Ks and 10-Qs from Gilead, AbbVie, and Merck

Not A, Not B

The story of hepatitis starts in the theater of war. For centuries, an infectious form of jaundice was observed in military campaigns and crowded, unsanitary living conditions. Those who contracted it exhibited characteristic yellowing of their skin and the whites of their eyes. At the time, catarrhal jaundice, as it was then called, was believed by many to be a mechanical issue, specifically a blockage of the bile duct by mucus. However, the sheer scale of outbreaks in military camps and the clear patterns of spread suggested an infectious pathogen was responsible. It was only in the 1940s when the desperate circumstances of World War II spurred scientists into action. Dr. W. Paul Havens and his team at Yale University were tasked with proving that catarrhal jaundice was a transmissible, infectious disease, even without the ability to see the virus under the microscopes of the era. To prove the mode of transmission, Havens and his team turned to controlled human experiments. In these studies, they worked with volunteer subjects, a common, though now deeply controversial, practice in the mid-20th century.

The researchers collected samples of blood serum and stool from patients who were suffering from acute cases of infectious hepatitis. These samples were processed to create filtrates, liquids that had been passed through fine filters to remove bacteria, leaving only the smaller, unidentified viral agents. In a series of trials, these filtrates were administered to volunteers via feeding or injection. By observing the volunteers over several weeks, the researchers were able to track who developed the classic symptoms of hepatitis, such as jaundice, fever, and liver enzyme elevation. Through these experiments, Havens successfully demonstrated that what we now know as Hepatitis A was primarily transmitted via the fecal-oral route. He showed that the agent was present in the stool of infected individuals, proving that contaminated food & water or poor sanitation were the primary engines of the disease’s spread. One of Havens’ most crucial contributions was his ability to clearly differentiate “infectious hepatitis” (Hepatitis A) from “serum hepatitis” (Hepatitis B) by comparing the incubation periods and transmission routes. his team observed two distinct patterns:

  • Hepatitis A (Infectious): Had a relatively short incubation period and was easily transmissible through the ingestion of contaminated stool or serum.

  • Hepatitis B (Serum): Had a much longer, more insidious incubation period and was primarily linked to the injection of blood or plasma products, such as the contaminated yellow fever vaccines that had caused massive outbreaks in the military.

These findings were instrumental in the wartime effort. By identifying the fecal-oral route of Hepatitis A, military leaders could finally implement effective sanitation protocols and food-handling safeguards to curb outbreaks. Beyond the immediate tactical gains, Havens’ research laid the essential groundwork for the future of virology. In 1973, a team led by Dr. Stephen Feinstone at the National Institutes of Health (NIH) used a technique called immune electron microscopy. They took samples from volunteers who had been infected with the virus and mixed them with serum from patients who had recovered from the illness. Under the powerful magnification of an electron microscope, they observed the antibodies from the recovered patients clumping together around tiny, circular particles. These particles were the Hepatitis A virus (HAV). By finally visualizing the virus, researchers were able to confirm its structure, paving the way for the development of a highly effective vaccine that would eventually make the disease largely preventable.

But, how could physicians diagnose a patient with Hepatitis A or B, aside from crude observations of symptoms? Dr. Baruch Blumberg, a researcher at the NIH, would stumble into that question and subsequently provide the answer. He was not initially looking for a hepatitis virus. Instead, he was studying human genetic diversity, specifically looking at how different populations responded to blood transfusions. Dr. Blumberg was analyzing the blood of diverse groups, including Indigenous Australians and hemophiliacs, to see how their antibodies reacted to foreign proteins. In 1963, Blumberg discovered an unusual reaction: the blood of a hemophiliac patient reacted with an antibody found in the blood of an Australian Aboriginal person. He dubbed this mysterious protein the Australia Antigen.

For several years, Blumberg worked to identify what this antigen actually was. In a profound realization in 1967, he linked the presence of this antigen directly to patients suffering from serum hepatitis (Hepatitis B). He had accidentally stumbled upon a surface protein of the virus, and the name of the Australia Antigen was changed to the more appropriate Hepatitis B surface antigen (HbSAg). This discovery was revolutionary. It meant that for the first time, scientists could test blood for the presence of this antigen, effectively creating the first screening test to keep the blood supply safe from Hepatitis B. For his persistent detective work in identifying this new virus, Baruch Blumberg was awarded the Nobel Prize in Physiology or Medicine in 1976.

By the mid-20th century, Hepatitis A and Hepatitis B were well understood by the medical community. Researchers had developed vaccines and screening tests for these viruses, which significantly improved the safety of the blood supply. However, by the 1970s, a frustrating trend emerged: a significant number of patients who received blood transfusions continued to develop hepatitis, even though their blood had been meticulously screened for both Hepatitis A and B. Clinicians were baffled. If the two known culprits were ruled out, what was causing this transfusion-associated hepatitis? For nearly 15 years, the medical community was forced to label this mysterious, stealthy pathogen as Non-A, Non-B hepatitis. It was deadly and chronic, leading to liver cirrhosis and cancer, but invisible to the tests of the time.

Dr. Harvey J. Alter, working at the National Institutes of Health (NIH), took on the role of investigating this illusive disease. He started by observing the patterns of Non-A, Non-B hepatitis in patients. Similar to the discovery of Hepatitis A & B, Alter demonstrated that blood from patients with this mysterious hepatitis could transmit the disease to chimpanzees, the only animal model susceptible to it at the time. Crucially, Alter’s experiments showed that the agent was a virus. He and his team discovered that the infectious material could be filtered in a way that captured viral particles but excluded bacteria. It was a breakthrough, but the virus was present in such incredibly low concentrations that it remained impossible to capture or see. It also refused to grow in any laboratory cell culture. For over a decade, Alter’s work hit a wall.

In 1989, Dr. Michael Houghton and his colleagues Qui-Lim Choo and George Kuo at the Chiron Corporation picked up where Alter left off, but they took a radically different approach. Instead of trying to grow the virus on petri dishes, they searched for its genetic footprint using shotgun sequencing. Shotgun sequencing is a laboratory method used to determine the entire DNA sequence of an organism’s genome. Instead of reading a long DNA strand from start to finish, the process shatters the genome into millions of smaller fragments (“shotgun“). Each of these small fragments is sequenced independently using automated technology to determine the order of its chemical bases (A, T, C, and G). Powerful computer algorithms close the loop by looking for overlapping sections to figure out how they fit back together. Like assembling a giant jigsaw puzzle without the original picture, the computer matches the overlapping edges to reconstruct the original, long, continuous sequence of the entire genome.

The Chiron team started with a massive amount of serum taken from a chimpanzee that had been infected with Non-A, Non-B hepatitis. They extracted all the genetic material (RNA) from the serum and converted it into DNA. They then inserted these millions of DNA fragments into bacteria, creating a library of clones. This library contained genetic material from the chimpanzee, the bacteria, and, hopefully, the hidden virus. The team had to figure out which clone belonged to the virus. The team created an innovative probe. They took serum from a patient who was known to have Non-A, Non-B hepatitis, reasoning that this patient must have developed some antibodies against the virus, even if they were too weak to detect by standard means. They used this serum to scan the millions of clones in their library, looking for any interaction between the patient’s antibodies and the bacterial clones. For years, the team screened millions of clones with no luck. Finally, in 1989, they hit upon a clone, which they labeled “5-1-1.” It reacted with the patient’s antibodies. When they sequenced the DNA of this clone, they confirmed it was not from the chimpanzee or the bacteria. It was a piece of the viral genome.

Once they had the virus’ genetic sequence, the impact was immediate and profound. Within months, Chiron developed a blood test that allowed screening centers to identify and remove virus-contaminated blood from the supply, virtually eliminating transfusion-transmitted infections. They officially named the virus Hepatitis C. For his decade of tireless, innovative work Michael Houghton was jointly awarded the 2020 Nobel Prize in Physiology or Medicine, alongside Harvey J. Alter and Charles M. Rice.

Panning for Medicines

For those who aren’t familiar with the California Gold Rush, it was a transformative event in American history that turned a quiet, remote Mexican territory into a bustling state almost overnight. It began on January 24, 1848, when James Marshall, working for Swiss immigrant John Sutter, discovered gold flecks in the tailrace of a sawmill being built in Coloma. While the news was initially met with skepticism, it quickly ignited a global migration. By 1849, Forty-Niners were flooding into California from across the U.S., Europe, China, and South America. The sudden influx of hundreds of thousands of people resulted in the rapid development of cities like San Francisco and Sacramento, as prospectors harvested gold nuggets worth tens of billions of dollars.

1850 advertisement about sailing to California, depicting scenes from the gold rush; Source: Wikimedia

Much like the California Gold Rush, the discovery of a diagnostic for Hepatitis C in the early 1990s lit a fuse that ended in the explosive realization of how large the unmet need truly was. It is estimated that in the 1970s and 1980s, about 4% of patients who received a blood transfusion contracted Hepatitis C. Some reports say that the risk was as high as 10% for recipients of blood transfusions in some settings. Since the virus had been invisible for so long, millions of people were unknowingly infected through medical procedures, blood products, or injection drug use years or decades prior. Epidemiologists at the time began to realize that they were standing at the base of a coming tsunami of potentially fatal end-stage liver disease. Since the virus can remain asymptomatic for 20 to 30 years, the surge in liver cancer and cirrhosis cases seen in the 1990s was actually the result of infections contracted in the 1960s and 1970s. This meant that even if new infections were stopped instantly, the public health burden of the disease would continue to climb for decades. It was a chance for biotech and pharma to make a substantial impact on health outcomes by bringing safe and effective medicines to market, and it would soon become the talk of the town amongst drug hunters.

Of course, the Gold Rush also had its cast of characters. The most successful underdog was, arguably, Samuel Brannan. He was a Mormon businessman who, like many, moved to California. Unlike many, he did not dig for gold. Brannan famously ran through the streets of San Francisco waving a bottle of gold dust to announce the discovery, knowing his stores were perfectly positioned to supply the incoming tide of prospectors. By buying up all the mining supplies in the region and reselling them at massive markups, he became California’s first millionaire. Samuel Brannan reminds us that a small, but scrappy player can outmaneuver established giants that are initially thought to be in the best position to capitalize on a new trend. One such established giant was John Sutter, the owner of the land where gold was first discovered in California. Instead of being the ultimate winner, the Gold Rush destroyed his agricultural empire. Prospectors overran his land, squatters seized his property, and his workers abandoned him to search for gold. He died a man of modest means, having lost his “Nuevo Helvetia” empire to the very event he inadvertently started. James Marshall, the man who actually spotted the gold at the mill never realized a fortune from it either. Like his employer Sutter, his claim was overrun by others, and he spent the later years of his life in obscurity, unable to capitalize on his own discovery.

The race for the Hepatitis C cure has a similar cast of characters. Unlike, the folly of the established giants in the Gold Rush, the giants in the Hepatitis C race would still end up with blockbusters on their hands. So, no hard feelings. However, it was a hard fought battle against Gilead, a scrappy pioneer in the field of virology, but an underdog nonetheless. Gilead had earned its keep with its HIV/AIDS franchise. When the race truly kicked off in 2010, the company was generating annual revenues of around $8 billion. As a traditional big pharma powerhouse, Merck was significantly larger, with 2010 annual revenues exceeding $45 billion. It had a much broader portfolio spanning various therapeutic areas, including vaccines, oncology, and cardiovascular health. They also had a 16-year head start in Hepatitis C compared to Gilead. Abbott Laboratories was another a massive, diversified giant, with revenues in the range of $35 billion to $40 billion in 2010. At the time, it included a vast array of medical devices, diagnostics, and branded pharmaceutical products (the latter of which would be spun off into AbbVie in 2013). Most importantly, AbbVie was ramping sales of the soon-to-be best selling drug of all time, Humira, giving them a formidable war-chest for cracking whichever market they decided to compete in.

Cast of characters in the race for a Hepatitis C cure

Of course, how could we forget about the prospectors? The prospectors of the California Gold Rush were a diverse group of people driven by the “Gold Fever”. However, their lived experience was far removed from the romanticized image of striking it rich overnight. Prospecting involved standing in icy mountain streams for 10 to 12 hours a day, manual labor that led to chronic rheumatism, pneumonia, and exhaustion. While a tiny minority returned home with generational wealth, the vast majority found only marginal earnings and headed back home. Much like the prospectors of the Gold Rush, the prospectors of the Hepatitis C race waded into the icy competition long enough to get an FDA-approved product across the line. Rebuffed by the breakneck speed of innovation, they ultimately bowed out of the race and returned to the comfort of their core franchises.

California Miner with Pack Horse (1887) by Henry Raschen, oil on canvas; Source: Wikimedia

The Interferon Incumbent

James Marshall discovered the first gold flecks in the California Gold Rush, but who was the “James Marshall of Hepatitis C”? The story begins in 1957 at the National Institute for Medical Research (NIMR) in Mill Hill, London. Two virologists, Alick Isaacs and Jean Lindenmann, were studying how cells fought off influenza viruses. Alick Isaacs was a Scottish physician and microbiologist and served as the head of the World Influenza Centre at NIMR. His counterpart, Jean Lindenmann, was a Swiss virologist and immunologist who had joined Isaacs at the NIMR in 1956. They discovered that when cells were exposed to an inactivated virus, they released a protein that seemed to “interfere” with the ability of other viruses to infect surrounding cells. They named this miraculous, protective protein interferon.

For years, interferon remained a laboratory curiosity because it was incredibly difficult and expensive to harvest from human cells in sufficient quantities. However, with the advent of recombinant DNA technology in the 1970s and 80s, the very same technology that would later allow for the mapping of the Hepatitis C genome, scientists finally learned how to manufacture human interferon on an industrial scale.

When Hepatitis C was finally unmasked in 1989, the medical community was desperate for a weapon. The virus was causing chronic liver disease in millions, and the options for treatment were nonexistent. Schering-Plough, a pharmaceutical company that had heavily invested in interferon research, recognized that this protein could be the key to attacking the newly identified virus. When Intron A (recombinant interferon alfa-2b) was under development and review for hepatitis C, the clinical trials focused on assessing its ability to normalize serum aminotransferases (ALT), which was used as a surrogate biomarker for reducing liver inflammation. Across the combined Phase 3 studies, patients receiving extended-term therapy (72 or 96 weeks) achieved a 24% sustained ALT response rate, compared to 12.5% for those treated for only 24 weeks. This represents a statistically significant improvement of 11.4% (95% CI: 2, 21) for the extended treatment group. At the end of the treatment period (when the drug is still active in the patient’s system), response rates were 40-48% for the 24-week group and 44-49% for the extended treatment group. On November 6, 1997, the FDA approved Intron A, the first therapy for Hepatitis C. It was a milestone moment: for the first time, there was a drug that could potentially slow the progression of the virus.

Sustained ALT response rate versus duration of therapy in chronic Hepatitis C patients; Source: Intron A label, Table 2

While interferon was a revolutionary discovery, its use as a Hepatitis C treatment was fraught with immense difficulty. Intron A required three injections per week, and in later years, as combinations with ribavirin were introduced (Rebetron approved on June 3, 1998), the physical toll became even more apparent. Patients often described the side effects as feeling like having a perpetual, debilitating flu. Symptoms included severe fatigue, depression, high fevers, and body aches. Since the treatment had to be taken for up to 48 weeks for optimal effect, many patients found it nearly impossible to complete. Cures could be achieved with interferon, but it was rare. In Hepatitis C, a cure rate refers to the percentage of patients who successfully clear the virus from their bodies completely after finishing treatment. A blood test must confirm the virus is undetectable 12 or 24 weeks after stopping all treatment (SVR12 or SVR24), in order to meet the medical criteria for a cure. A cured patient will still test positive for Hepatitis C antibodies, but the actual virus should be below the lower limit of detection. In the early years of interferon, the cure rate for interferon-based therapy was often less than 10%.

One of the primary issues with interferon was its short half-life in the body. Since the drug was cleared from the system quickly, patients had to endure the physical and emotional burden of three injections per week. Even with this frequent dosing, the drug remained in the bloodstream only for a short time, which limited its ability to maintain a consistent antiviral effect. Schering-Plough addressed this limitation through a process called pegylation. By chemically attaching a large, inert molecule called polyethylene glycol (PEG) to the interferon molecule, Roche created a shield that:

  • Extended Half-Life: Significantly slowed the absorption of the drug and its clearance from the body.

  • Enabled Once-Weekly Injections: Allowed the drug to remain at therapeutic levels in the bloodstream for an entire week, enabling a transition from three injections per week to just one.

  • Improved Efficacy: The more consistent drug levels achieved with once-weekly dosing led to higher sustained virologic response (SVR) rates compared to the older, non-pegylated interferons.

Schering-Plough refined the drug into pegylated interferon and PEG-Intron approved August 9, 2001). Two months later, Swiss pharmaceutical company Roche (a prospector) introduced their own pegylated interferon called Pegasys to the market on October 15, 2002. However, cure rates stubbornly remained at 40-50% for about a decade. Despite the severe side effects and limited efficacy, Schering-Plough’s pioneering work with interferon established a powerful precedent for Hepatitis C therapy, showing that the virus was susceptible to antiviral intervention. They also created the clinical infrastructure that would eventually bridge the gap to the modern era (diagnostic testing, patient monitoring, and specialized treatment centers).

Evolution of Hepatitis C cure rates in the Interferon Era

The ensuing decade saw a meaningful consolidation of the pharmaceutical industry (and the Hepatitis C landscape), due to the loss of patent protection for various blockbuster drugs. Merck sought to bolster its R&D pipeline by doubling its number of late-stage development compounds from 9 to 18. On March 9, 2009, Merck & Co. announced a definitive merger agreement to merge with Schering-Plough for approximately $41 billion. The deal combined Merck’s strengths with Schering-Plough’s leading franchises in areas like respiratory, oncology, and women’s health. It consolidated their cholesterol-lowering franchises: the two companies were already joint partners for the drugs Zetia (ezetimibe) and Vytorin (ezetimibe + simvastatin combo pill), and the merger allowed Merck to simplify and fully control this portfolio. The merger with Schering-Plough officially closed on November 3, 2009, transforming Merck into the world’s second-largest prescription drug maker at the time. Of course, Merck also in-housed Schering-Plough’s established hepatitis C franchise, which included its interferon-based products. This acquisition provided Merck with the infrastructure and expertise to support the development and launch of a new class of Hepatitis C medicine that dramatically shifted the treatment paradigm.

Hepatitis C landscape in the Interferon Era

Wrench in the Works

In the 2000s, the standard of care for treating chronic Hepatitis C was a grueling endurance test. Patients faced up to 48 weeks of peginterferon and ribavirin, a combination that induced severe fatigue, flu-like symptoms, and depression. For many, the virus persisted, mocking the effort. The medical community needed something that could target the virus more precisely. But how?

Back in 1989, when Michael Houghton and his team at Chiron sequenced the Hepatitis C virus, they revealed its infernal machinery. They found that Hepatitis C had a positive-strand RNA genome that was approximately 9.6 kilobases long. Its 5’ Untranslated Region (5’ UTR) contained a highly structured internal ribosome entry site (IRES) that directed the host’s cellular machinery to initiate protein translation in a cap-independent manner. This was the most critical RNA domain for translation. It adopted a complex tertiary structure that bound directly to the 40S ribosomal subunit, bypassing the need for canonical eukaryotic initiation factors and starting to making protein right away. The virus’ single large open reading frame (ORF) encoded a large polyprotein precursor of roughly 3,000 amino acids in length. This polyprotein was processed by both host and viral proteases into at least 10 functional proteins (see below):

  • Structural Proteins: These were found at the N-terminus and included the Core protein (forming the viral nucleocapsid), as well as the envelope glycoproteins E1 and E2.

  • Non-Structural (NS) Proteins: These constituted the enzymatic machinery for viral replication and included NS2, NS3 (protease and helicase), NS4A (protease cofactor), NS4B, NS5A (a multi-functional protein involved in replication and assembly), and NS5B (the RNA-dependent RNA polymerase).

Genetic organization and functional RNA domains in the HCV genome; Source: Romero-López et al. Scientific Reports (2018), Figure 1

Specific stem-loop structures called the Cis-Acting Replication Elements (CREs) located within the coding regions (such as in the NS5B gene) and the UTRs were essential for the initiation of viral RNA synthesis. These structures acted as beacons for the viral RNA-dependent RNA polymerase (NS5B). Finally, the 3’ Untranslated Region (3’ UTR) was essential for viral replication and consisted of a variable region, a poly-U/UC tract, and a highly conserved 3’ X-tail, which formed the complex secondary RNA structures necessary for polymerase recognition. Out of all of these structures and substructures, scientists at Merck zeroed in on the NS3/4A protease for two reasons:

  • Essentiality for Viral Replication: As I mentioned before, the Hepatitis C genome produces a single, long polyprotein chain that must be cut into individual functional proteins to create new viral particles. Without the activity of the NS3 protease to perform these cuts, the virus cannot replicate. By blocking this molecular scissor, scientists could effectively halt the viral production line.

  • Druggable Binding Site: A major scientific discovery was that the NS3 protease is largely inactive on its own. It requires a viral protein called NS4A to act as a cofactor, which helps fold the protease into its active shape and anchor it to the cellular membrane where replication occurs. This specific NS3/4A complex provided a binding pocket for rational drug design that was different from any human proteases, theoretically allowing for a drug that would kill the virus while minimizing harm to the host’s normal cellular functions.

Once researchers solved the X-ray crystal structure of the NS3/4A complex, they could see the exact shape of the active site, a shallow groove where the viral polyprotein would normally fit. This allowed scientists to use structure-based drug design to create small molecules that mimicked the natural shape of the NS4A binding site (see graphic below). These molecules were designed to fit into that groove and act as a permanent, immovable plug, preventing the protease from cutting its natural substrate.

Crystal structure of Hepatitis C NS3/4A D168A protease (dark purple) in complex with protease inhibitor NR01-129 (light purple carbon backbone); Source: Protein Data Bank (PDB)

Originally initiated by Schering-Plough, Merck utilized a rigorous structure-based drug design process to develop Victrelis (boceprevir), the first direct-acting antiviral for Hepatitis C. Their starting point was an undecapeptide (a chain of 11 amino acids) with a high molecular weight of 1,265 Da, which readily occupied the NS4A binding site but was too bulky to use as an oral drug. Using X-ray crystallography to visualize the enzyme-inhibitor complex, researchers trimmed the peptide down to a tripeptide (about 500 Da). The resulting molecule was then fashioned as an α-ketoamide inhibitor. This electrophilic group acts as a trap for the serine-139 residue in the NS3 protease’s active site. When the inhibitor binds, it forms a reversible covalent bond, creating a tetrahedral intermediate that mimics the natural transition state of the protein-cleavage process. Next, medicinal chemists narrowed their focus into the bicyclic [3.1.0]proline moiety (the “P2” fragment). This specific structure served as a superior surrogate for the natural amino acid leucine, improving the drug’s binding potency by 1,000-fold.

Victrelis (boceprevir) molecular structure with key functional groups highlighted in purple; Source: Fvasconcellos, Public domain, via Wikimedia Commons

The design team faced significant hurdles in balancing potency with “drug-likeness” (pharmacokinetics). Early potent analogs were often charged (e.g., containing carboxylic acids), which prevented them from crossing cell membranes. Merck scientists substituted these groups with neutral alternatives, such as a dimethylamide, to enhance cell penetration. By systematically removing unnecessary residues at the “prime side” (the part of the inhibitor that extends out of the binding site) and identifying that non-substituted primary ketoamides maintained high potency, they successfully reduced the drug’s molecular weight into the range required for oral bioavailability.

This iterative, structure-guided approach allowed researchers to evolve a bulky, weakly active peptide into boceprevir, a potent, selective, and orally active inhibitor. By plugging the NS3 protease active site, the drug prevented the virus from cleaving its own polyprotein, thereby halting viral replication. This success served as a landmark proof-of-concept for the entire field of direct-acting antiviral (DAA) therapy. On May 13, 2011, that long-awaited shift finally arrived when the FDA approved Victrelis (boceprevir), supported by data from two pivotal, Phase 3 randomized, double-blind, placebo-controlled clinical trials:

  • SPRINT-2 (Treatment-Naïve Patients): This trial enrolled 1,097 patients who had never previously been treated for Hepatitis C. Patients receiving boceprevir in combination with SOC achieved SVR rates of approximately 63-66%, compared to 38% for those receiving standard-of-care alone.

    Results from Phase 3 SPRINT-2 trial in treatment-naïve Hepatitis C patients; Source: Victrelis label, Table 10

  • RESPOND-2 (Treatment-Experienced Patients): This trial enrolled 403 patients whose prior therapy with pegylated interferon and ribavirin had failed, including relapsers and previous non-responders. The addition of boceprevir similarly resulted in a significantly higher SVR rate of 59-66% compared to 23% in patients who received only the standard-of-care.

Results from Phase 3 RESPOND-2 trial in treatment-experienced Hepatitis C patients; Source: Victrelis label, Table 12

Since Victrelis markedly increased cure rates, it allowed physicians to adopt response-guided therapy. Patients who showed a strong, early virologic response could potentially shorten their total treatment duration to 28 weeks, sparing them months of the severe, flu-like side effects associated with the longer 48-week interferon-based course. A testing algorithm was included within the FDA label itself (see below), providing crucial guidance to the physician community.

Algorithm for response-guided therapy; Source: Victrelis label, Table 1

Protease Pile-on

Merck’s wasn’t the only company with a crack team of medicinal chemists working on this problem. Vertex Pharmaceuticals was founded in 1989 by Joshua Boger, who had previously spent a decade at Merck as the Senior Director of Basic Chemistry and headed the Departments of Biophysical Chemistry and Medicinal Chemistry of Immunology & Inflammation. During his time there, he became a pioneer in the application of computer modeling to drug design, effectively organizing one of the first major efforts in what is now known as structure-based drug design.

In fact, Vertex was established specifically to be the first pharmaceutical company built entirely around the strategy of structure-based drug design. While other companies utilized this approach, Vertex made it the core, defining philosophy of its entire R&D operation, relying on computer modeling to visualize and manipulate the 3D structures of proteins and enzymes to design custom inhibitors. Vertex’s approach stood in contrast to the prevailing combinatorial chemistry or trial-and-error methods common at the time. Their work, including early efforts to target HIV protease, helped demonstrate the power of rational, structure-guided discovery. The story of Vertex’s early years, including its intense focus on these scientific pioneers and their rational design methods, was famously chronicled in Barry Werth’s 1994 book, The Billion-Dollar Molecule, which I highly recommend.

However, the Vertex of 2011 was not the same as the Vertex of 2026. Back then, Vertex was know as “The Hepatitis C” company rather than its modern moniker as “The Cystic Fibrosis” company. In 2011, Vertex was only in the final stages of its pivotal Phase 3 clinical program for CFTR corrector ivacaftor. They had just announced positive Phase 3 STRIVE results (in February 2011) showing significant improvements in lung function for patients with a specific cystic fibrosis mutation. They were preparing to submit regulatory applications for approval in the U.S. and Europe by the second half of 2011, which led to the drug’s approval (as Kalydeco) in early 2012. In parallel to Merck’s efforts, Vertex and collaborators Mitsubishi Tanabe Pharma Corporation & Janssen had put substantial weight behind their NS3/4A protease inhibitor Incivek (telaprevir), which was approved just 10 days after Victrelis on May 23, 2011 after their Phase 3 ADVANCE trial in treatment-naïve patients showed a 79% SVR rate compared to 46% in patients given standard of care. Incivek for Hepatitis C was, in fact, Vertex’s very first approved medicine.

Results from the Phase 3 ADVANCE trial in treatment-naïve patients; Source: Incivek label, Table 10

While Merck’s Victrelis and Vertex’s Incivek were both peptidomimetic inhibitors designed to block the NS3 protease active site, their core chemical compositions featured distinct structural choices. Like Victrelis, Incivek utilized an α-ketoamide warhead, but its scaffold was distinctly optimized to fit the protease’s binding groove differently. Vertex’s approach prioritized a structure that offered high potency but, ultimately, presented unique challenges regarding formulation and administration. The most significant differences emerged during clinical use. Post-market reports identified serious and sometimes fatal skin reactions, which led to the FDA adding a black box warning to its label in 2012.

Incivek black box warning; Source: Incivek label, Table 10

A year later, Vertex’s partner Janssen arrived on the scene with a follow-up compound. This time, Janssen partnered with Medivir to design a second generation NS3/4A protease inhibitor, characterized by structural and pharmacological improvements. First generation inhibitors utilized a linear, α-ketoamide chemical structure, forming a reversible covalent bond with the catalytic serine residue in the Hepatitis C NS3/4A protease. Janssen’s new molecule Olysio (simeprevir) was a macrocyclic compound. This cyclic structure was engineered to lock the molecule into a shape that fits more precisely and securely into the protease’s binding site, allowing for higher binding affinity and greater specificity. Clinically, this translated to improved potency and a more favorable side-effect profile compared to the first-generation drugs. On the convenience front, simeprevir in combination with peginterferon and ribavirin reduced patients’ pill burden to three pills a day compared to four pills a day for Incivek and five pills a day for Victrelis.

Olysio (simeprevir) molecular structure with key functional groups highlighted in purple; Source: Ed (Edgar181), Public domain, via Wikimedia Commons

The approval of Olysio (simeprevir) on November 22, 2013 was primarily supported by three pivotal Phase 3 clinical trials:

  • QUEST-1 and QUEST-2 (Treatment-Naïve Patients): A pooled analysis of these studies showed that 80% of treatment-naïve patients receiving Olysio achieved a sustained virologic response 12 weeks after the end of treatment (SVR12), compared to 50% in the placebo groups.

    Virologic Outcomes in Treatment-Naïve Adult Subjects with HCV Genotype 1 Infection (Pooled Data QUEST 1 and QUEST 2 Trials); Source: Olysio label, Table 17

  • PROMISE (Treatment-Experienced Patients): This trial focused on patients who had relapsed after prior interferon-based treatment. In this study, 79% of patients in the Olysio group achieved SVR12, compared to 37% in the placebo group.

Virologic Outcomes in Adult Subjects with HCV Genotype 1 Infection who Relapsed after Prior IFN-Based Therapy (PROMISE Trial); Source: Olysio label, Table 19

However, it wasn’t all smooth sailing for Janssen. During Olysio’s clinical development and subsequent review, it was discovered that its efficacy was significantly lower in patients infected with the HCV genotype 1a virus that contained the Q80K polymorphism, a naturally occurring variation in the virus’s protease enzyme. As a result, the FDA label included a recommendation to screen for this mutation and consider alternative therapies for these patients. Olysio’s liability and Incivek skin toxicity reminds us of the unpredictable nature of small molecule drug design: a single out-of-place atom can dramatically alter a drug’s pharmacokinetics and pharmacodynamics in ways that are difficult to detect until its tested in a 100+ patient Phase 3 trial.

Sun Sets on the Protease Era

Hepatitis C landscape in the Protease Era

The Interferon Era and Protease Era represent the first two legs of the race for the Hepatitis C cure. Researchers at Chiron mapped the virus’ genome and developed a biomarker-based diagnostic, revealing the enormous scope of Hepatitis C’s scourge. Schering-Plough figured out how to manufacture interferon at scale, pioneering the first FDA-approved treatment for Hepatitis C. Schering-Plough and Roche introduced a long-acting peginterferon, which reduced the injection burden from three times weekly to once weekly. After Schering-Plough merged with Merck, the team hosted a second act and pioneered NS3/4A protease inhibitors with Vertex close behind. By the end of 2013, Schering-Plough/Merck had a 16-year track record as the juggernaut in Hepatitis C. Two years later, Janssen lowered the overall pill burden from five a day to three a day. All told, Hepatitis C went from a public health epidemic to an 80% cure rate.

Evolution of Hepatitis C cure rates in the Interferon & Protease Eras

In a vacuum, this progress is astounding, but the story doesn’t end here. It’s only with the clarity of hindsight that we can talk about the weaknesses of the standard of care regimen for Hepatitis C circa 2013. NS3/4A protease inhibitors could not be used alone. They required co-administration with pegylated interferon and ribavirin, which were notorious for debilitating side effects like severe fatigue, depression, flu-like symptoms, and anemia. These regimens required complex dosing schedules (e.g., every 8 hours) and specific dietary protocols (Victrelis with a light snack and Incivek with a high-fat meal) to ensure proper absorption. Since they had a low barrier to resistance, any lapse in adherence could quickly render the virus resistant not only to the drug being taken but potentially to other protease inhibitors in the same class.

Beyond the specific issues of the first-generation drugs, the protease inhibitor class as a whole faced persistent clinical challenges. Early protease inhibitors were contraindicated or carried strong warnings for patients with moderate to severe liver impairment (Child-Pugh B or C cirrhosis). In these cases, the drugs could cause further liver dysfunction, failure, and death, likely due to altered hepatic metabolism. Protease inhibitors were also typically potent inhibitors or substrates of cytochrome P450 enzymes (particularly CYP3A). This made them prone to significant interactions with a wide array of other medications, necessitating careful clinical management when treating patients with comorbidities. Finally, the efficacy of certain protease inhibitors (such as Olysio) was compromised by pre-existing viral resistance mutations, most notably the Q80K polymorphism in HCV genotype 1a. This required mandatory baseline resistance testing, adding complexity and cost to the treatment process.

As the sun set on the Protease Era, Shering-Plough/Merck looked back on a 16-year track record of success and a blockbuster Hepatitis C franchise (see below). Roche, Vertex, and Janssen also constructed blockbuster franchises, racking up peak annual sales of $1 billion (mid-2000s), $1.2 billion (2012), and $2.3 billion (2014), respectively. High fives all around.

Estimated annualized revenue run rates for Merck’s Hepatitis C medicines based on 10-Ks and 10-Qs from Merck

Hold a second. Something is missing.

Remember Gilead, the underdog of our story? They’re about to shift into overdrive. The Gold Rush has barely begun. The race for the cure is just getting started.

Read Part 2 (linked here), where we explore how Pharmasset teamed up with Gilead and bested big pharma in the race for a cure.

Subscribe so you don’t miss it!

Subscribe

If you enjoyed Part 1, don’t forget to like and share.

Share

Love biotech? Check out Biotech Readout’s full library of content, or navigate directly to a segment that interests you:

Biotech Readout is a reader-supported publication. To receive new posts and support my work, consider becoming a free subscriber.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

]]><![CDATA[Approvals for cholesterol-lowering and breast cancer, another tau attempt in Alzheimer's, and more]]>https://biotechreadout.xyz/p/approvals-for-cholesterol-loweringhttps://biotechreadout.xyz/p/approvals-for-cholesterol-loweringFri, 17 Jul 2026 21:59:02 GMTDisclaimer: This newsletter is for educational and informational purposes only and does not constitute medical, investment, or financial advice, nor does it establish a provider-patient relationship. Content may include forward-looking statements and discussions of investigational therapeutic candidates that are not FDA/EMA approved; their safety and efficacy remain unestablished and clinical outcomes are unpredictable. While we strive for accuracy, all information is provided as is without guarantees. As of the date of publication, the author holds no direct equity positions in the specific companies mentioned in this issue nor receives third-party compensation for this coverage. Please find a complete version of our disclaimers at the bottom of this article and on our About page.

Press ⬇️ to go down to a section and ⬆️ to go back up to the Table of Contents

Table of Contents

This week, we discuss:

  • China Biotech

    • Financing Activity for China versus Rest of World ⬇️

    • U.S Biotech Startups Have Become More Secretive to Protect Their IP ⬇️

  • Acquisitions ⬇️

    • Eli Lilly to Acquire AtaiBeckley

  • Approvals

    • Merck - Lipfendra (oral PCSK9 inhibitor) / Approved (hypercholesterolemia & HeFH) ⬇️

    • Celcuity - Revtorpyk (Pan-PI3K/mTOR inhibitor) / Approved (2L HR+ HER2- BC) ⬇️

    • Biogen - Leqembi IQKLIK (anti-Aβ mAb) / Approved (Alzheimer’s) ⬇️

    • Pfizer - Padcev (Nectin-4 ADC) / Approved (MIBC) ⬇️

    • Novartis - Fabhalta (factor B inhibitor) / Approved (IgAN) ⬇️

  • Clinical Trial Data

    • Q32 Bio - Bempikibart (anti-IL-7Rα mAb) / Phase 2a (alopecia) ⬇️

    • Veradermics - VDPHL01 (ER oral minoxidil) / Phase 2 (female androgenetic alopecia) ⬇️

    • Biogen - Diranersen (tau ASO) / Phase 2 (Alzheimer’s) ⬇️

    • Ipsen - Iqirvo (PPARa/d dual agonist) / Phase 3b (PBC) ⬇️

    • Takeda - Zasocitinib (TYK2 inhibitor) / Phase 3 (psoriasis) ⬇️

    • Merck - Sac-TMT (TROP2 ADC) / Phase 3 (1L PDL1-negative metastatic non-sq NSCLC) ⬇️

    • GSK - Jemperli (anti-PD1 mAb) / Phase 3 (Stage 3/4 MMRd rectal cancer) ⬇️

China Biotech

Financing Activity for China versus Rest of World

for the week ending July 17, 2026

Link to top ⬆️

U.S Biotech Startups Have Become More Secretive to Protect Their IP

This week, both WSJ and Endpoints reported that U.S. biotech startups are adopting unprecedented levels of secrecy, using code names in offices and withholding crucial details (such as specific genes or protein targets) from websites, conferences, and even their own investors. This marks a dramatic shift for an industry that historically relied on open scientific collaboration and public disclosures after funding milestones. According to numerous industry executives and investors, this paranoia is driven by the rapid evolution, scale, and agility of the Chinese biopharma industry. Chinese companies have mastered the ability to quickly optimize, scale, and reverse-engineer experimental therapies originating in Western labs. Backed by cheaper lab staff, reagents, and clinical development pipelines, Chinese firms can fast-follow and outpace US drugmakers the moment a drug target or patent becomes public. The shift toward genetic and RNA-based therapies (such as siRNA and mRNA) has amplified these fears. Since drug targets and genes cannot be patented (only the specific drug structure can), identifying the target biology is where most of a company’s value lies. For RNA therapies, knowing the target sequence makes the drug incredibly easy to copy, forcing leading companies to hide their pipelines until they are ready for clinical trials. To defend their intellectual property, US biotechs are altering their behaviors:

  • Delayed Patenting: Companies are delaying patent filings or repeatedly pulling and refiling provisional patents to avoid public disclosure.

  • Calls for Reform: Industry leaders are advocating for patent reforms, such as extending the timeline before a patent is published or keeping certain filings redacted/classified.

  • Heightened Espionage Fears: Trade organizations like the Biotechnology Innovation Organization (BIO) have warned members to be wary of potential investors or partners who may actually be gathering intelligence for industrial espionage.

While some experts note that political tensions may lead to scapegoating China and that China’s internal IP protection has actually improved, the overarching trend is clear. Industry leaders warn that this pervasive secrecy in response to increasing competition from China is creating a chill in the scientific community, drastically reducing the communication and collaboration that historically drove major medical breakthroughs.

Sources: Endpoints article, WSJ article

Link to top ⬆️

Acquisitions

Link to top ⬆️

Approvals

Merck - Lipfendra (oral PCSK9 inhibitor) / Approved (hypercholesterolemia & HeFH)

On July 16, 2026, the U.S. Food and Drug Administration (FDA) approved Lipfendra (enlicitide), developed by Merck, as the first and only once-daily oral PCSK9 inhibitor. Lipfendra is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia or heterozygous familial hypercholesterolemia (HeFH), an inherited genetic disorder that limits the body’s ability to clear LDL-C from the bloodstream. It represents a major shift in the second line treatment of high cholesterol (patients who are uncontrolled with statins), as previous FDA-approved PCSK9 inhibitors were exclusively available as injections. Lipfendra uses a novel macrocyclic peptide technology that allows it to be taken as a 20 mg oral tablet. The tablet must be taken once daily in the morning, ideally 30 minutes before consuming food. Merck has indicated plans to offer patient coupons and make the drug available through the TrumpRx direct-to-consumer sales channel.

The approval was supported by two pivotal Phase 3 trials from the CORALreef clinical program. CORALreef Lipids in patients with hypercholesterolemia demonstrated a 56% reduction in LDL-C compared to placebo at week 24 and CORALreef HeFH demonstrated a 59% reduction in LDL-C compared to placebo at week 24. While Lipfendra is proven to lower LDL-C, researchers are currently conducting the CORALreef Outcomes trial (involving over 14,500 participants) to determine if this reduction translates into a decrease in major adverse cardiovascular events (MACE), which includes heart attacks, strokes, cardiovascular-related death and sometimes hospitalization for unstable angina or coronary revascularization. In clinical trials, the safety profile of Lipfendra was generally similar to that of a placebo. In the HeFH trial, the most commonly reported adverse reactions occurring more frequently than with placebo were diarrhea (7% Lipfendra versus 2% placebo) and dizziness (9% Lipfendra versus 4% placebo). Rates of treatment discontinuation due to adverse events were comparable between the treatment and placebo groups.

Cross-trial comparison of FDA-approved PCSK9 inhibitors, with Lipfendra highlighted in light blue

Sources: Merck press release, Lipfendra label

Link to top ⬆️

Celcuity - Revtorpyk (Pan-PI3K/mTOR inhibitor) / Approved (2L HR+ HER2- BC)

On July 14, 2026, the FDA approved Revtorpyk (gedatolisib), developed by Celcuity, as first and only FDA-approved therapy that inhibits all class I PI3K isoforms (α, β, δ, γ) for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation. Revtorpyk is indicated in combination with Faslodex (fulvestrant), with or without Ibrance (palbociclib), for patients whose disease has progressed following at least one line of endocrine therapy. This approval addresses a significant unmet need for the roughly 60% of HR+/HER2- breast cancer patients who are PIK3CA wild-type and have historically had fewer targeted treatment options after endocrine therapy resistance.

The approval was based on the Phase 3 VIKTORIA-1 trial, which showed that Revtorpyk significantly improved progression-free survival (PFS) compared to Faslodex alone in PIK3CA wild-type patients. We covered their ASCO 2026 presentation here in early June. Their triplet Regimen (Revtorpyk + palbociclib + fulvestrant) reduced the risk of disease progression or death by 76%. The most notable safety concern is stomatitis, which occurred in 72% of patients in the triplet group (22% Grade 3). Prophylactic use of a steroid-containing, alcohol-free mouthwash is required.

Efficacy Results in Patients with Locally Advanced or Metastatic Breast Cancer in Study 1 of VIKTORIA-1, with the primary endpoint highlighted in blue; Source: Revtorpyk label, table 6

Separately, Celcuity has reported strong efficacy for Revtorpyk in patients with PIK3CA mutations, where it has demonstrated a 50% risk reduction in disease progression compared to Piqray (alpelisib) plus Faslodex (fulvestrant). Celcuity plans to submit a supplemental New Drug Application (sNDA) in 3Q 2026 to seek label expansion for this patient population. The company is also evaluating the drug in the Phase 3 VIKTORIA-2 trial as a potential first-line treatment.

Sources: Celcuity press release, Revtorpyk label

Link to top ⬆️

Label Expansions

  • Biogen - Leqembi IQKLIK (anti-Aβ mAb) / Approved (Alzheimer’s): On July 13, 2026, the FDA approved a label expansion for Leqembi IQLIK (lecanemab-irmb), an anti-amyloid monoclonal antibody for early Alzheimer’s disease, authorizing the use of a weekly subcutaneous autoinjector as an initiation dose for patients. Previously, this at-home, under-the-skin injection was only indicated as a maintenance therapy for patients who had already completed 18 months of intravenous infusions. This new approval allows patients and their caregivers to transition to home-based administration from the start of their treatment journey. Supported by clinical data demonstrating that subcutaneous administration achieves drug exposure and biomarker benefits equivalent to the IV formulation. This change could significantly reduce the logistical burden of recurring clinic visits and potentially provide greater flexibility for patients managing early-stage Alzheimer’s. Sources: Biogen press release, new Leqembi IQKLIK label

  • Pfizer - Padcev (Nectin-4 ADC) / Approved (MIBC): On July 10, 2026, the FDA approved a label expansion for the combination of Padcev (enfortumab vedotin-ejfv) and Keytruda (pembrolizumab) or the subcutaneous formulation Keytruda Qlex as a perioperative (neoadjuvant and adjuvant) treatment for adults with muscle-invasive bladder cancer (MIBC). Previously limited to cisplatin-ineligible patients, this expanded indication allows the use of the regimen for all patients with MIBC who are candidates for radical cystectomy, regardless of their cisplatin eligibility. The approval is supported by findings from the Phase 3 KEYNOTE-B15 (EV-304) trial, which demonstrated that this platinum-free combination significantly outperformed standard-of-care neoadjuvant chemotherapy, reducing the risk of disease progression, recurrence, or death by 47% and the risk of death by 35%, thereby establishing a new potential standard of care in the curative-intent setting. Sources: Pfizer press release, new Padcev label

  • Novartis - Fabhalta (factor B inhibitor) / Approved (IgAN): On July 17, 2026, the FDA granted traditional approval to Novartis’ Fabhalta (iptacopan) to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. This milestone converts the drug’s previous 2024 accelerated approval (was based on the surrogate endpoint of proteinuria reduction) into a full approval, supported by robust data from the Phase 3 APPLAUSE-IgAN clinical trial. Results from the trial demonstrated that patients treated with the oral Factor B inhibitor experienced a significantly slower annualized decline in estimated glomerular filtration rate (eGFR) compared to those on placebo, reinforcing the drug’s role in preserving long-term kidney health by targeting the alternative complement pathway. As part of its safety profile, Fabhalta remains available through a Risk Evaluation and Mitigation Strategy (REMS) program due to the risk of serious infections from encapsulated bacteria, requiring patients to be appropriately vaccinated prior to initiating treatment. Sources: Novartis press release

Link to top ⬆️

Clinical Trial Data

Q32 Bio - Bempikibart (anti-IL-7Rα mAb) / Phase 2a (alopecia)

On July 13, 2026, Q32 Bio announced positive topline results from Part B of the Phase 2a SIGNAL-AA clinical trial, evaluating bempikibart (ADX-914) in patients with severe or very severe alopecia areata (AA).

Severe alopecia areata is an autoimmune disease characterized by a loss of hair follicle immune privilege, leading to T-cell-mediated destruction and significant hair loss, currently managed by JAK inhibitors like Olumiant (baricitinib) and Litfulo (ritlecitinib) that suppress inflammatory signaling at the cost of potential systemic safety risks. Bempikibart offers a novel therapeutic approach as a fully human anti-IL-7Rα antibody, which differentiates itself from these broad-acting JAK inhibitors by specifically blocking IL-7 and TSLP signaling to re-regulate the adaptive immune system. This targeted mechanism aims to reset immune balance rather than simply suppressing inflammation, potentially providing a safer and more durable treatment alternative for patients who require systemic intervention for their condition.

In the Phase 2a SIGNAL-AA open-label trial, 33 patients with severe or very severe alopecia areata (baseline SALT score 50–100) received a 36-week regimen of bempikibart, demonstrating meaningful clinical efficacy with a mean 35.3% reduction in SALT scores and up to 30.3% of the ITT population achieving ≥20% scalp coverage (SALT-20). On a cross-trial basis, this 30% SALT-20 responder rate compares favorably to FDA-approved JAK inhibitors Olumiant (baricitinib) and Litfulo (ritlecitinib), which generally show SALT-20 response rates in the range of 30-40% in severe patient populations. The treatment was generally well-tolerated, with no treatment-related serious or Grade ≥3 adverse events, and only mild injection-site reactions reported. These results position bempikibart as a potentially disruptive, safer alternative to the currently dominant JAK inhibitor class, offering the possibility of a remittive effect without the systemic safety risks associated with chronic JAK-STAT pathway suppression.

Bempikibart achieved clinically meaningful SALT-20 responses at Week 36; Source: Q32 Bio presentation, slide 12

Q32 Bio intends to advance bempikibart into a pivotal clinical program in the first half of 2027. Full results from Part B will be presented at a future medical meeting. The company is also continuing to monitor patients through a 52-week off-drug follow-up and an ongoing open-label extension (OLE) study to further evaluate the durability of the treatment effect.

Sources: Q32 Bio press release, Q32 Bio slide deck

Link to top ⬆️

Veradermics - VDPHL01 (ER oral minoxidil) / Phase 2 (female androgenetic alopecia)

On July 15, 2026, Veradermics announced positive topline results from the Phase 2 Study ‘207’ (NCT06527365) evaluating VDPHL01, a proprietary extended-release oral minoxidil formulation, for the treatment of female pattern hair loss (androgenetic alopecia).

Female androgenetic alopecia is a progressive condition driven by genetic sensitivity to androgens that causes follicular miniaturization and thinning, typically managed with burdensome topical minoxidil or off-label hormonal therapies that often yield inconsistent results. VDPHL01 addresses this clinical gap as a novel, extended-release oral minoxidil formulation designed to stimulate hair regrowth by prolonging the anagen phase through sustained follicular exposure. By utilizing this specialized delivery technology, VDPHL01 aims to provide the efficacy of systemic minoxidil while mitigating the high plasma concentration spikes that cause cardiac side effects in immediate-release formulations, potentially offering a more convenient and safer oral alternative for long-term treatment.

In the Phase 2 Study ‘207’, 28 women with mild-to-moderate androgenetic alopecia treated with VDPHL01 demonstrated robust hair regrowth, achieving mean increases in non-vellus hair counts of 22.7 to 23.3 hairs/cm² and reporting high patient satisfaction, with approximately 90% noting improvements in hair coverage as early as two months into the trial. The formulation was well-tolerated with no treatment-related serious adverse events or cardiac issues of special interest, confirming that the extended-release technology successfully maintains efficacy while avoiding the systemic safety risks typical of immediate-release oral minoxidil. These proof-of-concept results establish VDPHL01 as a potentially best-in-class, non-hormonal oral therapy that addresses a significant unmet need for a more convenient and standardized treatment for female pattern hair loss.

Veradermics is currently enrolling patients in a registration-directed Phase 2/3 trial (Study ‘306’). The company anticipates topline results from the Phase 2/3 study in the first half of 2027, aims to further validate the drug’s potential for U.S. regulatory approval.

Sources: Veradermics press release

Link to top ⬆️

Biogen - Diranersen (tau ASO) / Phase 2 (Alzheimer’s)

On July 17, 2026, Biogen announced results from the Phase 2 CELIA trial of diranersen, an investigational antisense oligonucleotide (ASO) targeting tau protein, for the treatment of early-stage Alzheimer’s disease. Results were presented the Alzheimer’s Association International Conference (AAIC) 2026 in London, UK.

Alzheimer’s disease is a progressive neurodegenerative disorder driven by the accumulation of amyloid-beta plaques and tau-containing neurofibrillary tangles, which currently relies on symptomatic management alongside recently approved anti-amyloid monoclonal antibodies that provide modest clinical benefit by targeting amyloid clearance. Diranersen offers a distinct therapeutic approach as an antisense oligonucleotide (ASO) designed to intervene in this pathology by binding to the pre-mRNA of the MAPT gene to reduce tau protein expression. By specifically decreasing the production of this key component of neurofibrillary tangles, diranersen aims to address the tau-driven component of the disease, potentially offering a complementary or alternative strategy to existing treatments that primarily target amyloid pathology.

In the Phase 2 CELIA trial, patients with early-stage Alzheimer’s disease treated with intrathecal diranersen demonstrated a 26% reduction in clinical decline on the CDR-SB scale, a result numerically comparable to established anti-amyloid therapies like Leqembi and Kisunla. Despite this efficacy signal, the trial revealed an unexpected inverse dose-response relationship, where the lowest dose provided the most robust benefit while higher doses showed diminishing returns. This finding could pose a significant regulatory challenge, necessitating further investigation into whether higher levels of tau knockdown trigger compensatory mechanisms or off-target effects, and highlighting the critical need to identify the optimal biological window for therapeutic tau modulation in future development.

Cross-trial comparison of diranersen versus anti-amyloid therapies in Alzheimer’s patients; Source: Biogen AAIC 2026 presentation, slide 12

Biogen plans to conduct extensive post-hoc analyses. The company has not yet provided a definitive timeline for a Phase 3 transition. Future studies may need to focus on refining the dosing regimen and identifying the specific patient sub-populations most likely to benefit from this precise level of tau reduction.

Sources: Biogen press release, Biogen AAIC 2026 slide deck

Link to top ⬆️

Ipsen - Iqirvo (PPARa/d dual agonist) / Phase 3b (PBC)

On July 13, 2026, Ipsen announced positive topline results from the Phase 3b ELSPIRE trial, which evaluated the efficacy and safety of Iqirvo (elafibranor) in patients with primary biliary cholangitis (PBC).

Primary biliary cholangitis (PBC) is a chronic, autoimmune-mediated cholestatic disease that destroys small intrahepatic bile ducts, causing bile acid accumulation, inflammation, and potential progression to cirrhosis, making the normalization of biomarkers like alkaline phosphatase (ALP) the primary target to improve patient outcomes. While ursodeoxycholic acid (UDCA) serves as the first-line standard of care, second-line treatments are essential for patients who remain at risk due to inadequate responses. Iqirvo (elafibranor) addresses this need as an oral, once-daily dual PPAR α and δ agonist that modulates bile acid synthesis, detoxification, and transport to decrease bile toxicity and provide anti-inflammatory and anti-fibrotic effects, thereby offering a more targeted approach to achieving biochemical normalization and slowing liver injury.

The Phase 3b ELSPIRE trial demonstrated the therapeutic potential of Iqirvo in early-stage primary biliary cholangitis by enrolling 92 patients with modest baseline alkaline phosphatase (ALP) elevations (1-1.67x ULN) who had an inadequate response to ursodeoxycholic acid. Patients randomized to once-daily Iqirvo showed statistically significant superiority, with 85% achieving ALP normalization (≤1 ULN) at 52 weeks compared to only 23% in the placebo group, all while maintaining a consistent and favorable safety profile. These findings are highly significant as they confirm that achieving optimal biochemical normalization is feasible in a less severe disease population, providing the clinical evidence needed to support a potential label expansion that could facilitate earlier therapeutic intervention and potentially improve long-term patient prognosis.

Ipsen plans to submit these data to regulatory authorities (including the FDA and EMA) to support the expanded use of Iqirvo. The company intends to present the full results from the ELSPIRE trial at an upcoming medical meeting.

Sources: Ipsen press release

Link to top ⬆️

Descriptive data releases without numerical data

  • Takeda - Zasocitinib (TYK2 inhibitor) / Phase 3 (psoriasis): In Phase 3 trials (LATITUDE PsO 3001 and 3002), Takeda’s once-daily oral TYK2 inhibitor, zasocitinib, demonstrated robust and consistent skin clearance across the body, including historically difficult-to-treat areas. Building upon topline results announced in December 2025 and data presented in March 2026, these secondary endpoint results revealed that approximately 75% of patients with scalp psoriasis and 70% of those with palmoplantar disease achieved clear or almost clear skin (ssPGA/hfPGA 0/1) at week 16, significantly outperforming both placebo and the active comparator apremilast. Furthermore, the drug showed statistically significant improvements in nail psoriasis as measured by the NAPSI score (scalp, nails, hands and feet), with benefits across these high-impact sites sustained through week 24, reinforcing zasocitinib’s potential to offer meaningful, whole-body skin clearance as a leading oral treatment option for moderate-to-severe plaque psoriasis. Sources: Takeda press release

  • Merck - Sac-TMT (TROP2 ADC) / Phase 3 (1L PDL1-negative metastatic non-sq NSCLC): In the Phase 3 OptiTROP-Lung06 trial, the combination of sacituzumab tirumotecan (sac-TMT), a TROP2-directed antibody-drug conjugate (ADC), and Keytruda (pembrolizumab) achieved its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to the standard-of-care regimen of pembrolizumab plus platinum-based chemotherapy in patients with previously untreated, PD-L1-negative, metastatic non-squamous non-small cell lung cancer (NSCLC). These results, announced by Kelun-Biotech on July 14, 2026, represent the first instance of an ADC-plus-immunotherapy regimen successfully replacing conventional platinum-doublet chemotherapy in this difficult-to-treat population, where checkpoint inhibitors alone typically demonstrate limited benefit. In addition to the significant PFS improvement, a positive trend in overall survival was observed, and the safety profile remained consistent with prior studies. Sources: Kelun press release

  • GSK - Jemperli (anti-PD1 mAb) / Phase 3 (Stage 2/3 dMMR/MSI-H rectal cancer): In the registrational Phase 2 AZUR-1 trial, GSK’s anti-PD-1 monoclonal antibody Jemperli (dostarlimab) demonstrated a clinically meaningful and sustained clinical complete response (cCR) rate at 12 months in patients with stage II/III mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) locally advanced rectal cancer. By meeting this primary objective, the data support the potential for Jemperli to become the first immunotherapy capable of enabling some patients to avoid the significant morbidity associated with traditional trimodality therapy, specifically the long-term impacts of chemotherapy, radiation, and surgery. The interim analysis confirmed that the safety and tolerability profile of the drug remains consistent with its established performance in other solid tumors, with no new safety signals identified. GSK plans to share these results with global regulatory authorities, including for accelerated review in the United States, to potentially transform the standard of care for this biomarker-defined population. Sources: GSK press release

Link to top ⬆️

Love biotech? Check out Biotech Readout’s full content library, or navigate directly to a segment that interests you:

Biotech Readout is a reader-supported publication. To receive new posts and support my work, consider becoming a free subscriber.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

]]><![CDATA[Eli Lilly to Acquire AtaiBeckley]]>https://biotechreadout.xyz/p/eli-lilly-to-acquire-ataibeckleyhttps://biotechreadout.xyz/p/eli-lilly-to-acquire-ataibeckleyFri, 17 Jul 2026 02:47:56 GMTDisclaimer: This newsletter is for educational and informational purposes only and does not constitute medical, investment, or financial advice, nor does it establish a provider-patient relationship. Content may include forward-looking statements and discussions of investigational therapeutic candidates that are not FDA/EMA approved; their safety and efficacy remain unestablished and clinical outcomes are unpredictable. While we strive for accuracy, all information is provided as is without guarantees. As of the date of publication, the author holds no direct equity positions in the specific companies mentioned in this issue nor receives third-party compensation for this coverage. Note that several of the compounds discussed, including psilocybin, DMT, and MDMA, are classified as Schedule I controlled substances under the U.S. Controlled Substances Act. Please find a complete version of our disclaimers linked here.

If you are a paid subscriber, go to this article’s premium charts & analysis here ⬇️

If you are a free reader or subscriber, enjoy the whole article free of charge and consider upgrading for premium charts & analysis on the depression landscape.

Introduction

On July 16, 2026, Eli Lilly and Company announced a definitive agreement to acquire AtaiBeckley for upfront cash consideration of approximately $2.8 billion plus up to approximately $1.0 billion Contingent Value Right (CVR), for a total deal value of up to $3.8 billion (Eli Lilly press release, AtaiBeckley press release). This acquisition centers on AtaiBeckley’s portfolio of investigational psychedelics for depression or anxiety:

  • BPL-003 (nasal 5-MeO-DMT): This their lead program and is being developed for treatment-resistant depression (TRD). It has been granted FDA Breakthrough Therapy Designation and is ready for Phase 3 clinical development.

  • VLS-01 (oral 5-MeO-DMT): This is a proprietary oral transmucosal film formulation of DMT. By utilizing a dissolving film (similar to a breath strip), it is designed to provide a more patient-friendly, in-clinic alternative to intravenous administration, with a targeted psychedelic effect duration of roughly 30-45 minutes. It is currently in Phase 2 clinical development.

  • ELE-101 (IV psilocin): This is a synthetic intravenous formulation of psilocin, the active metabolite of psilocybin. By administering the active compound directly, it is designed to offer more consistent dosing, a faster onset of action, and a shorter overall treatment duration (approximately two hours) compared to traditional oral psilocybin. It is currently in Phase 1/2a clinical development for major depressive disorder (MDD). A peer in the space, Compass Pathways, recently reported a positive Phase 3 trial for their formulation of synthetic psilocybin (COMP360) in TRD, which bodes well for this class.

  • EMP-01 (oral R-MDMA): This is an oral formulation of the R-enantiomer of MDMA, which is being investigated for the treatment of social anxiety disorder (SAD). Unlike traditional MDMA (which is typically a racemic mixture), EMP-01 is being studied for its potential therapeutic effects without requiring adjunctive psychotherapy. It has completed an exploratory Phase 2a trial, but it unfortunately missed its primary endpoint.

We will cover a more comprehensive history and landscape of depression medicines in a future Frontiers in Medicine piece. In this article, we briefly opine on the medical challenges of managing depression, dive into the story of AtaiBeckley, and explore how their neuroplastogen approach differs from traditional anti-depressants.

I should note that, as of the time of this publication, substances such as psilocybin, DMT, and MDMA remain classified as Schedule I controlled substances by the U.S. Drug Enforcement Agency (DEA). This classification underscores the significant regulatory framework that Eli Lilly/AtaiBeckley must navigate to move these investigational candidates through clinical development, as well as the ethical challenges that different people may have about this type of clinical research.

Reconnecting the Dots

The complexity of the human brain is often described as the most challenging frontier in modern science. With roughly 86 billion neurons and trillions of synaptic connections, the brain functions as a dynamic, non-linear network where structure and activity are in constant flux. When we attempt to map this complexity onto a condition like depression, we encounter a tension between our ability to observe the brain and our conceptual ability to understand it.

Most organs are defined by their specialized mechanical or chemical outputs. The heart is a pump. Its primary function (moving blood) remains consistent throughout life. The kidneys filter toxins based on blood pressure and osmolarity. While they react to environmental stressors, their functional goals (e.g., maintain fluid balance, clear waste) are fixed. The brain has no singular output in the traditional sense. It processes information, stores memory, generates consciousness, and regulates behavior. Crucially, it exhibits neuroplasticity: if a region of the brain is damaged, other regions can often be recruited to take over those functions. No other organ exhibits this degree of structural and functional re-allocation.

The complexity of the brain is further compounded by its vast connectivity. Organs like the stomach or pancreas function as distinct modules. They communicate with the rest of the body through hormones and the endocrine system, but their internal operation is largely self-contained. The brain is the only organ that must integrate inputs from every other system to function. It receives feedback from the endocrine system, the immune system, the gut microbiome, and the sensory organs, and integrates these into a unified internal map of the world. It is the only organ that is in communication with the entirety of the body simultaneously.

The brain’s ever-changing and highly interconnected nature makes neuroscience a study of emergent properties, rather than a study of discrete and well-defined bodily functions. Thoughts arise from the interplay of biochemical signaling (neurotransmitters), electrical activity (neuronal firing), and structural connectivity (white matter tracts). A change in one area, such as the prefrontal cortex, triggers a cascade of changes in distant regions like the amygdala or the hippocampus. It constantly rewires itself based on experience, environment, and internal chemistry. As a result of this plasticity, a snapshot of a depressed brain at one moment may look entirely different minutes or weeks later, making it difficult to establish fixed biomarkers.

The single factor that makes the study of depression challenging is this: there is no universal definition for what a depressed brain looks like. The biological underpinnings of depression in one person may be radically different from those in another, ranging from chronic systemic inflammation to genetic predisposition or dysregulated circadian rhythms. Although hard to measure through traditional medical technology, our lived experience tells us that depression is very much real.

Despite decades of research, our comprehension of the mechanisms causing depression remains incomplete, largely due to several systemic challenges. For many years, psychiatry operated under the monoamine hypothesis, the idea that depression was caused primarily by a deficiency of neurotransmitters like serotonin or norepinephrine. While effective treatments like selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) target these systems, the medical community has come to recognize this view is overly reductionist. For the 1 in 3 people living with Major Depressive Disorder (MDD) who are failed by at least two conventional treatments, the standard of care offers little more than chemical maintenance. Raising serotonin levels helps many, but it does not fix the underlying circuit-level dysfunction for everyone, suggesting that serotonin is a downstream effect rather than the root cause.

Perhaps the most difficult aspect of studying depression is that the condition itself creates a biological feedback loop. Stress hormones (like cortisol) have neurotoxic effects on the hippocampus, the very region responsible for learning and emotional regulation. This means that if someone has been depressed for a long time, the physical architecture of their brain has been altered by the condition, making it incredibly difficult to isolate the cause from the effect.

In recent years, the field has shifted away from looking for broken chemicals to looking for broken circuits. We now understand that depression often involves abnormal communication between the Default Mode Network (DMN), which governs self-referential thought, and the brain’s executive control centers. However, we do not fully understand why these circuits become rigid or hyper-connected in the first place, or how to reliably reset them without global side effects. In this vein, a class of small-molecule drugs called neuroplastogens have recently emerged as a potential way to remodel these brain circuits.

Unlike traditional antidepressants (such as SSRIs) that are once-daily pills aimed at chemical rebalancing of the brain, neuroplastogens are characterized by their ability to induce profound brain-level changes quickly. The class is comprised of two prototypic buckets:

  • Ketamine-based: Spravato (esketamine) was the first ketamine-derived medication to receive FDA approval for Treatment-Resistant Depression (TRD) on March 5, 2019. Developed by Janssen (a Johnson & Johnson company), pivotal Phase 3 studies demonstrated that Spravato, when combined with an oral antidepressant, provided rapid and statistically significant improvements in Montgomery-Åsberg Depression Rating Scale (MADRS) scores compared to placebo plus an oral antidepressant. MADRS is an doctor-rated scale aimed at estimating the severity of depression. Benefits were frequently observed within 24 hours, providing a stark contrast to traditional antidepressants that often take several weeks to show effect.

    Least Squares Mean Change from Baseline in MADRS Total Score Over Time in Patients with TRD in Phase 3 TRANSFORM trial; Source: Spravato label, Table 5

  • Serotonergic Psychedelics: Compounds like psilocybin, DMT, 5-MeO-DMT, and LSD are potent neuroplastogens. They function through complex agonism of the 5-HT2A serotonin receptor and downstream activation of growth-signaling pathways like mTOR. As of the time of this publication, there are no FDA-approved serotonergic psychedelics for the treatment of depression, but this is the area that AtaiBeckley focused on.

Meeting of Minds

Meeting of Minds

AtaiBeckley is, in fact, a fusion of two companies that decided take on depression together. atai Life Sciences N.V. was founded in 2018 with the objective of developing medicines for mental health disorders, which the founders identified as a space suffering from a significant lack of innovation and high unmet medical need. The company was co-founded by three key individuals:

  • Christian Angermayer: A prominent investor and entrepreneur (founder of Apeiron Investment Group) who provided the foundational vision and early financial backing.

  • Florian Brand: Served as a key driver of the company’s operational and strategic growth, later becoming the CEO.

  • Lars Christian Wilde: Contributed specialized expertise to the company’s early development and platform strategy.

The founders were motivated by the disparity between the limited efficacy of existing psychiatric treatments and the growing global mental health crisis. They aimed to develop rapid-acting, durable, and convenient therapies for conditions like depression, anxiety, and addiction. Like others before them, they decided to utilize a hub-and-spoke model (centralize resources with modular programs), rather than operating as a traditional, monolithic pharmaceutical firm. atai was designed as a decentralized platform that incubates and supports subsidiary companies. This allowed the company to pool resources, regulatory expertise, and scientific best practices to accelerate the development of multiple assets simultaneously. From its origins as a startup based in Berlin, Germany, atai Life Sciences grew rapidly, securing significant capital from high-profile investors like Peter Thiel. The company eventually transitioned to a publicly traded entity, listing on the NASDAQ in June 2021. In late 2025, atai Life Sciences N.V. merged with Beckley Psytech Limited to form the current entity, AtaiBeckley Inc.

Beckley Psytech was founded in 2019 in Oxford, United Kingdom, as a for-profit clinical-stage biopharmaceutical company. The company was co-founded by a mother-son duo deeply embedded in the field of psychedelic research. Cosmo Feilding Mellen served as the company’s CEO and was the primary driving force behind its transition into a clinical-stage drug development firm. Lady Amanda Feilding was a globally recognized pioneer in psychedelic science who established the non-profit Beckley Foundation in 1998.

Beckley Psytech was built upon the decades of scientific research and advocacy work conducted by the Beckley Foundation. While the non-profit Foundation focused on scientific exploration and policy advocacy to reignite interest in psychedelic science, Beckley Psytech was established to take those scientific insights and translate them into licensed, regulated pharmaceutical medicines. The core mission of the company was to address the limitations of existing mental health treatments by developing rapid-acting, psychedelic-based therapies. Their research focus specifically prioritized compounds with a short time-in-clinic duration, aiming to create scalable treatments that could be safely administered and monitored in a healthcare setting, ideally with patient discharge possible within a few hours. Over its years as an independent private company, Beckley Psytech built a robust pipeline of novel psychedelic compounds, including their flagship asset BPL-003 (intranasal 5-MeO-DMT).

In July 2025, Beckley reported topline data for a Phase 2b study demonstrating that a single dose of BPL-003 produced statistically significant and durable reductions in depression scores (MADRS) in patients with Treatment-Resistant Depression (TRD). At Day 29, the 8mg dose showed a 12.1-point mean reduction in MADRS scores from baseline (vs. 5.8 in control). Statistically significant improvements were observed as early as Day 2 and were maintained through Week 8. This clinical success served as the catalyst for the merger and led to an FDA Breakthrough Therapy Designation. By mid-2026, the company had successfully aligned with the FDA on End-of-Phase 2 (EOP2) requirements, clearing the path for the initiation of Phase 3 trials. While the company’s current data is promising, it remains a hypothesis that these results will be replicated in larger, late-stage trials.

Single-dose of BPL-003 met primary endpoint (MADRS) in a Phase 2b trial, with effects sustained out to Week 8; Source: AtaiBeckley presentation, slide 23

The evolution of AtaiBeckley culminated in its acquisition by Eli Lilly and Company, announced on July 16, 2026. The move signaled that a big pharma was willing to bet on the neuroplastogen thesis. Not just any big pharma, but an anti-depressant powerhouse that developed SSRI Prozac (fluoxetine) in the 1970s and SNRI Cymbalta in the early 2000s.

Conclusion

The acquisition of AtaiBeckley accelerates a shift in how the pharmaceutical industry approaches depression. By bringing BPL-003 and its neuroplasticity-focused pipeline into the fold, Eli Lilly evolves from the era of chronic chemical maintenance typified by Prozac and Cymbalta to an era of interventional, circuit-level repair. While the road to commercializing psychoplastogens remains fraught with clinical and regulatory hurdles, clinical & commercial successes like J&J’s Spravato suggests that the future lies in rewiring brain connections rather than rebalancing more brain chemicals.

Premium Charts & Analysis

All charts reflect data current as of the specified date and may not include every drug development program, although we aimed to capture the vast majority. Please feel free to email me at biotechreadout@gmail.com with “CHARTS” in the subject line to share suggestions or request chart updates.

Press ⬇️ to navigate to a section

  • Notable Acquisitions in Depression ⬇️

  • Top Selling Medicines in Depression ⬇️

  • Top 20 Targets in Depression ⬇️

  • Depression Pipeline of Strategic Acquirers ⬇️

Read more

]]><![CDATA[First positive Phase 3's for B7-H3 in cancer and psilocybin in depression, and more]]>https://biotechreadout.xyz/p/first-positive-phase-3s-for-b7-h3https://biotechreadout.xyz/p/first-positive-phase-3s-for-b7-h3Fri, 10 Jul 2026 19:07:24 GMTDisclaimer: This newsletter is for educational and informational purposes only and does not constitute medical, investment, or financial advice, nor does it establish a provider-patient relationship. Content may include forward-looking statements and discussions of investigational therapeutic candidates that are not FDA/EMA approved; their safety and efficacy remain unestablished and clinical outcomes are unpredictable. While we strive for accuracy, all information is provided as is without guarantees. As of the date of publication, the author holds no direct equity positions in the specific companies mentioned in this issue nor receives third-party compensation for this coverage. Please find a complete version of our disclaimers at the bottom of this article and on our About page.

Press ⬇️ to go down to a section and ⬆️ to go back up to the Table of Contents

Table of Contents

This week, we discuss:

  • China Biotech

    • China has caught up in biotech. How screwed are we? ⬇️

  • Acquisitions ⬇️

    • Vertex to Acquire Crinetics, how R. Scott Struthers and his crew from Neurocrine went out on their own and struck gold in rare metabolic disease

    • Novartis to Acquire Myricx Bio, another preclinical ADC payload company exits north of a billion dollars

  • Approvals

    • Sanofi - Sarclisa Escena (anti-CD38 mAb via subcutaneous on-body injector) / Approved (multiple myeloma) ⬇️

    • Vera - Trutakna (APRIL/BAFF inhibitor) / Approved (IgAN) ⬇️

  • Clinical Trial Data

    • Compass Pathways - COMP360 (synthetic psilocybin) / Phase 3 (TRD) ⬇️

    • Forte Biosciences - FB102 (anti-CD122 mAb) / Phase 1b (vitiligo) ⬇️

    • Fate - FT819 (allogeneic CD19 CAR-T) / Phase 1 (SSc) ⬇️

    • Ipsen - Dysport (Botulinum toxin) / Phase 3 (migraine) ⬇️

    • GSK - Risvutatug rezetecan (B7-H3 ADC) / Phase 3 (ES-SCLC) ⬇️

China Biotech

China has caught up in biotech. How screwed are we?

Here, I briefly discuss an article of the same title that was written by fellow Substacker and biotech enthusiast . It’s a data-rich piece about the rapid growth of the Chinese biotech industry and asks whether it represents an existential threat to American pharmaceutical hegemony. Three points stood out to me:

  1. Chinese companies out-licensed $137.7 billion in drug assets in 2025, capturing 44% of global licensing value.

  2. Approximately 1/3 of the global clinical-stage pipeline now originates in China.

  3. It is about 2-3 times cheaper to run a successful clinical program in China compared to the West (see graph below).

Source: China has caught up in biotech. How screwed are we? by Alex Kesin

As a student of history, my favorite part about Alex’s article was the parallel he drew between the rise of Japanese biotech in the 1980s and the rise of Chinese biotech today. Both have leveraged their robust manufacturing bases and government collaboration to seed their industries. Both countries have also struggled to build out a commercial infrastructure that is large enough to launch medicines outside of their home countries, which is perhaps why licensing agreements have so far been their status quo. Yet, pharmas hailing from both countries have recently started making progress on this front:

My discussion here only skims the surface of Alex’s article. I highly recommend you read it yourself:

Alex Kesin's Pharmacopoeia
China has caught up in biotech. How screwed are we?
On July 19th, Yoni Ben-Shimon and I are hosting a half-day Bay Area retreat to dig into the ideas in this piece. We’re bringing together biotech operators and policy people. If that's you, apply here…
Read more
a month ago · 19 likes · 3 comments · Alex Kesin

Sources: China has caught up in biotech. How screwed are we? by Alex Kesin

Link to top ⬆️

Acquisitions

Link to top ⬆️

Approvals

Sanofi - Sarclisa Escena (anti-CD38 mAb via subcutaneous on-body injector) / Approved (multiple myeloma)

On July 9, 2026, the FDA approved Sarclisa Escena (isatuximab-irfc), a subcutaneous formulation of the CD38-directed monoclonal antibody, for the treatment of multiple myeloma (MM). This approval is a significant development in oncology care, as it introduces the first anticancer treatment capable of being administered via an on-body injector (OBI). It is approved for use with an on-body delivery system (the CirCLIQ OBI) and can also be administered manually via a syringe and infusion set. The approval applies to all existing indications for the intravenous (IV) formulation of Sarclisa. Approval was supported by the IRAKLIA phase 3 study, which demonstrated that the subcutaneous formulation provided non-inferior efficacy (ORR 71.1% subcutaneous versus 71.1% IV), pharmacokinetics, and safety compared to the traditional IV infusion, while offering a significantly shorter treatment time and fewer infusion-related reactions. The safety profile was comparable between the two arms, with one critical advantage: systemic infusion-related reactions occurred in only 1.5% of the subcutaneous arm, compared to 25% in the intravenous arm. Beyond efficacy and safety, the IRAKLIA study highlighted significant benefits for the patient experience. Subcutaneous delivery is significantly faster than the multi-hour IV infusion. A majority (74.5%) of patients who experienced both administration methods preferred the on-body injector over manual injection. Patients reported higher satisfaction levels with the subcutaneous treatment compared to the intravenous arm.

Sources: Sanofi press release, FDA press release

Link to top ⬆️

Vera - Trutakna (APRIL/BAFF inhibitor) / Approved (IgAN)

Vera Therapeutics’ Trutakna (atacicept) received FDA accelerated approval on July 7, 2026, to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. IgAN affects approximately 160,000 patients in the U.S. and is a leading cause of chronic kidney disease and failure. Trutakna is the first FDA-approved dual inhibitor of BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand). By blocking both cytokines, it reduces the production of pathogenic galactose-deficient IgA1 (Gd-IgA1) antibodies, which are central to the pathogenesis of IgAN. The approval was based on a prespecified interim analysis of the ongoing Phase 3 ORIGIN 3 trial. In the first 203 patients, Trutakna demonstrated a -46% reduction in proteinuria (protein in the urine) from baseline, compared to a -7% reduction in the placebo arm at week 36 (P < 0.0001). As an accelerated approval based on the surrogate marker of proteinuria, Vera is required to confirm clinical benefit, specifically regarding the long-term impact on kidney function decline. The company has aligned with the FDA on a revised analysis plan, with pivotal eGFR (estimated glomerular filtration rate) results, which they expected to report in 3Q 2026. Trutakna competes with Otsuka’s Voyxact (sibeprenlimab), a selective APRIL inhibitor that received FDA accelerated approval in November 2025. While Voyxact is administered once every four weeks, Trutakna is dosed via weekly subcutaneous injection.

Geometric Mean (95% CI) Percent Change from Baseline in UPCR by Visit in Origin 3 trial; Source: FDA label for Trutakna, Figure 1

Sources: Vera press release, Trutakna label

Link to top ⬆️

Clinical Trial Data

Compass Pathways - COMP360 (synthetic psilocybin) / Phase 3 (TRD)

Compass Pathways recently reported positive six-month data from its second pivotal Phase 3 trial (COMP006) for COMP360 (synthetic psilocybin) in patients with Treatment-Resistant Depression (TRD).

Treatment-Resistant Depression (TRD) is a complex condition driven by neuroinflammation, disrupted glutamatergic signaling, and impaired neural connectivity, necessitating multifaceted treatment approaches ranging from optimized pharmacotherapy and psychotherapy to interventional strategies like ECT, rTMS, and Spravato (esketamine). The “treatment resistant” part means that a patient has failed to respond to two or more adequate courses of antidepressant therapy. COMP360, a synthetic psilocybin formulation, offers a novel mechanism of action by acting as a 5-HT2A receptor agonist (serotonin receptor family). When administered with psychological support, it aims to facilitate profound neuroplasticity and neural reconfiguration, potentially interrupting the rigid depressive thought patterns that resist standard therapeutic interventions.

In a randomized, double-blind Phase 3 trial involving 581 patients with highly chronic treatment-resistant depression (TRD), COMP360 (25 mg) demonstrated clinical efficacy with 39% of participants achieving a ≥25% reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) scores at Week 6, a benefit maintained through six months in responders. For context, MADRS is a doctor-rated scale consisting of 10 core symptoms of depression. This clinical endpoint emphasizes psychological and cognitive symptoms, making it highly responsive to the effects of antidepressant medication. Additionally, nearly 30% of those retreated in the study achieved remission, while the safety profile remained consistent with previous findings, characterized by transient, day-of-dosing adverse events. By offering a “pulsed” dosing model that could require only a few sessions annually, COMP360 may provide a potentially differentiating alternative to the chronic daily medications or frequent clinical visits necessitated by existing standard-of-care therapies like Spravato (twice weekly to once every two weeks).

Compass Pathways is currently executing a rolling New Drug Application (NDA) submission with the FDA. They anticipate the final NDA submission for 4Q 2026. Pending FDA approval and DEA rescheduling of psilocybin, Compass expects to initiate a U.S. commercial launch the first half of 2027. Notably, COMP360 has been granted a Commissioner’s National Priority Voucher (CNPV). This program provides enhanced FDA communication and a significantly shortened review timeline (targeting 1–2 months) once the rolling NDA is finalized.

MADRS change from baseline in the Phase 3 COMP006 trial (solid lines) is consistent with another Phase 3 COMP360 trial (dotted lines); Source: Compass Pathways presentation, slide 8

Sources: Compass Pathways press release, Compass Pathways slide deck

Link to top ⬆️

Forte Biosciences - FB102 (anti-CD122 mAb) / Phase 1b (vitiligo)

Forte Biosciences recently announced positive results from its Phase 1b study of FB102, an investigational treatment for vitiligo.

Vitiligo is an autoimmune condition driven by the oxidative-stress-triggered activation of cytotoxic CD8+ T cells, which selectively destroy pigment-producing melanocytes and necessitate standard-of-care treatments ranging from topical corticosteroids and calcineurin inhibitors to phototherapy and targeted JAK inhibitors. FB102, an anti-CD122 monoclonal antibody, offers a novel mechanism of action by selectively modulating the IL-2 and IL-15 signaling pathways. By inhibiting the activation of pathogenic cytotoxic and tissue-resident memory T-cells while preserving regulatory T-cells, FB102 aims to provide a more precise and safer immunomodulatory approach to arresting disease progression and facilitating repigmentation.

In a randomized, double-blind, placebo-controlled Phase 1b trial of 43 patients with vitiligo, FB102 demonstrated significant clinical efficacy, achieving a 29.6% mean improvement in the Facial Vitiligo Area Scoring Index (FVASI) at Week 24 compared to -16.2% for placebo (p=0.005) in the intent-to-treat (ITT) population. Patients with more extensive baseline disease experienced an even more robust 43.2% mean improvement, and the therapeutic benefit was notable for being progressive and sustained even after the 12-week dosing period concluded. FB102 was generally well-tolerated, with all reported adverse events classified as mild to moderate and a safety profile that compared favorably to placebo.

Forte Biosciences is looking toward its upcoming Phase 2 celiac disease trial readout as the next major clinical catalyst for FB102. Management has indicated that the successful vitiligo data reinforces the drug’s broad potential across multiple autoimmune indications.

Sources: Forte press release, Forte slide deck

Link to top ⬆️

Fate - FT819 (allogeneic CD19 CAR-T) / Phase 1 (SSc)

Fate Therapeutics presented data at the International Society for Stem Cell Research (ISSCR) 2026 meeting regarding their Phase 1 basket trial of FT819 in systemic sclerosis (SSc).

Systemic Sclerosis (SSc) is a chronic, incurable autoimmune condition marked by immune dysregulation, vascular damage, and progressive organ fibrosis, currently managed through symptom-specific support and immunosuppression. However, FT819 offers a potential therapeutic shift as an off-the-shelf, iPSC-derived CD19 CAR T-cell therapy designed to deplete auto-reactive B-cells. By utilizing a standardized iPSC bank instead of patient-specific cells and incorporating a TRAC locus knockout to eliminate GvHD risk, FT819 provides a scalable, on-demand alternative to traditional autologous therapies for addressing the underlying drivers of severe autoimmune disease.

In the ongoing Phase 1 basket trial, the first four systemic sclerosis (SSc) patients treated with the off-the-shelf, iPSC-derived CAR T-cell therapy FT819 achieved significant clinical success, with all four participants meeting an rCRISS score of ≥25 and demonstrating meaningful improvements in skin thickness (mRSS) at three months. Notably, the treatment maintained a relatively clean safety profile (devoid of CRS, ICANS, or GvHD) and was successfully administered in outpatient or rapid-discharge settings without the need for intensive lymphodepleting chemotherapy. These results underscore the potential for FT819 to serve as a scalable, on-demand alternative to traditional autologous therapies, potentially overcoming key barriers to CAR T-cell access for patients with severe, treatment-resistant rheumatic diseases.

Investigators plan to continue monitoring the durability of responses and safety in the current SSc cohort. Efforts are underway to identify which specific patient subpopulations are most likely to derive the greatest benefit. Fate Therapeutics continues to advance FT819 in other autoimmune indications (e.g., lupus nephritis) and is preparing for further regulatory discussions regarding a potential pivotal/registrational trial.

Sources: Fate ISSCR 2026 slide deck

Link to top ⬆️

Descriptive data releases without numerical data

  • Ipsen - Dysport (Botulinum toxin) / Phase 3 (migraine): Ipsen recently announced positive Phase 3 results for Dysport (abobotulinumtoxinA), demonstrating that it successfully met its primary endpoint in two pivotal trials by significantly reducing monthly migraine days in patients with episodic migraine. This milestone marks the first time a botulinum toxin has shown clinical efficacy in improving symptoms for the episodic migraine population, a development that could potentially differentiate it from current botulinum toxin approvals, which are generally restricted to chronic migraine. Ipsen plans to present full results at an upcoming medical conference.

  • GSK - Risvutatug rezetecan (B7-H3 ADC) / Phase 3 (ES-SCLC): The pivotal Phase 3 ARTEMIS-008 trial of risvutatug rezetecan (Ris-Rez), a B7-H3-targeted antibody-drug conjugate (ADC), successfully met its primary endpoint of overall survival (OS) in patients with advanced or relapsed small-cell lung cancer (SCLC) in China. Conducted by GSK’s partner, Hansoh Pharma, the study demonstrated statistically significant and clinically meaningful improvements in OS compared to the standard-of-care chemotherapy, topotecan, while also showing consistent benefits in progression-free survival with a manageable safety profile. These findings mark the first positive Phase 3 overall survival data for a B7-H3-targeted ADC in any tumor type, validating the biological rationale for this target and supporting upcoming regulatory submissions in China. For GSK, which holds exclusive rights outside of Greater China, these results reinforce the potential of Ris-Rez as a priority asset and support the ongoing global development program, including the Phase 3 EMBOLD SCLC-301 trial, with pivotal data expected in 2027.

Link to top ⬆️

Love biotech? Check out Biotech Readout’s full content library, or navigate directly to a segment that interests you:

Biotech Readout is a reader-supported publication. To receive new posts and support my work, consider becoming a free subscriber.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

]]><![CDATA[Vertex to Acquire Crinetics]]>https://biotechreadout.xyz/p/vertex-to-acquire-crineticshttps://biotechreadout.xyz/p/vertex-to-acquire-crineticsTue, 07 Jul 2026 23:20:03 GMTDisclaimer: This newsletter is for educational and informational purposes only and does not constitute medical, investment, or financial advice, nor does it establish a provider-patient relationship. Content may include forward-looking statements and discussions of investigational therapeutic candidates that are not FDA/EMA approved; their safety and efficacy remain unestablished and clinical outcomes are unpredictable. While we strive for accuracy, all information is provided as is without guarantees. As of the date of publication, the author holds no direct equity positions in the specific companies mentioned in this issue nor receives third-party compensation for this coverage. Please find a complete version of our disclaimers linked here.

If you are a paid subscriber, go to this article’s premium charts & analysis here ⬇️

If you are a free reader or subscriber, enjoy the whole article free of charge and consider upgrading for premium charts & analysis on acromegaly and CAH (samples).

Introduction

On July 6, 2026, Vertex Pharmaceuticals Incorporated announced a definitive agreement to acquire Crinetics Pharmaceuticals, Inc. for a total equity value of approximately $10.0 billion (Vertex press release, Vertex slide deck, Crinetics press release). This acquisition centers on the two most advanced programs in Crinetics’ pipeline:

  • Palsonify (paltusotine; FDA-approved SST2 agonist): In September 2025, the FDA approved this drug for the treatment of adults with acromegaly who have had an inadequate response to surgery and/or who are not candidates for surgery. It is also being investigated in Phase 3 trials for carcinoid syndrome associated with neuroendocrine tumors (NETs). Palsonify is the first once-daily oral small molecule to achieve FDA approval in acromegaly, providing patients with a non-invasive alternative that maintains biochemical control (normalization of IGF-1 and growth hormone levels).

  • Atumelnant (ACTH inhibitor in Phase 3): This is an investigational agent currently in Phase 3 development (CALM-CAH trial). It is being developed for ACTH-dependent endocrine disorders, primarily Classic Congenital Adrenal Hyperplasia (CAH) and ACTH-dependent Cushing’s Syndrome (ADCS).

In this article, we tease out Vertex’s M&A strategy, learn how a team of Neurocrine scientists struck out on their own to start Crinetics, and do a deep pull of their under-discussed early stage pipeline.

A Peek Into Vertex’s M&A Strategy

During Vertex’s presentation regarding its $10 billion acquisition of Crinetics, CEO Reshma Kewalramani outlined a set of five criteria that the company looks for in order to gauge strategic fit, noting that she viewed both Palsonify and atumelnant as meeting all of them:

Adapted from Vertex presentation, slide 5

Together, Vertex contends that these five criteria act as a flywheel. Since they target specialty markets, they require limited SG&A (Sales, General & Administrative) expenses and infrastructure to market a drug. High-value transformative medicines command strong pricing power, leading to robust operating margins and significant cash flow. In other words, they follow the old adage of ‘doing well by doing good’. Vertex can then use that cash flow to invest the heavy majority of its operating expenses right back into internal R&D and external innovation to create new high-impact medicines, repeating the cycle.

Separately, Vertex originally set an ambitious internal goal in 2023 to launch 5 new medicines within 5 years. By acquiring Crinetics, which features the recently approved Palsonify and late-stage atumelnant, Vertex successfully checked off this strategic milestone more than two years ahead of its deadline and added a new vertical to their rare disease pipeline (see below). By acquiring a company with an existing commercial footprint (Palsonify) alongside a deep, mid-to-late-stage pipeline (atumelnant and others), Vertex aims to establish a scaled endocrinology franchise while building a potential runway for long-term growth.

Source: Vertex presentation, slide 16

Self-made Scientists

The pioneers of Silicon Valley’s technology boom are known as the “Traitorous Eight”, a group of eight employees who resigned from Shockley Semiconductor Laboratory in 1957 due to William Shockley’s authoritarian management and research direction to found Fairchild Semiconductor. Fairchild went on to invent the first commercially viable integrated circuit and members of this group spun out to found Intel, AMD, and some of the world’s largest venture capital firms (like Kleiner Perkins). The story of Crinetics starts less than 500 miles away in San Diego, and echoes the courageous founding story of Fairchild.

In May 2006, the FDA issued a crushing complete response letter (CRL) to Neurocrine Biosciences for indiplon, an experimental insomnia drug partnered with Pfizer in a deal worth up to $400 million, requesting an immediate-release version of the modified-release version. Pfizer immediately terminated the partnership, stripping Neurocrine of its primary funding engine. When a 2007 resubmission resulted in yet another CRL demanding costly new clinical safety studies, Neurocrine was forced to completely abandon the drug in the U.S. With its primary asset dead and its stock price tumbling, Neurocrine had to execute a brutal pivot to stabilize the business. Gary Lyons, who had served as CEO and President since the company’s founding in 1993, stepped down in January 2008. He was replaced by Dr. Kevin Gorman, who was tasked with completely re-architecting the company’s survival strategy. Neurocrine underwent consecutive rounds of workforce restructuring. In a short period, the company slashed its workforce from hundreds of employees down to a lean core of just about 60 people.

Neurocrine also decided to pool their remaining capital into just two high-value clinical assets, which they deemed to have the highest probability of success (what eventually became Orlissa for endometriosis & uterine fibroids and Ingrezza for tardive dyskinesia). This aggressive funneling of resources meant that excellent internal programs deemed “non-essential” for Neurocrine’s immediate survival were abruptly shelved or de-prioritized. Among these hidden gems was a deep, world-class exploratory research platform focused on peptide chemistry and G-protein coupled receptors (GPCRs) in endocrinology which included a team composed of Dr. R. Scott Struthers, Dr. Stephen Betz, Dr. Frank Zhu, and Dr. Ana Kusnetzow. Dr. R. Scott Struthers and his core team of fellow Neurocrine scientists knew this platform possessed immense therapeutic potential, particularly for rare endocrine diseases like acromegaly. However, they also recognized that Neurocrine, in its newly restructured state, could no longer fund broad, early-stage endocrine discovery.

Rather than letting decades of collective expertise evaporate in the layoffs, Struthers and his colleagues parted ways with the parent company in 2008 to form Crinetics Pharmaceuticals. By breaking away, they preserved that specialized GPCR chemistry engine, carrying forward a scientific torch that Neurocrine was forced to drop. They did not have millions in initial venture funding. Instead, they bootstrapped the early years through highly competitive NIH grants and peer-validated non-dilutive funding, focusing their brilliant chemical design engines on the human endocrine system. Endocrinology was historically dominated by large pharma companies manufacturing injectable peptide biologics. For rare endocrine diseases like acromegaly (severe overgrowth of bones and organs caused by excess growth hormone), the standard of care was burdensome: patients had to visit clinics for painful, large-needle, deep intramuscular or subcutaneous injections every month. The Crinetics founders asked a simple question: What if we could design an oral, once-daily non-peptide small molecule that binds to the same receptors just as powerfully?

In 2016, after years of iterative synthesis, the team crossed an early checkpoint. They synthesized a molecule called paltusotine (originally CRN00808). It was a selective, non-peptide oral somatostatin receptor type 2 (SST2) agonist designed to shut down excess growth hormone. Since it was a pill, it eliminated the need for a needle. Backed by this stellar chemistry, blue-chip healthcare venture firms like 5AM Ventures and OrbiMed took notice, infusing the company with the capital required to enter the clinic. To fund expensive late-stage clinical trials, Crinetics went public on the NASDAQ exchange in 2018.

Over the next several years, under the steady leadership of CEO Scott Struthers, the company transitioned from a lean discovery shop into a clinical execution powerhouse. They deliberately avoided diversifying into completely unrelated therapeutic areas, choosing instead to double down on endocrinology. They uncovered a second pipeline asset: atumelnant (CRN04894), the first oral, once-daily ACTH receptor antagonist designed to treat grueling conditions like Congenital Adrenal Hyperplasia (CAH) and Cushing’s syndrome.

A major inflection point arrived between 2023 and 2024 when Crinetics announced resounding success in its Phase 3 PATHFNDR trials for paltusotine. The data proved that a single daily pill could maintain disease control and suppress symptoms just as effectively as the painful, deep-tissue legacy injections. The first trial (PATHFNDR-1) addressed the hundreds of thousands of acromegaly patients worldwide already stabilized on standard-of-care monthly injectable somatostatin receptor ligands (SRLs) like octreotide or lanreotide. These patients were forced to endure deep, painful tissue injections that often left behind bruising, nodules, and breakthrough symptoms as the month waned. The trial showed that a stunning 83% of patients on paltusotine successfully maintained their IGF-1 levels at or below the upper limit of normal (≤1x ULN), compared to a dismal 4% of patients randomized to the placebo group who saw their disease biomarkers spike almost immediately after stopping their injections.

PATHFNDR-1 trial: Proportion of Participants Maintaining Biochemical Control (IGF-1 Levels ≤1.0×ULN) in Adults with Acromegaly and Previously Maintained on a Somatostatin Analog Injection; Source: Palsonify label, table 7

With PATHFNDR-1 proving that controlled patients could be safely transitioned onto paltusotine, Crinetics launched its second major front: PATHFNDR-2. This trial was designed to test the drug’s potency in sicker patients who had active, biochemically uncontrolled acromegaly. The trial enrolled 111 adult patients who were either entirely medication-naïve (had never received medical therapy after an unsuccessful surgery) or had completely washed out of prior medications, entering the trial with highly elevated, active baseline IGF-1 levels. By the end of the 24-week randomized control period, 55.6% of paltusotine-treated patients achieved complete biochemical normalization (≤1x ULN), obliterating the 5.3% response rate in the placebo arm (P < 0.0001). The majority of participants who achieved IGF-1 normalization during the trial did so within the first 2-4 weeks following initiation of treatment, with sustained response through the end of the treatment period. A posthoc subgroup analysis clarified the response rates in patient subpopulations with different disease severity (ie. better or worse responses to prior therapy), shown in the table below.

PATHFNDR-2 trial: Proportion of Participants Achieving Biochemical Control (IGF-1 Levels ≤1.0×ULN) at Week 24 in Adults with Acromegaly Based on Prior Biochemical Control; Source: Palsonify label, table 6

Crucially, across both trials, the safety profile remained relatively clean. There were no serious adverse events attributed to paltusotine during the randomized control phases. The only side effects noted were mild, transient gastrointestinal shifts (like mild diarrhea or abdominal discomfort) typically observed with any somatostatin-class medicine, which quickly resolved without forcing discontinuation. The final validation of the PATHFNDR program came from its Open-Label Extensions (OLE) data, which was presented at ENDO 2026. When given the choice at the end of the blind trials, an overwhelming majority of patients (93% from PATHFNDR-1 and over 97% from PATHFNDR-2) actively refused to go back to legacy monthly injections, choosing instead to enroll in the long-term oral tracking study. Long-term data tracking these extension cohorts out for a full two years confirmed that the oral drug’s efficacy never waned, maintaining stable biomarker and symptom control across the board.

Shortly after Palsonify’s topline Phase 3 success, Crinetics’ second program atumelnant posted stellar Phase 2 results. Historically, CAH patients have had to take massive, supraphysiologic doses of glucocorticoids just to suppress excess adrenal androgens, resulting in severe steroid-induced side effects like weight gain, diabetes, and osteoporosis. As a first-in-class, once-daily oral ACTH receptor antagonist, Atumelnant aimed to bypass this entire cycle by directly blocking androgens production in the adrenal cortex. In the Cohort 4 of atumelnant’s Phase 2 trial, the drug maintained a -67% mean reduction in A4 morning serum levels at week 12 (see graph below). This reduction was observed despite the trial’s strict protocol of titrating patients off their high-dose steroid regimens down to safe, physiologic replacement levels (i.e. removing background treatment). Furthermore, 88% of patients in the trial (7 out of 8) successfully transitioned down to physiologic daily doses of glucocorticoids without losing control of their androgens. These data suggest the potential to decouple the management of hyperandrogenism from high-dose steroid toxicity. Across all cohorts and extending into the Open-Label Extension (OLE) representing hundreds of cumulative weeks of exposure, atumelnant proved to be generally well-tolerated. There were zero treatment-related severe or serious adverse events (SAEs), no patients dropped out of the study due to drug tolerability issues, and there were no hepatic transaminase or liver-related adverse events. The most common mild side effects recorded were simple headaches and fatigue. The adult Phase 3 clinical development program evaluating atumelnant (CALM-CAH trial) officially began in late 2025. Shortly thereafter, in January 2026, Crinetics expanded the Phase 3 clinical footprint by initiating a separate pediatric Phase 2/3 trial (the Balance-CAH study) to evaluate the drug’s efficacy and safety in children and adolescents living with classic CAH.

Rapid, substantial and sustained A4 Reductions (key biomarker for CAH disease control) in the Phase 2 TouCAHn trial; Source: Crinetics presentation, slide 27

In September 2025, the FDA officially approved paltusotine under the brand name Palsonify. It made medical history as the first and only once-daily oral alternative to injectable therapies for adults living with acromegaly. Soon after, the European Medicines Agency (EMA) followed suit with its own approval. Crinetics immediately began setting up commercial infrastructure and gaining early momentum. For a drug that only recently launched, the awareness and intent among endocrinologists was exceptionally mature, as captured in Vertex’s market research (see below).

Source: Vertex presentation, slide 9

Among potential prescribing doctors (endocrinologists):

  • About 80% of doctors already knew Palsonify by name without being prompted, indicating highly effective scientific communication and medical affairs execution.

  • About 70% of doctors were actively prepared to write prescriptions for Palsonify.

  • Endocrinologists viewed Palsonify as equal to injectables in raw efficacy, but viewed it as a best-in-class (BIC) option across patient preference metrics: speed of onset, oral route of administration, once-daily dosing frequency, and duration of response.

In rare disease launches, commercial uptake is often throttled because a drug is only approved for a very narrow subset of patients (e.g., only those who fail surgery). Palsonify avoids this trap with a broad label covering both treatment-naïve patients and those switching from other therapies. Whether a patient is an injectable switch, completely treatment-naïve, on another add-on therapy, or one of the 45% who discontinued prior treatment entirely, they are all eligible. In its very first few months on the market, Palsonify has already captured up to half (40-50%) of all newly initiated or switched prescriptions in the space, according to Vertex’s Komodo Claims Analysis from April 2026. The biggest barrier to any biotech launch is getting insurance companies to pay for it. Palsonify is on an accelerated trajectory, on track to achieve 75% reimbursement coverage by the third quarter of 2026, according to Vertex. With half of the new prescription market share already captured, near-total physician awareness, and broad insurance coverage locking in by next quarter, Palsonify’s appears to be rapidly solidifying its place as the new standard of care for acromegaly.

Recognizing that Crinetics matched Vertex’s acquisition criteria for high-margin, low-overhead specialty assets, the biotech titan stepped in. On July 6, 2026, Vertex announced a definitive agreement to acquire Crinetics for approximately $10.0 billion. Reflecting on the monumental decades-long journey from a modest startup to a multi-billion dollar cornerstone of Vertex’s new endocrinology disease pillar, Dr. Scott Struthers remarked, “Nearly 18 years ago, we founded Crinetics with a clear goal of transforming the lives of patients living with endocrine-related diseases. Today marks a historic milestone as we embark on this next chapter with Vertex.”

Biotech Readout is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

Excavating Crinetics’ Hidden Gems

During Vertex’s presentation, Charles Wagner (EVP, COO and CFO at Vertex) briefly commented, “We also see value in Crinetics additional pipeline assets. We’ll discuss that post close [of the acquisition].” Well, consider this an unofficial preview, courtesy of Biotech Readout. I noticed that the Crinetics pipeline is much larger than the two programs headlining the acquisition announcement. These assets are not the typical long tail of low-priority programs or backup molecules for lead programs. These assets aim to pursue large metabolic indications and even introduce a whole new drug modality. I’ll start with the latter.

CRN09682 is a first-in-class non-Peptide Drug Conjugate (NDC), a spin on the antibody-drug conjugate (ADC) but with a small molecule for targeting instead of an antibody. It consists of a selective, small-molecule SST2 agonist chemically linked to a potent cytotoxic payload, monomethyl auristatin E (MMAE), via a spacer and a cleavable linker. Since small molecules exhibit distinct tissue penetration, stability, and clearance kinetics compared to large antibodies or peptides, this approach aims to deliver targeted cytotoxic agents deep into solid tumors with a shorter plasma half-life. The drug is being evaluated as a treatment for advanced, progressive metastatic, or locally inoperable neuroendocrine tumors (NETs), neuroendocrine carcinomas (NECs), and other solid tumors (e.g., small cell lung cancer, thyroid cancer, meningioma) that explicitly express somatostatin receptor type 2 (SST2). CRN09682 is in Phase 1/2 clinical development (the BRAVESST2 trial).

Okay, that’s intriguing. What else? How about once-daily oral small molecules for three large metabolic diseases that are currently dominated by injectables. So, I guess they were just getting warmed up with Palsonify.

But, wait there’s more. Hold on, I can’t quite make out the last two programs. Zoom and enhance that image.

Oh, it’s nothing; just two shots on goal for obesity, the largest drug market of all time. No wonder Vertex CEO Reshma Kewalramani spent so much time talking about the people and culture that they will gain by in-housing Crinetics. Clearly, the team has been hard at work creating expansive optionality for a cash-rich Vertex to potentially expand into a thriving ecosystem of franchises. I, for one, am very curious to hear what the Vertex team has to “discuss post close”.

Conclusion

The $10 billion acquisition of Crinetics is a testament to what happens when elite drug hunters double down on a scientific thesis. By transforming complex, burdensome peptide injections into elegant, once-daily oral therapies, R. Scott Struthers and his team are on track to redefine the standard of care for patients living with acromegaly and, perhaps someday, other rare metabolic diseases. As Crinetics integrates into the Vertex engine, the immediate commercial momentum of Palsonify and the potential of atumelnant are encouraging. But for long-term watchdogs, Crinetics’ early-stage pipeline could significantly sweeten the deal. If the Crinetics team can replicate their small-molecule magic in other markets like obesity and rare metabolic disease, Vertex’s ten-billion-dollar bet could look like the bargain of the decade.

Premium Charts & Analysis

All charts reflect data current as of the specified date and may not include every drug development program, although we aimed to capture the vast majority. Please feel free to email me at biotechreadout@gmail.com with “CHARTS” in the subject line to share suggestions or request chart updates.

Press ⬇️ to navigate to a section

  • Vertex Acquisitions Ranked ⬇️

  • Top Selling Medicines in Acromegaly and CAH ⬇️

  • R&D Pipeline in Acromegaly and CAH ⬇️

Read more

]]><![CDATA[Novartis to Acquire Myricx Bio]]>https://biotechreadout.xyz/p/novartis-to-acquire-myricx-biohttps://biotechreadout.xyz/p/novartis-to-acquire-myricx-bioMon, 06 Jul 2026 21:05:43 GMTDisclaimer: This newsletter is for educational and informational purposes only and does not constitute medical, investment, or financial advice, nor does it establish a provider-patient relationship. Content may include forward-looking statements and discussions of investigational therapeutic candidates that are not FDA/EMA approved; their safety and efficacy remain unestablished and clinical outcomes are unpredictable. While we strive for accuracy, all information is provided as is without guarantees. As of the date of publication, the author holds no direct equity positions in the specific companies mentioned in this issue nor receives third-party compensation for this coverage. Please find a complete version of our disclaimers linked here.

If you are a paid subscriber, go to this article’s premium charts & analysis here ⬇️

If you are a free reader or subscriber, enjoy the whole article free of charge and consider upgrading for premium charts & analysis on the antibody-drug conjugate (ADC) landscape (samples).

Introduction

On July 6, 2026, Novartis announced that it has entered into an agreement to acquire Myricx Bio for $1.1 billion upfront with up to $400 million in potential milestone payments, for a total deal value of up to $1.5 billion (Novartis press release, Myricx press release). This acquisition centers on a novel platform and three preclinical programs:

  • Antibody-drug conjugates (DCs) with N-myristoyltransferase inhibitor (NMTi) payloads

  • A preclinical NMTi-ADC targeting B7-H3

  • A preclinical NMTi-ADC targeting HER2

  • A preclinical NMTi-ADC targeting TROP2, which appears in an older Myricx press release

Right off the bat, it appears that Myricx was bought for a rather healthy premium, with the upfront payment being about 80% higher than the average preclinical-stage acquisition (see graph below).

Enterprise value (EV) of Myricx acquisition compared to other biotech acquisitions

In this article, we dive into the founding story of Myricx Bio, explore the strengths of their novel NMTi-ADC platform, and opine on why strategics have gotten excited about novel ADC payload companies.

From Malaria to MYC

The founding story of Myricx Bio is a prime example of how a decades-long academic research project has positioned itself to become a multi-billion dollar biotech success story.

The journey began more than 20 years ago in the laboratories of Imperial College London. Professor Ed Tate (now the GSK Chair in Chemical Biology) and his research group were trying to defeat malaria. Their target was N-myristoyltransferase (NMT), a vital protein-modifying enzyme that the malaria parasite relies on to survive. As the team engineered small molecules to block the parasite’s version of NMT, they hit upon a fascinating side effect. Some of the molecules they designed were incredibly potent against the human version of the enzyme. Professor Tate and his team realized that NMT is also a critical lifeline for human cells, and malignant cancer cells are uniquely addicted to it. Inhibiting NMT could cut off a tumor’s cellular machinery, forcing specific cancer cells to self-destruct. Remarkably, this mechanism showed immense promise in targeting MYC-driven cancers, an oncogene that had long been deemed difficult-to-drug.

Recognizing the massive therapeutic potential, Tate knew the science needed to leave the academic bench. Backed by critical, early-stage funding from Cancer Research UK, the team refined their molecules to identify drug-like candidates fit for human clinical trials. To transform this academic breakthrough into a commercial reality, Professor Tate partnered with two crucial co-founders:

  • Dr. Andrew Bell, a brilliant chemist with deep drug discovery expertise.

  • Dr. Roberto Solari, a seasoned biotech executive and Venture Partner at Brandon Capital.

In 2019, the trio officially spun the company out from Imperial College London and the Francis Crick Institute under the initial name Myricx Pharma. Dr. Solari stepped in as the founding CEO, and the fledgling startup secured a £4.5 million Seed round co-led by Brandon Capital and Sofinnova Partners to kickstart their operations. While Myricx initially set out to develop traditional small-molecule oral drugs, the team faced a common biotech hurdle: ensuring the drug selectively killed cancer cells while minimizing harm to healthy tissue. In 2021, the company executed a brilliant strategic pivot. Instead of delivering the NMT inhibitors broadly across the body, they transitioned to evaluating them as payloads for Antibody-Drug Conjugates (ADCs). For those new to ADCs, they are a drug modality that acts like a biology guided missile. An antibody seeks out and binds to a specific protein on a cancer cell, and then drops a highly toxic payload (often a topoisomerase-1 or tubulin inhibitor) directly inside the tumor. Instead of traditional payloads, Myricx loaded their ADCs with their NMT inhibitor with the goal of making targeted therapeutics that sought out two targets:

  • B7-H3, which has been correlated in meta-analyses with a 71% lower overall survival (OS) and a 110% lower progression-free survival (PFS).

  • HER2, which is a well known breast cancer antigen going back to the 1998 approval of Herceptin (trastuzumab), the first monoclonal antibody approved for a solid tumor.

  • TROP2, which is upregulated in a vast array of aggressive epithelial malignancies

Cartoon of NMTi- ADCs; Source: Myricx World ADC 2023 poster, Figure 2A

The pivot transformed Myricx from a niche spinout into a biotech heavyweight. Under the subsequent leadership of Dr. Robin Carr (first serving as Chief Development Officer starting in November 2019 and becoming CEO in August 2022 before settling on CTO in late 2025), the company raised a staggering £90 million ($114 million) Series A round in 2024, one of the largest ever achieved by a European academic spinout. The round attracted major global investors, including Novo Holdings, Eli Lilly, and Abingworth. By late 2025, biopharma veteran Mohit Rawat was brought on as CEO to steer the company toward global commercialization. Prior to joining Myricx, he served as President and Chief Business Officer at Fusion Pharmaceuticals, where he played a critical role in transforming the clinical-stage radiopharmaceutical company and secured a $2.4 billion acquisition by AstraZeneca in 2024.

Professor Tate’s 20-year scientific odyssey came to fruition in July 2026 when pharma giant Novartis announced a definitive agreement to acquire Myricx Bio for up to $1.5 billion ($1.1 billion upfront). What started as an accidental discovery in a British malaria lab, pivoted to cancer, and zeroed in on ADCs culminated in a significant early-stage exit.

Biotech Readout is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

Loading Up on Novel ADC Payloads

I realize that two points do not make a trend, but the rapid succession of +$1 billion novel ADC payload purchases has me seeing stars. Novartis’ buyout of Myricx Bio comes just one month after J&J’s $1 billion purchase of the preclinical ADC payload company Firefly Bio, which likewise commanded a healthy premium and was bought for its novel degrader antibody conjugate (DAC) platform. Furthermore, both are preclinical, suggesting that they have long-term strategic value (contrasts with Phase 3/Commerical stage companies that plug near-term revenue holes).

So, what is it about these novel ADC payloads that has piqued the interest of strategics? For years, the ADC boom relied heavily on two cytotoxic warheads: tubulin inhibitors (like MMAE) and topoisomerase I inhibitors (like DXd). While highly effective, these payloads suffer from narrow therapeutic windows, drug-resistance mutations, and systemic toxicities due to premature payload release in circulation. By acquiring Myricx and Firefly, pharma giants bypass traditional chemotherapies entirely, turning instead to differentiated mechanisms.

Firefly sits at the convergence of two powerhouse modalities: ADCs and Targeted Protein Degradation (TPD). Instead of slowly accumulating small-molecule toxins to kill a cell, a single degrader payload molecule works catalytically. It repeatedly hijacks the cell’s own ubiquitin-proteasome system to flag and destroy specific disease-driving proteins. Crucially, Firefly developed proprietary linker chemistry optimized to keep these complex degrader payloads stable in circulation, preventing the premature free payload release that plagues earlier-generation conjugates.

Myricx’s core innovation is shifting away from standard DNA/tubulin-damaging agents toward NMT inhibition. NMT is an enzyme responsible for protein myristoylation, a critical lipid modification that allows key signaling proteins to anchor to cellular membranes. Similar to Firefly, Myricx’s platform could offer an answer to tumors that have developed resistance to standard TOPO-1 or tubulin-targeting ADCs because NMT inhibition works via a completely distinct mechanism of action. However, there’s a different angle that makes NMT inhibitiors intriguing as a therapeutic class. Cancer cells, particularly those driven by the difficult-to-drug MYC oncogene, are uniquely addicted to NMT activity. Inhibiting it could cause a catastrophic collapse of intracellular signaling, triggering apoptosis. This is a big deal because the MYC proto-oncogene family is widely recognized as one of the most pervasive drivers of human tumorigenesis (see figure below). MYC is estimated to be deregulated or abnormally activated in approximately 50% to 70% of all human cancers. Even when the MYC gene itself is structurally normal, its protein product is overabundant, hyper-stable, and actively driving tumor hallmarks like metabolic reprogramming and immune evasion.

Prevalence of gene amplification of the three MYC paralogues MYC, MYCL and MYCN across 16 major human cancer types in The Cancer Genome Atlas; Source: Dhanasekaran et al. Nat Rev Clin Oncol (2023), Figure 1

For over three decades, MYC has been difficult to drug because the protein lacks a deep ligand-binding pocket for small molecules to latch onto. Direct inhibitors have historically failed in clinical development because of the difficulty of finding a chemical binder, and because broad systemic inhibition could lead to catastrophic toxicities in normal proliferating tissues. An ADC bypassing the protein structure entirely and instead dropping a payload that exploits a MYC-addicted cellular pathway (like protein myristoylation via NMT) is hypothesized to provide a workaround. Preclinical models suggest that attaching it to an antibody may make the payload delivery more localized, which researchers hope will translate to mitigated systemic toxicity in clinical evaluation.

To evaluate their NMT inhibitor (NMTi) platform, Myricx engineered several proof-of-concept and lead assets by tethering their novel payloads to clinically validated monoclonal antibodies. These candidates achieved extensive tumor regression in various cancer cell lines (first & second figure below) and in an in vivo solid cancer xenograft model (third figure below) at doses that were generally well-tolerated in male cynomolgus monkeys.

Antitumour effects of MYX2449 (NMTi-ADC targeting HER2) in HER2+ breast and gastric cancer cell lines; Source: Myricx World ADC 2023 poster, Figure 3C&D
Antitumour effects of MYX2470 (NMTi-ADC targeting B7-H3) in B7-H3+ prostate cancer cell lines; Source: Myricx World ADC 2023 poster, Figure 3C&D
Antitumour effects of MYX2468 (NMTi-ADC targeting TROP2) in TROP2+ prostate cancer xenograft model; Source: Myricx World ADC 2023 poster, Figure 3G

Conclusion

The acquisition of Myricx Bio could be a sign of where the oncology market is heading. For the past few years, the ADC boom has been defined by a race to find the best surface targets, largely relying on a handful of standard, off-the-shelf chemotherapy payloads. Novartis’ ten-figure bet on Myricx (and J&J’s similar play for Firefly Bio) signals that the industry is moving past the low-hanging fruit. By shifting the focus to novel payloads, these next-generation platforms could unlock doors that have been closed to drug developers for decades. If Myricx’s platform can successfully show a workable therapeutic window in human clinical trials and pass regulatory muster, what began as a hunt for a malaria cure in a London university lab could very well redefine the standard of care in a wide variety of solid tumors.

Premium Charts & Analysis

All charts reflect data current as of the specified date and may not include every drug development program, although we aimed to capture the vast majority. Please feel free to email me at biotechreadout@gmail.com with “CHARTS” in the subject line to share suggestions or request chart updates.

Press ⬇️ to navigate to a section

  • Notable Acquisitions of ADC Companies ⬇️

  • Top Selling ADCs ⬇️

  • Top 30 ADC Targets ⬇️

  • ADC Pipeline of Strategic Acquirers ⬇️

Read more

]]><![CDATA[Abivax addresses safety, first Treg approval, and more]]>https://biotechreadout.xyz/p/abivax-addresses-safety-first-treghttps://biotechreadout.xyz/p/abivax-addresses-safety-first-tregFri, 03 Jul 2026 19:17:46 GMTDisclaimer: This newsletter is for educational and informational purposes only and does not constitute medical, investment, financial, or legal advice, nor does it establish a provider-patient or advisory relationship. Content is based on publicly available topline data and includes forward-looking statements regarding investigational therapeutic candidates; their ultimate safety, efficacy, and clinical outcomes are unpredictable and remain subject to final regulatory determination. While we strive for accuracy, all information is provided “as is” without guarantees of completeness or timeliness. The author holds no direct equity positions in the specific companies mentioned in this issue nor receives third-party compensation for this coverage. Consult qualified professionals before making any medical or financial decisions. Please find a complete version of our disclaimers at the bottom of this article and on our About page.

Press ⬇️ to go down to a section and ⬆️ to go back up to the Table of Contents

Table of Contents

This week, we discuss:

  • China Biotech

    • Big Pharma Partnerships Draw Scrutiny ⬇️

    • FDA’s Push to Re-shore Drug Manufacturing Achieves a Major Milestone ⬇️

  • Acquisitions ⬇️

    • United Therapeutics to Acquire Thymmune, regenerative medicine titans join forces to grow a thymus

    • Ipsen to Acquire Memo, neutralizing the viral ghosts that haunt kidney transplant patients

    • Ipsen to Acquire Kartos, unleashing apoptotic p53 on myelofibrosis

    • Zymeworks to Acquire Theravance, M&A alchemy with a COPD sweetener

  • Approvals

    • Orca Bio - Tregzi (allo HSCT) / Approved (cGVHD) ⬇️

    • Viridian - Lumvoa (IGF-1R inhibitor) / Approval (TED) ⬇️

    • Vertex - Casgevy (BCL11A-KO HSCT) / Label Expansion (SCD/β-thal age 2+) ⬇️

    • Arcutis - Zoryve (topical PDE4 inhibitor) / Label Expansion (plaque psoriasis age 2+) ⬇️

  • Clinical Trial Data

    • Abivax - Obefazimod (miR-124 upregulator) / Phase 3 (UC) ⬇️

    • RevMed - Zoldonrasib (KRAS-G12D inhibitor) / Phase 1 (G12D mutated mPDAC) ⬇️

    • AbbVie - Epkinly (CD3 x CD20 mAb) / Phase 3 (DLBCL) ⬇️

    • AstraZeneca - Efzimfotase alfa (TNSALP ERT) / Phase 3 (hypophosphatasia ages 2-11) ⬇️

    • BeOne - Brukinsa (BTK inhibitor) / Phase 3 (1L MCL) ⬇️

    • Roche - Divarasib (reversible KRAS G12C inhibitor) / Phase 3 (2L NSCLC) ⬇️

    • Otsuka - Voyxact (anti-APRIL mAb) / Phase 3 (IgAN) ⬇️

    • Sanofi - Nexviazyme (M6P-GAA ERT) / Phase 3 (infant Pompe) ⬇️

China Biotech

Big Pharma Partnerships Draw Scrutiny

On June 30, 2026, Endpoints reported that the U.S. House Select Committee on China has opened a national security investigation into several major American pharmaceutical companies regarding their clinical trial operations in China. This specifically includes Bristol Myers Squibb, along with Merck, AbbVie, Pfizer, and Eli Lilly. Led by Chairman John Moolenaar (R-Mich.), the committee is investigating U.S. drugmakers for sponsoring clinical trials at Chinese military hospitals and medical centers, as well as in the Xinjiang region. According to the committee’s letters, lawmakers expressed concern that these trials could potentially present ethical risks and data security vulnerabilities that could inadvertently fuel China’s military biotechnology research. Public data from ClinicalTrials.gov revealed that Bristol Myers Squibb has sponsored at least 17 trials involving PRC military medical centers and at least eight trials in Xinjiang, where they allege is “where the Chinese Communist Party (CCP) is conducting a [redacted] of Uyghur Muslims and other minorities.” The trials involved drugs for conditions like multiple sclerosis and lupus. While companies like Bristol Myers, Merck, and AbbVie are facing heavy scrutiny, the committee commended Pfizer’s CEO, Albert Bourla, following indications that Pfizer plans to stop sponsoring trials in Xinjiang and at PRC military hospitals. The committee explicitly stated they are not accusing the drugmakers of illegal activity, but rather pointing out severe ethical and security blind spots. The panel has demanded that the companies hand over details on their due diligence processes, intellectual property protections, and trial data guidelines by July 17. This probe comes amid an escalating legislative push by the U.S. Federal Government to reduce U.S. biotech reliance on China. Lawmakers have previously introduced measures to block the FDA from accepting clinical data generated at trial sites in China to incentivize companies to bring drug development back to the U.S.

Sources: Endpoints article

Link to top ⬆️

FDA’s Push to Re-shore Drug Manufacturing Achieves a Major Milestone

This news doesn’t refer to China specifically, but more broadly relates to re-shoring of drug manufacturing in an effort to reduce supply chain reliance on foreign countries for essential healthcare needs. The PreCheck Pilot Program was launched on February 1, 2026, directly responding to Executive Order 14293 signed by President Trump on May 5, 2025 which aimed to provide regulatory relief and promote the domestic production of critical medicines. On June 29, 2026, the U.S. Food and Drug Administration (FDA) announced the selection of seven pharmaceutical and biotechnology companies to participate in the inaugural cohort of its FDA PreCheck Pilot Program. The seven chosen companies represent a mix of massive multinationals and emerging biotechs spanning various medical fields:

  1. Amneal Pharmaceutical (Long Island, NY): Will manufacture small molecule sterile liquid products for pain management, respiratory, and ophthalmic diseases.

  2. Cellares Corp. (Bridgewater, NJ): Will specialize in cell-based gene therapy products for oncology and hematology.

  3. Eli Lilly and Company (Lebanon, IN): Will manufacture active pharmaceutical ingredients (APIs) to support its existing and future medicines, including metabolic/GLP-1 drugs.

  4. FUJIFILM Biotechnologies (Holly Springs, NC): Will support commercial-scale cell culture biomanufacturing.

  5. Kriya Therapeutics, Inc. (Durham, NC): Will manufacture AAV-based gene therapy products to address chronic conditions.

  6. Kyowa Kirin, Inc. (Sanford, NC): Will manufacture biotechnology drug substance targeting rare diseases.

  7. Regeneron Pharmaceuticals, Inc. (Saratoga Springs, NY): Will manufacture biotechnology drug substances, sterile injectables, and novel protein therapeutics.

As congressional panels simultaneously probe U.S. Pharma reliance on Chinese clinical and manufacturing sites, this pilot serves as the “carrot” to Congress’s “stick.” The FDA’s selection of these partners is a concrete step toward building a self-sustaining, highly advanced domestic drug manufacturing ecosystem designed to foster national resilience.

Sources: FDA press release, Executive Order 14293

Link to top ⬆️

Acquisitions

Link to top ⬆️

Approvals

Orca Bio - Tregzi (allo HSCT) / Approved (cGVHD)

On June 30, 2026, the U.S. Food and Drug Administration (FDA) made a landmark decision by approving Tregzi, a precision-engineered cellular immunotherapy developed by Orca Bio. This milestone marks the first and only approved regulatory T-cell (Treg) therapy designed to improve survival free from chronic graft-versus-host disease (cGVHD) in adults undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Unlike a traditional stem cell transplant where a mixed bag of donor cells is infused directly into the patient, Tregzi is a personalized treatment formulated from a matched donor’s blood. It isolates and sequentially delivers three distinct components:

  • Hematopoietic stem and progenitor cells (HSPCs) to rebuild and reconstitute the patient’s blood-forming system.

  • Highly purified Regulatory T cells (Tregs) tasked with maintaining immune tolerance and actively suppressing GVHD.

  • Conventional T cells (Tcons), which are infused slightly later to eliminate any remaining cancer cells (the graft-versus-leukemia effect) and protect against infections.

The approval was driven by statistically significant data from the Phase 3 PRECISION-T clinical trial, which randomized 187 adult patients to receive either Tregzi or a standard hematopoietic stem cell transplantation. Approximately 78% of patients treated with Tregzi were alive and free from moderate-to-severe cGVHD after 1 year, compared to just 38.4% in the standard transplant control group (see graph below). The cumulative incidence of moderate-to-severe cGVHD was slashed to 12.6% in the Tregzi arm from 44% in the control group. Furthermore, the safety profile of Tregzi was strong and consistent with the toxicities typically expected during a stem cell reset (such as mouth sores and standard infections), but with lower non-relapse mortality and fewer serious infections than the traditional protocol. Fully capitalized for its upcoming launch, Orca Bio has already established reimbursement pathways across commercial and government programs to help eligible patients access this practice-changing therapy.

Tregzi reduced the risk of death by any cause or moderate to severe cGVHD by 74% (HR = 0.26, P < 0.00001); Source: Tregzi label, Figure 1

Sources: Orca Bio press release, Tregzi label

Link to top ⬆️

Viridian - Lumvoa (IGF-1R inhibitor) / Approval (TED)

On June 26, 2026, the U.S. Food and Drug Administration (FDA) approved Viridian Therapeutics’ Lumvoa (veligrotug-vvze) for the treatment of Thyroid Eye Disease (TED). This landmark regulatory milestone represents a paradigm shift for patients and clinicians alike. Lumvoa is the first direct competitor to Amgen’s blockbuster drug Tepezza, which was previously the only FDA-approved therapy for the condition since 2020. TED is a rare, debilitating autoimmune disorder that causes tissues behind the eyes to inflame and expand. This results in painful, disfiguring eye bulging (proptosis) and double vision (diplopia), profoundly impacting a patient’s quality of life. While both Lumvoa and Tepezza target the insulin-like growth factor-1 receptor (IGF-1R) pathway, Lumvoa enters the market with several distinct, patient-centric advantages:

  • The First Broad-Spectrum Label: Lumvoa is the first approved TED treatment to explicitly include data for both active and chronic stages of the disease directly on its label, giving physicians clear guidance to treat patients regardless of how long they have suffered from the condition.

  • A Faster, Shorter Dosing Schedule: Lumvoa provides a more efficient treatment course than historical options, requiring only five intravenous (IV) infusions administered over a 12-week period (one infusion every three weeks), compared to Tepezza’s standard eight-infusion regimen.

  • Superior Double Vision Resolution: Clinical results from its pivotal Phase 3 THRIVE and THRIVE-2 trials demonstrated rapid, significant reductions in eye bulging as early as three weeks, alongside unprecedented rates of complete double vision resolution.

Lumvoa’s approval was supported by two pivotal, global Phase 3 clinical trials: THRIVE and THRIVE-2. Both trials met their primary and all secondary endpoints at the 15-week primary analysis mark following a shorter, 12-week course of 5 intravenous (IV) infusions (10 mg/kg administered every 3 weeks). In the THRIVE Trial, Lumvoa achieved a 70% proptosis responder rate (defined as a ≥ 2 mm reduction in eye bulging without worsening in the fellow eye) compared to just 5% in the placebo group (see graph below). Lumvoa demonstrated a highly significant 56% proptosis responder rate by Hertel measurements, compared to 8% for placebo (a 48% placebo-adjusted difference, p < 0.0001; see graph below). In the chronic population (THRIVE-2), 56% of Lumvoa patients achieved a significant improvement (at least a 1-grade reduction on the Gorman scale) compared to 25% for placebo. Onset was rapid, showing divergence by week 6. Crucially, 32% of Lumvoa patients achieved complete resolution of their double vision (a Gorman score of 0) compared to 14% in the placebo arm (p = 0.0152). Lumvoa is immediately available for physicians to prescribe. To streamline adoption, the launch is fully supported by ViridianCares, a comprehensive hub providing insurance verification, coverage support, and patient co-pay assistance.

Change from Baseline in Proptosis by Exophthalmometer over 15 Weeks for Patients with Active Thyroid Eye Disease in Study 1 (left) and Study 2 (right); Source: Lumvoa label, Figure 1 & 2
Diplopia in Patients with Active Thyroid Eye Disease (Study 1) or Chronic Thyroid Eye Disease (Study 2); Source: Lumvoa label, Table 3

Sources: Viridian press release, Viridian slide deck, Lumvoa label

Link to top ⬆️

Vertex - Casgevy (BCL11A-KO HSCT) / Label Expansion (SCD/TDT age 2+)

On July 1, 2026, the U.S. Food and Drug Administration (FDA) granted a major label expansion for Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy (exagamglogene autotemcel), extending its indication to include children as young as 2 years old. Previously restricted to patients aged 12 and older, Casgevy is now the first and only CRISPR-based gene-editing therapy approved for young pediatric patients suffering from either severe sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent β-thalassemia (TDT). Both SCD and TDT stem from genetic defects in adult hemoglobin. Casgevy bypasses the mutated adult gene entirely by utilizing ex vivo CRISPR/Cas9 technology to edit a patient’s own hematopoietic stem and progenitor cells. The therapy precisely targets and knocks out the erythroid-specific enhancer region of the BCL11A gene. BCL11A acts as a genetic switch that normally shuts down the production of fetal hemoglobin (HbF) shortly after birth. By knocking out this switch, Casgevy permanently reactivates high-level HbF production. In SCD patients, the robust presence of HbF prevents red blood cells from sickling. In TDT patients, it corrects the severe hemoglobin deficiency, eliminating the root causes of both diseases.

The landmark expansion was supported by data from the ongoing Phase 3 open-label CLIMB-141 and CLIMB-151 pediatric trials. While Vertex initially sought approval for ages 5 to 11, the striking consistency of the data prompted the FDA to expand the label down to age 2:

  • Sickle Cell Disease Cohort (Ages 5 to <12): The FDA evaluated 11 young patients with severe SCD. Out of the 8 patients who reached the timeframe to be evaluable for efficacy, 100% (8/8) achieved complete freedom from severe vaso-occlusive crises (VOC-free status) for at least 12 consecutive months within the first two years post-infusion.

  • β-Thalassemia Cohort (Ages 5 to <12): In a trial of 15 pediatric patients with TDT, 88.9% (8/9) of the efficacy-evaluable children achieved complete transfusion independence for at least 12 consecutive months, boasting a median duration of 20.1 months without needing a single blood transfusion.

  • Extrapolation to Ages 2-4: Since trials for children aged 2 to 4 were still ongoing but showing nearly identical biological and product characteristics, the FDA utilized clinical extrapolation. Recognizing the highly predictable consistency of the gene-editing mechanism across age groups, regulators simultaneously granted the wider age clearance.

The approval was processed with remarkable speed through the FDA’s Commissioner’s National Priority Voucher (CNPV) pilot program, which shaved traditional 10-to-12-month review timelines down to just 53 days from the official filing date.

Sources: Vertex press release, updated Casgevy label

Link to top ⬆️

Arcutis - Zoryve (topical PDE4 inhibitor) / Label Expansion (plaque psoriasis age 2+)

In a significant advancement for pediatric dermatology, the U.S. Food and Drug Administration (FDA) has granted a major label expansion for Arcutis Biotherapeutics’ Zoryve (roflumilast) cream 0.3%. Previously indicated only for individuals aged 6 and older, Zoryve is now approved for the treatment of mild, moderate, and severe plaque psoriasis in pediatric patients as young as 2 years old. Plaque psoriasis in toddlers and young children can be exceptionally difficult to manage. The disease frequently presents in highly sensitive, thin-skin regions, such as the face, neck, and skin folds (intertriginous areas), where traditional mid-to-high-potency topical steroids are strictly restricted due to the risk of skin thinning, systemic absorption, and stretch marks. This expansion provides families and pediatricians with a much-needed, steroid-free alternative.

The regulatory clearance was supported by a comprehensive package demonstrating consistent safety and efficacy across age groups. Initial approvals in adults and older children were established by the twin, pivotal DERMIS-1 and DERMIS-2 Phase 3 trials, which demonstrated rapid plaque clearance, marked reduction in itch, and a highly favorable safety profile. To expand the label down to age 2, Arcutis conducted a specific open-label Phase 3 maximal usage pharmacokinetics (PK) study in toddlers. The data confirmed that the 0.3% dose was excellently tolerated, showed a predictable and safe systemic exposure profile identical to older demographics, and generated no new safety signals. Arcutis has ensured immediate commercial availability for this expanded age group, backed by its existing commercial access programs to minimize out-of-pocket friction for families seeking a steroid-free option for their young children.

Sources: Arcutis press release, updated Zoryve label

Link to top ⬆️

Clinical Trial Data

Abivax - Obefazimod (miR-124 upregulator) / Phase 3 (UC)

On June 29, 2026, Abivax reported highly anticipated topline data from Part 2 of its Phase 3 ABTECT maintenance trial for obefazimod in moderate-to-severe ulcerative colitis (UC). This readout addressed lingering market anxieties regarding a potential malignancy signal from the earlier Part 1 readout, positioning the asset for a planned regulatory submission.

Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by continuous mucosal inflammation of the colon, driven by a dysregulated immune response against intestinal microbiota that triggers epithelial barrier breakdown and an overproduction of pro-inflammatory cytokines (TNF-α, IL-6, IL-12/23). While standard treatment escalates from anti-inflammatory 5-ASAs and corticosteroids for mild disease to biologics and oral small molecules (JAK or S1P inhibitors) for moderate-to-severe cases, obefazimod introduces a potential first-in-class, oral mechanism of action to this therapeutic landscape. By selectively binding to the cellular cap-binding complex (CBC) 80/20, obefazimod enhances RNA splicing to upregulate microRNA-124 (miR-124), which functions as a physiological brake that systematically suppresses key pro-inflammatory cytokines (IL-6, TNF-α, IL-17) and limits pathogenic Th17 cell proliferation, effectively downregulating colonic inflammation without inducing broad, systemic immunosuppression.

The Phase 3 ABTECT maintenance program evaluated daily oral obefazimod (25 mg and 50 mg) against a placebo in moderate-to-severe ulcerative colitis (UC) across two parts: a 44-week randomized responder re-randomization trial (Part 1, n=580) and an expansion study in refractory or relapsed cohorts (Part 2). Part 2 demonstrated that dose optimization with continuous 50 mg obefazimod rescued 37.2% of initial induction non-responders into clinical remission and recaptured clinical remission in approximately 45% of patients who had relapsed during Part 1. Crucially, Abivax reported a pooled analysis of 1,704 patient-years of exposure demonstrating a malignancy rate (0.56 IR/100 PY) that the company noted falls within the expected UC background range (0.30–0.70 IR/100 PY), with non-melanoma skin cancers isolated to older patients with pre-existing risk factors.

Abivax is fully capitalized and remains on track to submit its formal New Drug Application (NDA) to the U.S. FDA for obefazimod in ulcerative colitis. The company anticipates the topline data readout from its Phase 2b ENHANCE-CD induction trial in mid-2027, which is currently evaluating obefazimod’s clinical utility in Crohn’s disease with the goal of expanding its IBD franchise footprint.

Obefazimod Achieved the Highest Endoscopic Remission Rate Among All UC Therapies, according to cross-trial comparisons highlighted in Abivax’s presentation (noting that cross-trial comparisons have inherent statistical limitations); Source: Abivax presentation, slide 14
All Active Combined Malignancy Other Than non-melanoma skin cancer (NMSC) Rates were Consistent with the Reference Range Across All Three Datasets; Source: Abivax presentation, slide 22

Sources: Abivax press release, Abivax slide deck

Link to top ⬆️

RevMed - Zoldonrasib (KRAS-G12D inhibitor) / Phase 1 (G12D mutated mPDAC)

At the 2026 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress, Revolution Medicines presented encouraging Phase 1/2 data for its candidate zoldonrasib (RMC-9805) in combination with its multi-RAS inhibitor daraxonrasib (RMC-6236). This readout established early signs of clinical efficacy in heavily pretreated, advanced KRAS G12D-mutant metastatic pancreatic ductal adenocarcinoma (mPDAC), a disease historically resistant to standard therapies.

KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma (mPDAC) is an aggressive malignancy where a specific missense mutation permanently locks the KRAS protein into an active, GTP-bound “ON” conformation, continuously fueling downstream proliferative pathways (MAPK/ERK, PI3K/AKT) and leaving patients with limited standard options beyond intense systemic chemotherapies like FOLFIRINOX or gemcitabine/nab-paclitaxel. Addressing this historically untargetable driver, zoldonrasib introduces a first-in-class, oral, mutant-selective mechanism that directly targets the active “ON” state of the mutated KRAS G12D protein. By utilizing a molecular glue approach, zoldonrasib binds the active KRAS G12D mutant and an abundant intracellular chaperone protein, cyclophilin A, to form a stable tri-complex. This steric block selectively modifies the mutant aspartic acid residue to turn off hyperactive MAPK signaling and prevent downstream effector interaction while minimizing disruption of wild-type RAS variants or harm to healthy tissue.

The multicenter, open-label Phase 1 RMC-9805-001 trial evaluated a daily oral combination of the mutant-selective covalent RAS(ON) G12D inhibitor zoldonrasib (1200 mg) and the pan-RAS(ON) inhibitor daraxonrasib (300 mg) in 60 patients with advanced, chemotherapy-refractory KRAS G12D-mutant metastatic pancreatic ductal adenocarcinoma (mPDAC). In the second-line setting (n=30), the combination achieved a 50% objective response rate (ORR), a 97% disease control rate (DCR), and an unprecedented median progression-free survival (mPFS) of 9.6 months, while maintaining a 47% ORR and 7.6 months mPFS in third-line or later patients (n=30). Furthermore, the combination exhibited a predictable and manageable safety profile. Treatment-emergent adverse events were primarily mild-to-moderate (Grade 1/2) on-target toxicities such as rash (90%), diarrhea (63%), nausea (57%), and stomatitis (53%). The combination also had low discontinuation rates and minimal severe toxicities. Building on this foundational late-line success, Revolution Medicine has pushed zoldonrasib into earlier settings. At the same congress, the company detailed its front-line (1L) combination strategies with chemotherapy (mFOLFIRINOX and GnP), which achieved staggering front-line ORRs up to 82%.

Revolution Medicine has initiated the global, randomized Phase 3 RASolute 305 trial. This study will evaluate zoldonrasib directly alongside investigator’s choice of standard chemotherapy backbones in treatment-naïve, first-line metastatic KRAS G12D PDAC patients, laying the groundwork for a future definitive regulatory approval.

Sources: RevMed press release

Link to top ⬆️

AbbVie - Epkinly (CD3 x CD20 mAb) / Phase 3 (R/R DLBCL)

On July 3, 2026, AbbVie and Genmab announced positive topline results from their Phase 3 EPCORE DLBCL-1 clinical trial evaluating Epkinly (epcoritamab-bysp) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). This successful readout provides a major clinical victory and redemption for the asset’s late-line franchise after it missed an overall survival milestone earlier in the year.

Diffuse large B-cell lymphoma (DLBCL) is an aggressive hematologic malignancy characterized by the uncontrolled clonal proliferation of malignant B-lymphocytes, driven by chromosomal translocations (MYC, BCL2, BCL6) and dysregulated signaling pathways (NF-κB) that block cellular differentiation. While frontline treatment relies on intense chemoimmunotherapy like R-CHOP or Polivy-R-CHP, and later-line options shift based on transplant eligibility to salvage chemotherapy, CAR-T, or targeted agents, Epkinly (epcoritamab-bysp) introduces a highly targeted therapeutic approach. As a first-in-class, subcutaneous CD3×CD20 T-cell engaging bispecific antibody, Epkinly simultaneously binds to CD20 on malignant B-cells and CD3 on mature T-cells. By physically bridging these cells, it bypasses traditional major histocompatibility complex (MHC) class I restrictions to trigger the direct activation of endogenous T-cells, which release cytotoxic perforins and granzymes to induce immunologically driven lysis of the lymphoma cells. Check out CAR-T, Part 2 if you are interested in learnings more about the history and cutting edge of TCEs.

The global, randomized, open-label Phase 3 EPCORE DLBCL-1 trial evaluated subcutaneous Epkinly monotherapy against standard salvage chemotherapy (primarily the R-GemOx regimen) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who were transplant-ineligible and had failed at least two prior systemic lines. Topline data demonstrated that Epkinly met its primary endpoint by remarkably reducing the risk of disease progression or death by 60% (HR=0.40) compared to standard chemotherapy, while maintaining a predictable safety profile with low-grade, manageable cytokine release syndrome (CRS) confined to the initial step-up dosing weeks. This decisive victory rehabilitates the Epkinly franchise after an earlier 2026 second-line clinical trial setback.

AbbVie and Genmab have announced they will immediately engage with global regulatory authorities (including the U.S. FDA and European Medicines Agency) to submit these data to expand Epkinly‘s label from its current accelerated status into a full, definitive regulatory approval for late-line DLBCL. The next major inflection point for the franchise will occur later in 2026, when AbbVie expects to read out pivotal Phase 3 data evaluating Epkinly moved up into first-line (1L) newly diagnosed DLBCL in combination with standard R-CHOP chemotherapy.

Sources: AbbVie press release, Genmab press release

Link to top ⬆️

AstraZeneca - Efzimfotase alfa (TNSALP ERT) / Phase 3 (hypophosphatasia ages 2-11)

On July 2, 2026, AstraZeneca announced positive topline results from its global, randomized Phase 3 clinical trial evaluating efzimfotase alfa (ALXN1850) in pediatric patients aged 2 to 11 with hypophosphatasia (HPP). This pediatric readout establishes a distinct clinical data package for the asset, which previously did not meet its primary endpoints in a separate Phase 3 trial evaluating adolescents and adults.

Hypophosphatasia (HPP) is a rare, inherited metabolic disorder caused by loss-of-function mutations in the ALPL gene that result in a deficiency of tissue-nonspecific alkaline phosphatase (TNSALP), leading to an extracellular accumulation of inorganic pyrophosphate (iPP), a potent biochemical inhibitor of hydroxyapatite crystal formation that causes rickets, progressive skeletal deformities, and muscle weakness. While standard care focuses on supportive management or the established enzyme replacement therapy (ERT) Strensiq (asfotase alfa) to restore bone mineralization, efzimfotase alfa (ALXN1850) introduces a next-generation, bone-targeted TNSALP enzyme replacement therapy to addressing this enzyme deficiency. Engineered as a recombinant soluble TNSALP fusion protein modified with a negatively charged, deca-aspartate peptide tail, efzimfotase alfa selectively binds with high affinity to hydroxyapatite crystals within the mineralizing bone matrix. Once localized, it directly cleaves accumulated iPP into inorganic phosphate, systematically removing the biochemical barrier to healthy bone architecture and mineralization.

The global, randomized, double-blind Phase 3 trial evaluated the efficacy and safety of subcutaneous efzimfotase alfa against a placebo over a 25-week primary evaluation period in 64 pediatric patients (aged 2 to 11) with pediatric-onset hypophosphatasia (HPP). Topline results demonstrated that the trial successfully met its primary endpoint, with the efzimfotase alfa cohort achieving a statistically significant mean Radiographic Global Impression of Change (RGI-C) score improvement of +1.67 points compared to 0.00 points in the placebo arm (P=0.0003), driving substantial radiographic healing of active rickets and skeletal lesions alongside robust improvements in growth velocity and motor function. The next-generation enzyme replacement therapy was well-tolerated, with mild-to-moderate injection-site reactions representing the most frequent adverse events and no severe systemic toxicities reported. This successful pediatric readout provides critical continuity for AstraZeneca’s Alexion rare disease franchise as a pipeline successor to Strensiq, demonstrating a highly effective targeted therapeutic window during early childhood development when bone turnover is highest, despite the asset’s previous clinical failures in less dynamic adolescent and adult populations.

Armed with a highly significant pediatric dataset, AstraZeneca intends to discuss these results with global regulatory bodies, including the U.S. FDA and the European Medicines Agency (EMA), to seek marketing authorization specifically for pediatric HPP patients. The trial is transitioning into its open-label extension phase to monitor the long-term durability of bone mineralization, growth parameters, and antibody safety profiles out to two years post-infusion.

Sources: AstraZeneca press release

Link to top ⬆️

BeOne - Brukinsa (BTK inhibitor) / Phase 3 (1L MCL)

On July 3, 2026, BeOne announced positive topline results from its global Phase 3 clinical trial evaluating Brukinsa (zanubrutinib) in treatment-naïve patients with mantle cell lymphoma (MCL). This successful frontline readout marks a major therapeutic milestone, positioned to disrupt the traditional chemoimmunotherapy paradigm for newly diagnosed patients.

Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy driven by the hallmark t(11;14) translocation that causes constitutive overexpression of cyclin D1, forcing unchecked cell cycle progression, which is further sustained by hyperactive B-cell receptor (BCR) signaling mediated by Bruton’s tyrosine kinase (BTK). The frontline standard of care is strictly stratified by patient fitness, relying on intensive cytarabine-based chemoimmunotherapy and autologous stem cell transplantation (ASCT) for younger patients, and regimens like bendamustine plus rituximab (BR) for transplant-ineligible individuals. As a next-generation, oral small-molecule BTK inhibitor, Brukinsa forms an irreversible, covalent bond within the ATP-binding pocket of the BTK enzyme to profoundly disrupt downstream proliferative networks (MAPK, NF-κB). It was specifically engineered to maximize target occupancy while minimizing off-target inhibition of structurally similar kinases (such as EGFR, TEC, and ITK), thereby turning off oncogenic survival signals while successfully reducing common class-related toxicities.

The global, randomized, open-label Phase 3 trial evaluated oral Brukinsa (zanubrutinib) monotherapy as a chemotherapy-free alternative against standard investigator-chosen chemoimmunotherapy (such as bendamustine plus rituximab) in previously untreated, transplant-ineligible adult patients with newly diagnosed mantle cell lymphoma (MCL). Topline data demonstrated that frontline Brukinsa significantly met its primary endpoint, cutting the risk of disease progression or death by 43% (HR=0.57) while showcasing a favorable selectivity profile with low rates of cardiac adverse events and significantly lower rates of severe myelosuppression and febrile neutropenia compared to the chemotherapy arm. Secondary endpoints, including objective response rate and a positive trend in overall survival, also favored Brukinsa.

BeOne plans to present the detailed, granular survival and response data at an upcoming major medical congress and will initiate discussions with global regulatory authorities (including the U.S. FDA and EMA) to file supplemental regulatory submissions for expanded frontline approval. Moving forward, next steps will focus on exploring Brukinsa-led combinations in earlier lines of therapy, including ongoing trials evaluating its synergy with BCL-2 inhibitors (such as venetoclax) to achieve deeper, fixed-duration molecular remissions.

Sources: BeOne press release

Link to top ⬆️

Descriptive data releases without numerical data

  • Roche - Divarasib (reversible KRAS G12C inhibitor) / Phase 3 (2L NSCLC): The Phase 3 Krascendo-1 trial evaluating Roche’s divarasib, a reversible KRAS G12C inhibitor, achieved a statistically significant and clinically meaningful success in the second-line relapsed or refractory non-small cell lung cancer (2L NSCLC) setting. The trial demonstrated that divarasib delivered robust improvements in both overall survival (OS) and progression-free survival (PFS) when compared directly against the investigator’s choice of standard covalent KRAS G12C inhibitors, specifically Amgen’s Lumakras (sotorasib) or Bristol Myers Squibb’s Krazati (adagrasib). While detailed data from this readout are slated for presentation at an upcoming medical conference, Roche is already advancing the asset’s clinical pipeline, with the Krascendo-2 trial actively ongoing to evaluate divarasib’s therapeutic potential in the frontline (1L NSCLC) setting.

  • Otsuka - Voyxact (anti-APRIL mAb) / Phase 3 (IgAN): Otsuka announced positive topline results from its Phase 3 trial evaluating Voyxact (sibeprenlimab-szsi), a first-in-class anti-APRIL monoclonal antibody, in patients with primary IgA nephropathy (IgAN). The trial successfully met its key long-term objectives, demonstrating that Voyxact treatment led to a statistically significant and clinically meaningful stabilization of kidney function after two years of follow-up compared to placebo. These critical 24-month data, slated for full presentation at an upcoming medical conference, establish the durable clinical efficacy of the therapy and serve as the foundational evidence required to secure full regulatory approval.

  • Sanofi - Nexviazyme (M6P-GAA ERT) / Phase 3 (infant Pompe): The Phase 3 trial evaluating Sanofi’s Nexviazyme (avalglucosidase alfa), a next-generation, mannose-6-phosphate-enriched receptor-targeted acid alpha-glucosidase (M6P-GAA) enzyme replacement therapy, achieved a clinical success in treatment-naïve, infant-onset Pompe disease. The study successfully met its primary efficacy endpoint, which measured the percentage of treatment-naïve infants aged 6 months and younger who were alive and free from the need for invasive ventilation at 52 weeks. Although specific data metrics and numbers were not disclosed in the initial announcement, Sanofi is scheduled to present the comprehensive data from this readout on July 8 at the International Congress on Neuromuscular Diseases.

Link to top ⬆️

Love biotech? Check out Biotech Readout’s full content library, or navigate directly to a segment that interests you:

Biotech Readout is a reader-supported publication. To receive new posts and support my work, consider becoming a free subscriber.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

]]><![CDATA[United Therapeutics to Acquire Thymmune]]>https://biotechreadout.xyz/p/united-therapeutics-to-acquire-thymmunehttps://biotechreadout.xyz/p/united-therapeutics-to-acquire-thymmuneThu, 02 Jul 2026 22:24:52 GMTDisclaimer: This newsletter is for educational and informational purposes only and does not constitute medical, investment, or financial advice, nor does it establish a provider-patient relationship. Content may include forward-looking statements and discussions of investigational therapeutic candidates that are not FDA/EMA approved; their safety and efficacy remain unestablished and clinical outcomes are unpredictable. While we strive for accuracy, all information is provided as is without guarantees. As of the date of publication, the author holds no direct equity positions in the specific companies mentioned in this issue nor receives third-party compensation for this coverage. Please find a complete version of our disclaimers at the bottom of this article and on our About page.

Introduction

On July 2, 2026, United Therapeutics Corporation announced that it has acquired Thymmune Therapeutics, Inc. for $140 million in cash plus up to $160 million based on the achievement of certain clinical and regulatory milestones by the end of 2031, for a total deal value of up to $300 million. This acquisition centers on THY-100, an investigational, preclinical neo-thymus cell therapy being evaluated to treat congenital athymia (infants born without a functional thymus).

In this article, we dive into the role of stem cell reprogramming in regenerative medicine, explore how foundational work in the George Church lab led to the spinout of Thymmune, and learn how Thymmune fits into United Therapeutics’ regenerative medicine ambitions.

The Church of Cell Reprogramming

Thymmune Therapeutics traces its roots back to foundational research in George Church’s laboratory at Harvard Medical School and the Wyss Institute. A major focus of his lab is regenerative medicine, which aims to do something pharmacological medicine struggles to achieve: repair, replace, or regenerate damaged tissues and organs rather than managing disease symptoms. Stem cells are a foundational engine of this field because they possess two unique properties that make them the cellular raw material for regeneration:

  • Self-Renewal: The ability to divide and replicate themselves indefinitely in a lab environment, creating an inexhaustible supply of starting material.

  • Potency: The ability to differentiate (mature) into specialized functional cells, such as heart muscle cells, neurons, or insulin-producing pancreatic cells.

An enabling technology for the Church lab’s research is the induced pluripotent stem cell (iPSC). The process of making iPSCs was discovered in 2006 by Shinya Yamanaka (which earned him a Nobel Prize). It involves taking adult cells and introducing a specific cocktail of four master genes, known as the Yamanaka Factors (Oct3/4, Sox2, Klf4, and c-Myc). These factors wipe the cell’s memory, rewinding its developmental clock back to zero. To be clear, iPSCs are different from embryonic stem cells (ESCs). Both types of stem cells are theoretically able to differentiate into virtually any cell type in the human body, but they diverge in their origin and the ethical considerations surrounding them. Embryonic stem cells are derived directly from the inner cell mass of a pre-implantation human embryo that is typically four to five days old. This derivation process inherently results in the destruction of the embryo, which has historically sparked intense ethical, religious, and political debates worldwide, leading to strict regulatory bottlenecks. In contrast, iPSCs come from fully mature adult cells (typically skin fibroblasts or peripheral blood cells) and are genetically reprogramed back into an embryonic-like state using Yamanaka Factors.

Yet, making stem cells is half the battle. In order to craft a regenerative medicine for a particular treatment context, you need to know how to program the stem cells into the specific type of mature cell that you need. For example, you would need to make collagen-producing fibroblasts in the context of knee regeneration, but you would need to make nerve cells in the context of spine regeneration. That last mile of cell programming is where the Church lab shines. The lab uses synthetic biology and machine learning techniques to figure out how to make specific cell types from iPSCs. By utilizing pooled screens of transcription factors, researchers in the lab systematically identified the master switches required to convert induced pluripotent stem cells (iPSCs) directly into highly specialized cell types.

Their 2020 Nature Biotechnology paper entitled “A comprehensive library of human transcription factors for cell fate engineering” was a major advance in the field of regenerative medicine. Traditional stem cell differentiation relied on recreating natural, slow, and expensive embryonic signaling pathways using chemical morphogens in specialized lab environments. The Church lab bypassed this developmental path by focusing entirely on transcription factors, the master genetic switches that control cell identity. By executing massive pooled genetic screens on human induced pluripotent stem cells (hiPSCs), the team identified 290 distinct transcription factors capable of driving stem cells to differentiate into mature target cells within just 4 days. Remarkably, 241 of these TFs were previously entirely unreported to possess cell-fate capabilities. The researchers validated their screening hits by programming stem cells into high-quality, fully functional adult tissue lineages that matched primary human tissue control profiles. The paper specifically demonstrated four distinct lineages:

  • Neurons & Fibroblasts: The team derived functional neurons that displayed proper electrophysiological patch-clamp readings and fibroblasts that successfully healed an in vitro wound-scratch monolayer.

  • Vascular Endothelial Cells: Utilizing a specific splice variant (ETV2 isoform 2), they achieved nearly 100% differentiation efficiency into endothelial-like cells that successfully formed functional, perfusable blood vessels integrated with host circulatory systems in vivo.

  • Oligodendrocytes: They co-cultured engineered, oligodendrocyte-inducible hiPSCs alongside unmodified hiPSCs to generate complex cerebral organoids. This allowed different cell types to mature synchronously, radically accelerating in situ myelination of axons.

Ultimately, the Church lab’s Human TFome project wrote the rules of cell reprogramming. The ability to program induced pluripotent stem cells (iPSCs) rapidly and autonomously provided the means to mass-produce complex, therapeutic tissues, setting the stage for spinouts like Thymmune to engineer a functional neo-thymus in vivo.

Growing a Thymus

The thymus is a small organ located behind your breastbone, and it acts as the training ground for the immune system. It takes immature immune cells from the bone marrow and teaches them to become T-cells, the specialized soldiers that fight off viruses, bacteria, and cancer. Unfortunately, this crucial organ is not as resilient as it ought to be.

Position of the human thymus; Source: Wikimedia

Unlike almost every other organ, the thymus begins to shrink and turn to fat starting at puberty. By the time you reach old age, your thymus is operating at a fraction of its capacity. This is a primary reason why older adults are far more vulnerable to new infections (like COVID-19 or influenza) and why their bodies are less effective at clearing emerging cancer cells. Patients with congenital athymia, a rare genetic condition where children are born entirely without a thymus, cannot produce T cells, leaving them with a severely weakened immune system. Historically, the condition is fatal within the first two years of life without an intervention.

If you want to fix an organ using a regenerative medicine approach with embryonic stem cells (ESCs), you could take a stem cell and expose it to a sequence of chemical growth factors (morphogens) that mimic human embryonic development. However, growing Thymic Epithelial Cells (TECs) was particularly challenging for three reasons:

  • The Complexity of the Epithelial Scaffold: The thymus isn’t just a collection of loose cells. It is a highly intricate, three-dimensional physical meshwork. As immature T-cells crawl through this biological maze, TECs must physically touch them to present self-antigens. This teaches the T-cells two things: how to recognize foreign invaders (positive selection) and how not to attack your own body (negative selection). Replicating this complex, interactive 3D behavior in a flat plastic dish using standard chemical signaling had proven nearly impossible.

  • High Instability and Loss of Identity: When researchers did manage to isolate primary thymic epithelial cells from tissue donors, they encountered a major hurdle: the moment these cells were cultured outside the body, they rapidly lost their functional identity in a process called dedifferentiation. Within a few cell divisions, they ceased expressing the critical genes, like FOXN1 (the master regulator of thymic development), needed to train T-cells.

  • The Yield Problem: Since the differentiation pathways are so convoluted, traditional methods resulted in horribly low yields. You might end up with a tiny fraction of functional cells hidden among a mess of chaotic, half-differentiated tissues. To treat a patient, doctors need hundreds of millions of highly pure, synchronized cells.

The George Church lab’s Human TFome project gave scientists much higher agency in making Thymic Epithelial Cells (TECs) from iPSCs. The actual translation of this platform specifically into the thymic lineage was driven by Stan Wang, during and immediately following a postdoctoral fellowship in the Church lab. Rather than publishing the specific iPSC-to-TEC cocktail in an open-access academic paper, the specialized genetic recipes, machine learning optimization algorithms, and methods for forming a functional neo-thymus in vivo were largely protected as proprietary intellectual property and patent filings. This proprietary execution of the Church lab’s screening methodology became the foundation upon which Wang spun out Thymmune Therapeutics in 2019.

The company established its operations in Kendall Square in 2021 and immediately captured the interest of major pharmaceutical players. That year, Thymmune won five “Golden Tickets” from major sponsors including Pfizer, Novo Nordisk, LG Chem Life Sciences, Boehringer Ingelheim, and Astellas. These awards equipped the fledgling company with critical early industry validation and lab space. Thymmune formally launched out of stealth in March 2023, securing a $7 million seed financing round led by Pillar VC, with participation from New York Blood Center’s NYBC Ventures, George Church, and former Alnylam CEO John Maraganore. The corporate trajectory accelerated significantly in September 2023, when Thymmune became one of the very first industry projects funded by the Biden administration’s newly formed Advanced Research Projects Agency for Health (ARPA-H). The agency awarded Thymmune up to $37 million under its Open Broad Agency Announcement to fund its “Thymus Rejuvenation” project. This non-dilutive capital gave Thymmune an immense runway to build out its infrastructure across two parallel validation phases:

  • Phase 1: Utilizing human induced pluripotent stem cell-derived thymic epithelial cells (iPS-TECs) to restore T-cell development in thymus-incompetent animals and slow immunologic aging.

  • Phase 2: Scaling up the manufacturing process for transplantation models to establish a viable clinical pathway.

With strong financial backing, leadership expanded the executive layer, bringing on veteran biopharma talent including Chief Scientific Officer Bing Lim, and Chief Technology Officer Manish Jain. The team directed their machine learning platform toward industrializing the production of off-the-shelf, scalable iPSC-derived thymic cells. The buildout centered heavily on THY-100, the company’s lead preclinical candidate for congenital athymia (infants born without a functional thymus). In animal models, Thymmune demonstrated that a less-invasive injection of their engineered cells could induce in vivo self-assembly, forming a functional, vascularized neo-thymus capable of facilitating independent T-cell development in these models. Beyond athymia, the company scaled its research into broader horizons, targeting age-related immune decline and post-transplant organ tolerance.

The rapid buildout of Thymmune’s platform culminated in a major consolidation of the regenerative medicine space. On July 2, 2026, Thymmune was acquired by United Therapeutics, a company that is not a stranger to regenerative medicine. Driven by CEO Martine Rothblatt’s mission to solve the global organ shortage, the company’s alternative organ pipeline is organized across three scientific pillars:

  • Xenotransplantation: Xenotransplantation relies on genetic engineering to strip porcine (pig) organs of the carbohydrate molecules that trigger hyperacute human immune rejection, turning them into immediate, viable alternatives for human transplant. They are developing UHeart for end-stage heart disease, UKidney for end-stage renal disease, and UThymoKidney to solve the problem of post-transplant rejection (the goal is to the train the patient’s recipient T-cells to recognize the foreign organ as self).

  • Allogeneic Bioengineered Organs: Acquired by United Therapeutics for over $100 million, the Miromatrix subsidiary bypasses gene-editing by leveraging a unique perfusion decellularization and recellularization technology. Scientists take an off-the-shelf porcine organ and use a specialized chemical wash to strip away all animal cells, leaving behind an intact, pristine, non-immunogenic three-dimensional collagen scaffold. This scaffold is seeded (recellularized) with human vascular and organ-specific cells. They are starting with an external liver assist product, which is similar to dialysis for liver failure.

  • Autologous iPSC Regenerative Medicine: The long-term holy grail of United Therapeutics’ pipeline is to completely eliminate human immune rejection by utilizing a patient’s own cells or universal, stealth cellular lines to manufacture personalized tissue. Here, they are starting with ULung and ULobe for end-stage lung disease. Developed through partnerships with 3D-bioprinting leaders like 3D Systems, this program prints complex, high-resolution synthetic lung scaffolds embedded with patient-derived or highly compatible human stem cells. The long-term developmental goal is to construct a fully functioning, cellularized human lung capable of independent gas exchange. The Thymmune acquisition falls squarely into this bucket.

Conclusion

The acquisition of Thymmune by United Therapeutics represents a textbook synergy between academic innovation and industry acceleration. The foundational work emerging from the George Church lab provided its enabling technology: a method for using transcription factors to orchestrate cellular reprogramming. Nevertheless, turning a brilliant academic insight into a scalable cell therapy requires a completely different set of capabilities. It demands the refinement of experiments into repeatable & scalable processes, the navigation of complex regulatory frameworks, and a long financial runway. By absorbing Thymmune, United Therapeutics is integrating a sophisticated cellular programming platform into their broader organ-manufacturing apparatus. Together, they hope to manifest their shared dream of engineering functional, patient-specific organs in vivo.

Love biotech? Check out Biotech Readout’s full content library, or navigate directly to a segment that interests you:

Biotech Readout is a reader-supported publication. To receive new posts and support my work, consider becoming a free subscriber.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

]]><![CDATA[Ipsen to Acquire Memo]]>https://biotechreadout.xyz/p/ipsen-to-acquire-memohttps://biotechreadout.xyz/p/ipsen-to-acquire-memoWed, 01 Jul 2026 21:22:35 GMTDisclaimer: This newsletter is for educational and informational purposes only and does not constitute medical, investment, or financial advice, nor does it establish a provider-patient relationship. Content may include forward-looking statements and discussions of investigational therapeutic candidates that are not FDA/EMA approved; their safety and efficacy remain unestablished and clinical outcomes are unpredictable. While we strive for accuracy, all information is provided as is without guarantees. As of the date of publication, the author holds no direct equity positions in the specific companies mentioned in this issue nor receives third-party compensation for this coverage. Please find a complete version of our disclaimers at the bottom of this article and on our About page.

Introduction

On July 1, 2026, Ipsen announced a definitive agreement to acquire Memo Therapeutics AG for €200 million (about $228 million USD) upfront at closing and up to a total of €700 million (about $797 million USD) contingent upon the achievement of specified development, regulatory approval and sales-based milestones (Ipsen press release, Memo press release). This acquisition centers on potravitug, an investigational first-in-class BK polyomavirus (BKV) monoclonal antibody that is currently being evaluated for the treatment of active BK polyomavirus associated nephropathy (BKVAN) and the prevention of graft loss or transplant failure in kidney transplant patients.

In this article, we dive into the history of BK polyomavirus (BKV), uncover the foundational discoveries that enabled Memo Therapeutics’ potravitug, and relive the company’s fascinating backstory.

Hidden Plague

BK polyomavirus (BKV) is a small, double-stranded DNA virus belonging to the Polyomaviridae family that is highly ubiquitous in the human population, with up to 90% of adults worldwide maintaining a lifelong, asymptomatic latent infection within the epithelial cells of the kidney and urinary tract. While the virus is benign in individuals with intact immune systems, it presents a severe clinical threat to kidney transplant recipients. For context, kidney transplant patients must take a cocktail of immune suppressing medicines after a transplant so that the donor organ can engraft and start working. However, that cocktail makes the patient functionally immunocompromised, with a diminished capacity to defend against infectious diseases. When host immunity is suppressed, BKV can reactivate and undergo unchecked lytic replication, leading to severe complications such as BK virus-associated nephropathy (BKVAN). BKVAN can cause premature kidney allograft failure, or hemorrhagic cystitis, characterized by painful bladder inflammation and bleeding.

But, how did we discover BKV if it’s invisible to most people? This story of its discovery is a journey from an accidental virological discovery to an emerging clinical challenge. The virus was first isolated in 1970 at the Virus Research Laboratory in London, England. A virologist named Dr. Sylvia Gardner was investigating the epidemiology of a different virus, cytomegalovirus (CMV). While examining the urine of a 39-year-old Sudanese kidney transplant recipient who had developed a severe ureteric stricture (narrowing of the ureter), Dr. Gardner noted numerous cells containing prominent viral inclusions. Using electron microscopy, Dr. Anne Field identified viral particles that structurally resembled papillomaviruses. Once successfully cultured and confirmed as a distinct, novel agent, the virus was named “BK” after the initials of that first patient. The original viral isolate is still referred to as the Gardner strain. The discovery was formally published in a landmark 1971 issue of The Lancet, in a back-to-back sequence with the discovery of the closely related JC polyomavirus (JCV).

Decoy cell cytology, using Papanicolaou stain. The high nuclear to cytoplasmic ratio makes it resemble cancer (thus the name “decoy cell”) but the inclusion body distinguishes it.; Source: Mikael Häggström, M.D. Author info - Reusing images- Conflicts of interest: NoneMikael Häggström, M.D.From original by Huang Y, Chen XT, Yang SC, Yang HF, Hou XT, Chen WF, CC BY 4.0, via Wikimedia Commons

Following the isolation of BKV, extensive serological and epidemiological studies revealed a striking paradox: while the virus was discovered in a severely ill transplant patient, it was actually ubiquitous in the general population. Researchers discovered that primary BKV infection typically occurs in early childhood (often by age 4 or 5), spreading asymptomatically via respiratory or fecal-oral routes. By adulthood, 80% to 90% of the global population is seropositive. Investigators realized that after the primary childhood exposure, the virus establishes a lifelong, silent residency (latency) within the renal tubular epithelial cells and the urothelium of the urinary tract. Since it remains completely benign and asymptomatic in healthy individuals, BKV was largely categorized as an opportunistic pathogen of low clinical priority throughout the 1970s and 1980s.

The clinical significance of BKV changed dramatically in the late 20th century, driven by a major evolution in transplant medicine: the introduction of highly potent, next-generation immunosuppressive drugs (such as tacrolimus and mycophenolate mofetil) in the mid-1990s. In 1993, at the University of Pittsburgh, clinicians documented the first definitive, biopsy-proven case of BK virus-associated nephropathy (BKVAN), then termed polyomavirus interstitial nephritis, in a kidney transplant recipient presenting with unexplained graft dysfunction. As these potent triple-drug immunosuppressive regimens became the global standard of care to prevent organ rejection, rates of BKV reactivation skyrocketed. Unchecked viral replication leads to a vicious cascade: viruria (shedding in urine), progressing to viremia (virus entering the bloodstream), and ultimately resulting in BKVAN, a leading cause of premature kidney allograft loss. Concurrently, BKV emerged as a primary culprit behind hemorrhagic cystitis (characterized by severe, painful bladder inflammation and bleeding) in bone marrow and stem cell transplant recipients.

Today, BKV remains a factor in transplant success. Since there are still no universally approved, highly effective antiviral medications specifically targeting BKV, clinical management historically relies on a delicate balancing act: reducing a patient’s immunosuppression to allow their own immune system to clear the virus, which simultaneously spikes the risk of acute organ rejection.

Secrets in the Serum

For decades after the discovery of the virus in 1971, the role of antibodies in controlling BKV was highly debated. Researchers knew that 80% to 90% of adults were seropositive for BK virus, yet immunosuppressed patients still suffered from severe viral reactivation leading to BK virus-associated nephropathy (BKVAN). Early serology relied on hemagglutination inhibition (HI) assays, which lacked the sensitivity to distinguish true virus neutralization from broad cross-reactive binding. Since patients with high antibody titers still developed active viremia, the initial medical consensus was that humoral immunity was largely ineffective, and that viral control depended almost entirely on cell-mediated (T-cell) immunity.

The modern understanding of BKV neutralizing antibodies was unlocked by a critical technological breakthrough: the development of BK polyomavirus pseudoviruses (BK-PsVs), pioneered heavily by researchers like Diana Pastrana and Christopher Buck at the National Institutes of Health (NIH). By engineering pseudoviruses that packaged a reporter gene (such as green fluorescent protein or luciferase) inside recombinant viral capsid proteins (VP1, VP2, VP3), scientists could finally measure actual in vitro neutralization in cell culture. Utilizing these pseudovirus systems, researchers demonstrated that the four major genomic variants of BKV (Genotypes I-IV) behaved as completely distinct serotypes. An antibody that neutralized Genotype I would often fail to neutralize Genotype IV, explaining why a patient could have high total antibody titers but still be susceptible to a different, donor-derived strain of the virus.

Equipped with functional neutralization assays, clinical cohorts were closely monitored. The landmark 2018 study published in the Journal of the American Society of Nephrology (JASN) was conducted by a highly collaborative, multidisciplinary team of clinical and research experts based out of Strasbourg University Hospital (Hôpitaux Universitaires de Strasbourg) and the University of Strasbourg. It demonstrated that kidney transplant recipients who possessed high pre-transplant neutralizing antibody titers specifically matched to their donor’s BKV serotype were profoundly protected against post-transplant viruria (virus in the urine) and viremia (virus in the blood). A neutralizing antibody (NAb) titer <4 log10 IC50 on the day of transplantation was associated with an 88% higher risk of BKV replication after transplantation (HR, 1.88; 95% CI, 1.06 to 3.45; P=0.03).

Neutralizing antibody (NAb) levels above 4 log10 IC50 before transplantation before transplantation correlate with the relative risk of developing BKV infection, as detected in the urine (left) and blood (right); Source: Solis et al. JASN (2017), Figure 4

Why did patients with neutralizing antibodies above the threshold still develop BKV infection? About 17% of patients with viruria lacked neutralizing antibodies against the specific strains of BKV that they contracted, a mismatch that allowed infection to slip through the cracks. While patients with neutralizing antibody titers during the observation period came with a 56% lower risk of transitioning from viruria (local infestation) to viremia (more global infestation), antibody mismatch with the replicating strain nevertheless resulted in a 2.3-fold increased risk of viremia. It’s not enough to simply have neutralizing antibodies. They have to hit the relevant strain in order to effectively reduce the risk of infection.

Links between various neutralizing antibody (NAb) characteristics and the transition from viruria (local infestation) to viremia (more global infestation); Source: Solis et al. JASN (2017), Figure 3C

Making Medicines

With clinical pathophysiology established, the race began to isolate potent, pan-serotype human monoclonal antibodies capable of blocking all four genotypes without allowing for easy mutational escape.

Researchers at Amplyx Pharmaceuticals successfully isolated P8D11, a human-derived antibody with picomolar affinity that targeted a highly conserved structural epitope on the major capsid protein VP1. P8D11 blocked the viral attachment mechanism to host sialic acid receptors. This antibody was subsequently humanized and advanced into clinical development as MAU868. When Pfizer acquired Amplyx for an undisclosed amount in 2021 to secure its anti-fungal portfolio, the BKV program sat outside Pfizer’s core therapeutic focus. In late 2021, Vera Therapeutics acquired MAU868 from Amplyx/Pfizer for a rather paltry $5 million upfront plus up to $7 million upon reaching certain regulatory milestones. For Vera, a biotechnology company heavily anchored in serious kidney-related diseases, MAU868 was a good fit in its pipeline.

Vera took over and presented data from a randomized, double-blind, placebo-controlled Phase 2 study evaluating MAU868 in adult kidney transplant recipients who had developed active BK viremia within one year post-transplant. Participants were randomized (2:1) to receive four intravenous doses every 28 days across two distinct treatment cohorts or a matching placebo. Vera first presented the interim 12-week topline data for MAU868 at the American Transplant Congress (ATC) on June 4, 2022, in a late-breaking oral presentation. Following that initial look, Vera shared the final, full 36-week results later that year at the American Society of Nephrology (ASN) Kidney Week annual meeting in November 2022. By Week 36, more MAU868-treated patients achieved a ≥1 log10 reduction in plasma viral load (75% versus 50% for placebo), and reduced viral loads below the lower limit of quantification (30% versus 0% for placebo), showing that a passive antibody therapy can effectively manage post-transplant BK virus replication without requiring hazardous adjustments to a patient’s core immunosuppressive regimen.

Despite this early success, Vera has shifted nearly all of its near-term corporate energy, funding, and public focus toward their lead asset, atacicept, whose PDUFA target action date for IgA Nephropathy (IgAN) is less than a week away from this article’s time of publication (July 7, 2026). The molecule appears to be in limbo, neither discontinued nor advanced into the larger Phase 2b/3 that Vera telegraphed back in 2022.

However, progress in the field didn’t stop with MAU868. Memo Therapeutics was founded in 2012 as a spin-off from the Swiss Federal Institute of Technology (ETH Zurich). Headquartered in the biotech hub of Schlieren/Zurich, Switzerland, the company was co-founded by Dr. Christoph Esslinger (who long served as Chief Scientific Officer) and a team of molecular biologists. In 2018, Memo raised their Series A, bringing in Swiss-based Verve Ventures, which anchored the company’s early expansion. The company was built entirely around a singular technological breakthrough: the DROPZYLLA platform. Rather than engineering synthetic antibodies in a lab or using humanized mice, DROPZYLLA was designed as an “antibody repertoire copying engine.” It used single-cell microfluidics to isolate individual memory B cells from rare human donors, specifically elite neutralizers, or rare patients who had naturally beaten severe viral infections or cancers. This could effectively capture the best blueprints of the human immune system.

In 2021, they pointed their DROPZYLLA platform not at BKV, but at COVID-19. Amid the global pandemic, Memo closed a CHF 13.8 million Series B round led by Swisscanto and rapidly validated its platform by isolating a highly potent, fully human neutralizing antibody (MTX-COVAB) from convalescent COVID-19 donors in just three weeks. Preventative vaccines beat them to the punch, and COVID-19 dropped off of the priority list. However, they had been working on a second program. Scientists at Memo had begun screening the B-cell repertoires of elite neutralizers of BKV, rare transplant patients who rapidly cleared massive BK viral loads on their own. They once again leveraged their DROPZYLLA platform to clone the paired antibody genes from elite neutralizers of BKV into mammalian expression vectors, creating a recombinant library of their immune responses. They then ran high-throughput functional screens using BKV pseudoviruses to identify candidates that blocked cell entry. Out of millions of candidates, mAb 319C07 (potravitug) emerged as the winner. It exhibited exceptional picomolar binding affinity to a highly conserved, conformationally complex structural epitope on the VP1 capsid pentamer. Since this specific epitope is indispensable for the virus to attach to host sialic acid receptors, potravitug exerts a structural blockade that prevents cell-to-cell viral spread across all four major BKV serotypes (see graph below).

Armed with this ultra-potent molecule, Memo raised a $25 million Series C round in late 2023 led by Pureos Bioventures. In May 2024, they secured a CHF 20 million Series C extension (bringing the total round to CHF 45 million), adding investors like Ysios Capital and Kurma Partners. This capital was deployed to evaluate potravitug in the Phase 2 SAFE KIDNEY II trial (NCT05769582), the largest randomized, double-blind, placebo-controlled trial ever conducted for the treatment of BKV-associated nephropathy (BKVAN). The study enrolled 95 kidney transplant recipients across 22 sites in the U.S. who had active, high-load BKV DNAemia (≥ 10,000 IU/mL). Patients received four intravenous infusions of either potravitug (500 mg or 1000 mg) or a placebo, spaced 4 weeks apart, on top of standard-of-care immunosuppression adjustments. Initial analyses from the study were first shared at the 63rd European Renal Association (ERA) Congress in early June 2026, followed immediately by the presentation of the complete, long-term 38-week dataset at the American Transplant Congress (ATC) on June 23, 2026. By week 38, 24.4% of potravitug-treated patients achieved plasma BKV-DNAemia below the lower limit of quantification compared to 13.0% in the placebo cohort, with a ≥2 log10 reduction in viral load observed in 40.3% versus 24.7% of patients, respectively. Crucially, protocolized kidney biopsies at week 20 revealed that active, biopsy-proven BKVAN declined from 51.2% to 31.6% in the treatment arm while remaining completely unchanged in the placebo group, all while demonstrating a generally well-tolerated safety profile with no treatment-related serious adverse events.

A few weeks lated on July 1, 2026, the global biopharmaceutical giant Ipsen announced a definitive agreement to acquire Memo Therapeutics, securing potravitug for its expanding rare disease portfolio. To separate the drug from the platform in the transaction, a condition of the acquisition required a corporate split. While Ipsen absorbed the potravitug program to push it into global Phase 2/3 trials, Memo’s original discovery foundations are set to be spun off into a newly incorporated entity named Memorises Bio that encompasses:

  • The proprietary DROPZYLLA platform

  • An ongoing recombinant polyclonal IgG collaboration with CSL

  • Its early-stage oncology pipeline

Memorises Bio is to remain held by Memo’s original shareholders and will continue finding the next generation of human antibodies.

Conclusion

Memo Therapeutics’ development effort is a text-book validation of reverse-translational medicine. By hunting for answers within the immune systems of rare elite neutralizers, scientists bypassed traditional lab-bench guesswork to uncover a neutralizing antibody optimized by nature. In acquiring potravitug, Ipsen secures a pan-serotype weapon against a historically hard to treat post-transplant threat. As potravitug marches toward global Phase 2/3 trials under Ipsen’s rare disease banner, the legacy of the DROPZYLLA engine lives on. The birth of Memorises Bio ensures that the hunt for the next generation of natural human antibodies continues. If pivotal trials succeed and the medicine passes through regulatory review, it could someday allow clinicians to treat active BKVAN without forcing a hazardous compromise on a patient’s core immunosuppressive safety net.

Love biotech? Check out Biotech Readout’s full content library, or navigate directly to a segment that interests you:

Biotech Readout is a reader-supported publication. To receive new posts and support my work, consider becoming a free subscriber.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

]]><![CDATA[Zymeworks to Acquire Theravance]]>https://biotechreadout.xyz/p/zymeworks-to-acquire-theravancehttps://biotechreadout.xyz/p/zymeworks-to-acquire-theravanceWed, 01 Jul 2026 13:42:13 GMTDisclaimer: This newsletter is for educational and informational purposes only and does not constitute medical, investment, or financial advice, nor does it establish a provider-patient relationship. Content may include forward-looking statements and discussions of investigational therapeutic candidates that are not FDA/EMA approved; their safety and efficacy remain unestablished and clinical outcomes are unpredictable. While we strive for accuracy, all information is provided as is without guarantees. As of the date of publication, the author holds no direct equity positions in the specific companies mentioned in this issue nor receives third-party compensation for this coverage. Please find a complete version of our disclaimers at the bottom of this article and on our About page.

Introduction

On June 29, 2026, Zymeworks Inc. announced a definitive agreement to acquire Theravance Biopharma, Inc. for approximately $929 million in cash consideration subject to customary adjustments (Zymeworks press release, Zymeworks slide deck, Theravance press release). This acquisition centers on Yupelri, a nebulized, once-daily, long-acting muscarinic antagonist (LAMA) for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

In this article, we dive into the story of Yupelri’s development, identify its place in the COPD landscape, and discuss the deal’s unique business development angle.

Breathing Room

Chronic Obstructive Pulmonary Disease (COPD) is a progressive, inflammatory lung condition that causes long-term breathing difficulties by restricting airflow into and out of the lungs. Primarily caused by smoking or long-term exposure to airborne irritants, it encompasses chronic bronchitis (inflammation and mucus buildup in the bronchial tubes) and emphysema (the destruction of the lung’s fragile air sacs). Over time, this damage leads to persistent symptoms like shortness of breath, a chronic cough, and wheezing, which gradually worsen but can be managed with bronchodilators, lifestyle changes, and targeted anti-inflammatory therapies.

Yupelri represents an effort to deliver a long-acting bronchiodilator directly to the lungs, with the goal of relax airway smooth muscle and improve airflow in patients with COPD. Muscarinic antagonists are a relatively old drug class in the COPD space. Boehringer Ingelheim’s Atrovent (ipratropium bromide) achieved first-in-class status with its FDA approval on December 29, 1986. However, it was a short-acting muscarinic antagonist (SAMA), requiring patients to use it 3 to 4 times a day due to its short half-life. The early 2000s oversaw a race for long-acting muscarinic antagonists (LAMAs), which could provide similar relief as SAMAs but with the convenience of once daily dosing. Boehringer Ingelheim once again stood at the vanguard, securing the first LAMA approval for COPD with Spiriva HandiHaler (tiotropium bromide) on January 30, 2004. Today, LAMAs are the drug class with the most FDA approvals in COPD (see graph below).

Target landscape for COPD as of June 2026

So, where did Yupelri come in? The active pharmaceutical ingredient in Yupelri is called revefenacin (initially designated as TD-4208) and was discovered by Theravance in the early 2000s. With their new medicine, Theravance set out to raise the bar for the COPD treatment landscape in two ways:

  • Enhance inhaled delivery using a nebulizer: While several long-acting LAMAs existed for handheld dry-powder or metered-dose inhalers, patients with severe or advanced COPD often lacked the inspiratory flow rate necessary to use those devices effectively. Theravance specifically developed TD-4208 as an inhalation solution designed to be compatible with standard jet nebulizers.

  • Make it safer by reducing systemic exposure: They applied their lung-selective chemistry platform to create a LAMA that was designed to provide sustained bronchodilation locally in the lungs while rapidly breaking down if it entered systemic circulation. This could minimize classic anticholinergic side effects, such as dry mouth and urinary retention, that frequently occur with systemic exposure.

In 2015, Theravance entered into a strategic collaboration with Mylan to advance the asset through late-stage global clinical trials and commercialization. Under the agreement, Theravance led the U.S. clinical development program, while Mylan heavily financed the registrational path and managed ex-U.S. expansion. Theravance retained a U.S. profit-sharing model and global rights to alternative delivery formats (like MDI/DPI inhalers).

The clinical path to approval culminated in an extensive Phase 3 program evaluating more than 2,300 patients with moderate-to-very-severe COPD. Two identical 12-week pivotal Phase 3 efficacy trials demonstrated that a once-daily dose of revefenacin led to statistically significant and clinically meaningful improvements in trough forced expiratory volume in one second (FEV1) compared to placebo (+102-127 mL for Yupelri versus -19-45 for placebo; see table below). In July 2017, Theravance and Mylan announced positive results from a large, 1,055-patient, 12-month Phase 3 safety study. The data showed that revefenacin was well-tolerated over long periods, whether used as a standalone maintenance bronchodilator or as an add-on to other COPD regimens, such as LABAs or ICS/LABA combinations.

LS Mean Change from Baseline in Trough FEV1 (mL) on Day 85 (ITT); Source: Yupelri label, Table 2

Backed by successful Phase 3 efficacy and safety data, Yupelri’s New Drug Application (NDA) was filed in late 2017. On November 9, 2018, the U.S. Food and Drug Administration officially granted market authorization for Yupelri (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. In June 2019, Theravance and Mylan expanded their collaboration agreement to grant Mylan exclusive development and commercialization rights for nebulized revefenacin in China and adjacent territories, tapping into an underserved market of nearly 100 million COPD patients. In late 2020, Mylan merged with Pfizer’s off-patent medicine division (Upjohn) to form Viatris. Consequently, commercial marketing and co-promotion responsibilities for Yupelri transitioned under the Viatris banner.

While the success of Yupelri created breathing room for Theravance, the rest of their pipeline was defined by a sequence of high-profile clinical trial stumbles. Ampreloxetine, a once-daily selective norepinephrine reuptake inhibitor (NRI), was Theravance’s flagship late-stage asset behind Yupelri. It was designed to treat neurogenic orthostatic hypotension (nOH), a severe drop in blood pressure upon standing, in patients with rare neurodegenerative conditions. However, it failed three separate Phase 3 trials (Study 0169 in 2021, REDWOOD in 2022, CYPRESS in 2026) and ultimately landed on the out-licensing list. Nezulcitinib (TD-0903) was an inhaled, lung-selective Janus kinase (JAK) inhibitor being developed to treat acute lung injury, chronic lung inflammation, and fibrotic lung diseases (including severe COVID-19-associated lung injury). It was discontinued after a Phase 2 trial reported in 2023 failed to show clinical efficacy. Before focusing exclusively on ampreloxetine and respiratory medicine, Theravance attempted to develop an oral, gut-selective JAK inhibitor for inflammatory bowel disease (IBD) in collaboration with Janssen (Johnson & Johnson). That too met an untimely end when, in late 2021, it missed its primary endpoint of clinical remission in a Phase 2b/3 trial for ulcerative colitis.

In June 2026, oncology and immunology biopharma company Zymeworks announced a definitive agreement to acquire Theravance Biopharma for roughly $929 million. The acquisition explicitly absorbed Theravance’s remaining financial stakes in Yupelri. While Yupelri generated an impressive $266.6 million in U.S. net sales in 2025, it has been overtaken by dual or triple single-inhaler therapies that combine muscarinic agonists, beta agonists, and corticosteroids (Trelegy Ellipta, Breztri, and others) and novel mechanisms (such as the anti-IL5 mAb Nucala for eosinophilic phenotypes of COPD).

Annualized revenue run rate of select FDA-approved medicines for COPD as of 1Q 2026, with Yupelri colored in dark green

Acquisition Alchemy

To be clear, the Biotech Readout is not a financial newsletter. However, Zymeworks’ deal structure is creative enough to merit a brief discussion.

While the total cash consideration of acquiring Theravance is approximately $929 million, Zymeworks only expects to pay out $119 million in net cash at close (see graph below). How is it that they only need to pay out about 1/8 of the total deal value? Theravance’s net cash on the balance sheet, a non-recourse note backed by U.S. YUPELRI profit share, and a milestone from Royalty Pharma for Trelegy Ellipta expected in 1Q 2027 reduce Zymeworks’ net cash requirements by a combined $810 million. That’s not even the half of it.

Estimated Zymeworks capital at risk (blue) at closing; Source: adapted from Zymeworks presentation, slide 15

When accounting for other milestones and tax offsets mentioned in their press release, Zymeworks could actually gain $319 million in net cash from the acquisition (see graph below) leaving them with Yupelri, an asset pro-forma modeled to generate an estimated $15 million per year (derived from the ~$60 million annualized cash flow mentioned in the press release minus the 75% profit share owed to OMERS Life Sciences). Yes, there is a scenario where Zymeworks could actually get paid to acquire another company. Out-licensing the investigational asset ampreloxetine could add additional cash to Zymeworks’ haul.

Clever investment bankers indeed.

Estimated Zymeworks capital at risk (blue) after closing plus additional milestones & tax offsets; Source: adapted from Zymeworks presentation, slide 15

Conclusion

The saga of Theravance and Yupelri highlights the unpredictable nature of drug development. Pipeline stumbles can dismantle even the most veteran R&D organizations, but a single well-designed, organ-selective molecule can establish a permanent footprint within the standard of care. As for Zymeworks, their acquisition of Theravance is a masterclass in creative deal structures. While Yupelri never quite transformed into the commercial blockbuster its early developers envisioned, its durable cash flows in a highly resilient niche provided Theravance with an exit. By structuring a transaction that mitigates capital risk, Zymeworks has secured a steady commercial baseline while preserving its firepower for downstream oncology innovation.

Love biotech? Check out Biotech Readout’s full content library, or navigate directly to a segment that interests you:

Biotech Readout is a reader-supported publication. To receive new posts and support my work, consider becoming a free subscriber.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

]]><![CDATA[Ipsen to Acquire Kartos]]>https://biotechreadout.xyz/p/ipsen-to-acquire-kartoshttps://biotechreadout.xyz/p/ipsen-to-acquire-kartosTue, 30 Jun 2026 10:51:26 GMTDisclaimer: This newsletter is for educational and informational purposes only and does not constitute medical, investment, or financial advice, nor does it establish a provider-patient relationship. Content may include forward-looking statements and discussions of investigational therapeutic candidates that are not FDA/EMA approved; their safety and efficacy remain unestablished and clinical outcomes are unpredictable. While we strive for accuracy, all information is provided as is without guarantees. As of the date of publication, the author holds no direct equity positions in the specific companies mentioned in this issue nor receives third-party compensation for this coverage. Please find a complete version of our disclaimers at the bottom of this article and on our About page.

Introduction

On June 29, 2026, Ipsen announced a definitive agreement to acquire Kartos Therapeutics for $450 million upfront at closing and up to $1.3 billion of regulatory and sales-based milestones, for a total deal value of up to $1.75 billion. This acquisition centers on navtemadlin, an oral MDM2 inhibitor that is currently being evaluated in a Phase 3 myelofibrosis trial. This is the second acquisition in the myelofibrosis space in about two months, with the first being Eli Lilly’s $2.3 billion purchase of Ajax Therapeutics.

In this article, we explore the recent interest in myelofibrosis acquisitions and unravel the novel mechanism behind Kartos’ lead molecule.

The Duality of Myelofibrosis

In Roman mythology, Janus is the god of duality. He is uniquely depicted with two faces looking in opposite directions, a representation known as Janus Bifrons (Janus Two-Faced). The two heads symbolize fundamental dualities of the human experience and the natural universe.

Statue representing Janus Bifrons in the Vatican Museums; Source: Vatican Museums, CC BY 3.0, via Wikimedia Commons

Myelofibrosis has a duality of its own: it is both big (by sales) and small (by the number of R&D candidates). As of the 1Q 2026, FDA-approved myelofibrosis medicines account for an almost $6.3 billion annualized revenue run rate, placing the indication comfortably in the blockbuster zone. Nevertheless, clinical-stage R&D pipeline is rather sparse. Ironically, the duality of myelofibrosis’ big market and small competition has emerged due to biotech/pharma crowding around inhibitors of Janus kinase (JAK), a protein named after Roman god Janus.

Annualized revenue run rate of selected myelofibrosis medicines, as of 1Q 2026

As of June 2026, all FDA-approved myelofibrosis drugs target JAK. To be clear, they each have their nuances. They span two generations, each with unique safety and efficacy profiles, but all target JAK nonetheless (we covered that history here). Of course the relentless the pursuit of JAK inhibitors that isn’t surprising, given that JAK mutations are the most common genetic drivers of primary myelofibrosis (50-60% of cases), followed by CALR mutations (25-35% of cases; 2 mutant CALR inhibitors in development) and MPL mutations (remaining 5-10% of cases; no drugs directly targeting this). Kartos’ navtemadlin stands alone as the first and only myelofibrosis drug that targets MDM2.

Distribution of myelofibrosis targets by development stage, as of June 2026

Programming Cancer Cell Death

The central thesis of Kartos’ navtemadlin centers on harnessing the therapeutic potential of the p53 pathway. In many cancers, the crucial tumor-suppressor protein p53 remains un-mutated (wild type), but is functionally inactivated by the overexpression of its negative regulator, MDM2. By blocking the MDM2-p53 interaction, Kartos’ candidate is designed to force the reactivation of p53 to drive apoptosis in cancer cells. In other words, navtemadlin a de-represses of programmed cell death. If it’s confusing to you, don’t be alarmed. The legendary scientists who discovered p53 were just as baffled.

Navtemadlin mechanism of action; Source: Kartos EHA 2023 poster

The path to uncovering the role of p53 in oncology is one of the most famous plot twists in biomedical history. When p53 was first discovered in 1979 by several independent groups (including David Lane, Arnold Levine, and Lloyd Old), it was completely mischaracterized. Researchers isolated p53 because it physically bound to the SV40 Large T-antigen, a viral protein known to transform normal cells into cancerous ones. Since high levels of p53 were found in tumor cells but were nearly undetectable in healthy cells, scientists reasoned that p53 was an oncogene, a gene that accelerated tumor growth. This theory was accidentally formulated when early labs cloned p53 DNA and showed it could transform healthy cells in vitro. What they didn’t realize was that they had unknowingly cloned a mutated isoform of p53 DNA rather than the normal, wild-type version.

In 1989, Arnold Levine’s lab and Bert Vogelstein’s team discovered that wild-type p53 actually inhibited cell transformation. Vogelstein found that the TP53 gene was frequently deleted or mutated in human colorectal cancers. The scientific community realized they had it backward: p53 was a tumor suppressor gene (slows tumor growth), not an oncogene (accelerates tumor growth). When functioning correctly, wild-type p53 acts as a transcription factor activated by cellular stress (like DNA damage or low oxygen). It forces the cell into cell-cycle arrest to repair the damage or triggers apoptosis if the damage is catastrophic. If p53 is mutated or inactivated, cells can accumulate genetic mutations unchecked, paving the way to malignancy.

How does this relate to myelofibrosis? For years, the molecular focus remained largely fixed on its three genetic driver mutations (JAK, CALR, MPL). However, next-generation sequencing and longitudinal tracking revealed that p53 plays a crucial, distinct role in disease architecture and progression. While p53 mutations are relatively rare in the early, chronic phases of primary or secondary myelofibrosis (occurring in only 3-5% of patients), their emergence is heavily tied to blast-phase progression (transformation into secondary Acute Myeloid Leukemia, or sAML). Once a myelofibrosis clone acquires a TP53 mutation, the cells rapidly accrue massive chromosomal structural variations and deletions.

The status of p53 mutations in myelofibrosis significantly impacts overall survival and relapse incidence, according to retrospective cohort data from a 349-patient study of patients with myelofibrosis undergoing an allogeneic hematopoietic stem cell transplantation (HSCT) published in Blood. Patients with a mutation in only one allele, while the other remains wild-type, often experience a clinical course similar to non-mutated patients. When a patient suffers a multi-hit mutation event, such as losing the second allele through a deletion (like 17p deletion) or a second mutation, their prognosis drops dramatically. Multi-hit TP53 status is associated with about half the overall survival after 6 years (only 25% of multi-hit survived versus 56% single-hit, P< 0.001) and is associated with a 42% higher risk of disease recurrence compared to patients with single-hit TP53 status (P=0.03), following a haematopoietic stem cell transplant (HSCT).

Myelofibrosis patients with multi-hit p53 mutations have lower overall survival (left) and a higher incidence of disease recurrence following a haematopoietic stem cell transplant (HSCT); Source: Gagelmann et al. Blood (2023), Figures 3B & 3C

Crucially, even when the TP53 gene is not mutated in myelofibrosis, the pathway is frequently hijacked. In many high-risk MF patients, the wild-type p53 protein is functionally suppressed because the cell overexpresses MDM2, a principal negative regulator that tags p53 for degradation. MDM2 has “high expression” in 71% of CD34+ hematopoietic progenitor cells from patients with myelofibrosis compared to 34% in healthy people (see graph below). In fact, Nakatake et al. Oncogene (2012) suggests that JAK2V617F driver mutations may cause MDM2 overexpression via the abnormal accumulation of the La autoantigen (a protein that significantly boosts MDM2 protein levels by binding & stabilizing MDM2 mRNA). This overabundance of MDM2 forces the continuous degradation of p53, preventing apoptosis even when the cell undergoes DNA damage. By either downregulating the La protein or treating the cells with an MDM2 antagonist (using Nutlin-3 as a tool compound), the team successfully rescued the p53 response to DNA damage and restored normal cytokine dependence to JAK2V617F mutant cells, curbing their unchecked growth.

MDM2 overexpression in hematopoietic progenitor cells is more common in patients with myelofibrosis (teal triangles) compared to healthy people (grey circles); Source: Kartos ASH 2024 presentation, slide 3

This biological interplay is precisely where Kartos’ lead program steps into the spotlight. Navtemadlin is designed to restore apoptotic p53 signaling by blocking MDM2-mediated degradation. In a therapeutic landscape heavily saturated with successive generations of JAK inhibitors, Kartos’ investigational candidate stands out as a mechanically distinct approach under evaluation for patients who have exhausted standard options.

Spinning Out

The founding of Kartos Therapeutics is a classic story of biotech spin-outs, where a highly promising molecule developed by a pharma giant was given a dedicated, laser-focused home to reach its clinical potential. Its scientific foundation started inside the research engines of Amgen, where navtemadlin was originally developed. While the molecule (then known as AMG 232) showed immense structural promise, pharmaceutical giants often have to ruthlessly prioritize their vast pipelines. Recognizing the asset’s potential but needing a dedicated team to push it through complex clinical development, Amgen looked for a strategic way to externalize the program.

In 2018, Kartos Therapeutics was officially launched to breathe new life into the asset, establishing its operations with dual headquarters in Redwood City, California, and Bellevue, Washington. The company was co-founded by industry veterans, most notably Jesse McGreivy, who stepped in as Chief Medical Officer (CMO) and Chief Executive Officer (CEO). McGreivy brought immense credibility to the venture, having previously served as a CMO at Acerta Pharma, where he played a pivotal role in the clinical development of the blockbuster blood cancer drug Calquence (acalabrutinib) before its $7 billion acquisition by AstraZeneca in 2016. Upon launch, Kartos secured an exclusive worldwide licensing agreement with Amgen for the MDM2 inhibitor, renaming the drug candidate KRT-232 (later given the generic name navtemadlin). This molecule became the sole cornerstone of the company’s pipeline. The company secured robust financial backing from premier life science institutional investors, including SR One and OrbiMed Advisors, and got straight to work.

Shortly after licensing the molecule, Kartos launched a broad clinical screening strategy. Since MDM2 inhibition restores wild-type p53 to trigger apoptosis, the company initiated parallel Phase 1 and Phase 2 trials across several oncology indications. Navtemadlin was clinically tested in multiple p53 wild-type malignancies, including acute myeloid leukemia (AML), polycythemia vera (PV), and Merkel cell carcinoma (MCC). While solid tumor cohorts encountered the traditional dose-limiting toxicities historic to the MDM2 class (primarily thrombocytopenia and gastrointestinal distress), a more favorable therapeutic window emerged in myelofibrosis.

These efforts culminated in the open label Phase 3 BOREAS trial, which represents a landmark attempt to introduce a non-JAK-inhibitor mechanism to a patient population who have relapsed or become refractory to frontline JAK inhibitor therapies. The study enrolled 183 patients with confirmed wild-type p53 primary or secondary myelofibrosis. They wanted to address the true unmet need, so approximately 65% of their recruited patients were refractory to previous JAK inhibitors, 30% presented with severe baseline thrombocytopenia (platelets < 100,000 / μL), and over 60% carried high molecular risk mutations. Topline clinical data and correlative biomarker data were first presented at the 66th American Society of Hematology (ASH) Annual Meeting in December 2024.

Navtemadlin tripled the percent of patients who achieved a ≥35% reduction in spleen volume compared to best available therapy at week 24 (SVR35: 15% versus 5%), although it narrowly missed statistical significance (P=0.0815) due to adjustments in the trial’s accrual targets. It also doubled the percent of patients who experienced a ≥50% reduction in disease-related constitutional symptoms compared to best available therapy (TSS50 24% versus 12%, P=0.05). While the primary endpoint did not achieve traditional statistical significance in this specific cohort, investigators noted that the observed data trends provided a rationale for further clinical evaluation of navtemadlin’s potential impact on tumor bulk and constitutional symptoms.

Spleen volume reduction ≥30% (SVR35) at Week 24 in the intent-to-treat (ITT) population of the Phase 3 BOREAS trial; Source: Kartos ASH 2024 presentation, slide 13
Total symptom score reduction ≥50% (TSS50) at Week 24 in the intent-to-treat (ITT) population of the Phase 3 BOREAS trial; Source: Kartos ASH 2024 presentation, slide 15

Where BOREAS truly generated excitement in the hematology community was in its exploratory, correlative biomarker readouts. Unlike JAK inhibitors, which primarily mask symptoms, navtemadlin demonstrated anti-clonal activity based on three orthogonal readouts:

  • CD34+ Cell Clearance: Circulating CD34+ cells, the hallmark malignant driving cells of myelofibrosis, dropped -70% at Week 24 in the navtemadlin arm compared to just -38% in the BAT arm.

  • Variant Allele Frequency (VAF): Navtemadlin doubled the molecular response rate, achieving a ≥50% reduction in the underlying driver gene VAF (such as JAK2 or CALR) in 21% of patients versus 12% for BAT.

  • Bone Marrow Fibrosis Reversal: At 24 weeks, nearly half of the evaluable navtemadlin patients (48%) achieved a documented reduction of at least 1 grade in bone marrow fibrosis, compared to just 24% in the control wing.

Navtemadlin resulted in numerical improvements in VAF reduction (left; 21% versus 12%) and bone marrow fibrosis (47% versus 24%; right) compared to best available therapy; Source: Kartos ASH 2024 presentation, slide 19

The adverse event profile yielded the expected on-target effects of the MDM2 inhibitor class, characterized by hematologic suppression and gastrointestinal distress. The enrollment of the BOREAS trial was eventually halted prior to its original total accrual target. This was a deliberate corporate pivot. The Kartos team believed that they had enough evidence from BOREAS to convince them that navtemadlin possessed robust monotherapy activity and genuine disease-modifying capability. With proof-of-concept secured, Kartos chose to push navtemadlin into a pivotal Phase 3 POIESIS trial, testing it as an add-on combination therapy to rescue suboptimal frontline Jakafi responders before their disease progresses to a completely relapsed/refractory state. It’s a much needed addition given that 60-70% of myelofibrosis patients treated with the frontline JAK inhibitor Jakafi fail to hit optimal clinical responses (defined as ≥35% spleen volume reduction and ≥50% symptom improvement). Ipsen plans to report topline data from POIESIS are expected in 2027.

Conclusion

For years, the myelofibrosis field remained tethered to JAK inhibition, a class that masterfully treats symptoms but is prone to resistance in a majority of patients. By charting a course as the MDM2 lone wolf, Kartos’ navtemadlin forged a new therapeutic approach. In doing so, it taps into a legacy of p53 biology nearly fifty years in the making. As Ipsen prepares to steer this molecule through the global expanse of the Phase 3 POIESIS trial, we will soon see whether the p53 pathway can be safely harnessed to alter the trajectory of myelofibrosis.

Love biotech? Check out Biotech Readout’s full content library, or navigate directly to a segment that interests you:

Biotech Readout is a reader-supported publication. To receive new posts and support my work, consider becoming a free subscriber.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

]]>